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Summary
The central aim of this study was to characterise the expression of the candidate
tumour suppressor gene, LV/-J (lentivirus integration-I] and its products. The LVI-J
gene (WDR76) was discovered as a target for disruption by proviral insertional
mutagenesis in a case of pre-B cell lymphoma in a FIV infected cat {Beatty, 1998 5
lid; Beatty, 2002 7 lid}. As LV/-J is highly conserved, my work focused on the
human and murine orthologues to take advantage of the superior resources available
for these species. My work showed potentially important differences in expression of
the human and mouse genes with respect to promoter use and length of 3'
untranslated sequences. The murine gene is transcribed mainly from the distal PI
promoter, which appears to be a bi-directional element shared with the adjacent
MJapJ gene, while the human gene transcripts are derived exclusively from the
proximal P2 promoter. Direct analysis by RT-PCR showed that the murine gene
could also be expressed from the P2 promoter. These findings have significant
implications for Lvi-l protein expression as the P2 transcripts are predicted to express
larger proteins with a distinct N-terminal sequence. To characterise the LV/-J gene
products, rabbit polyclonal antisera were raised to GST fusion proteins expressed in
bacteria. Use of the murine anti-ml.vi-I antiserum in Western blotting identified a
protein of the expected size (58 kDa) based on translation of the major mRNA species
from the PI promoter. Immunofluorescence and confocal microscopy suggested that
this protein is localised mainly in the cytoplasm. Although the function of LVI-I is
unknown, its closest relative in the human genome is DDB2, a protein involved in
repair of UV-induced DNA damage. Regulation of LVI-I expression was examined
after UV irradiation, providing preliminary evidence of responses at transcriptional
and post-transcriptional levels. Further leads were followed by analogy with the yeast
orthologue of LVI-I, YDLI56W, but no evidence of a complex between LVI-I and
MSH6 was found. In conclusion, while function of the LVI-I gene remains to be
establishes, it provides the basis for future characterisation of this highly conserved
and potentially important eukaryotic gene.
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Chapter I
General Introduction
1.1 Retroviruses
The study of retroviruses began with the isolation of the first transmissible cancer-
causing agents by Ellermann and Bang in 1908 (1) and by Rous in 1911 (2).
Retroviruses are associated with a variety of diseases including malignancies,
neurological disorders, wasting diseases and immunodeficiency, however some
retroviruses are apathogenic. Their name derives from their capacity for reverse
transcription, a process by which the viral RNA genome is converted into DNA by the
viral enzyme reverse transcriptase (RT). The DNA copy can incorporate stably into
the host cell genome as a provirus and, in some cases after a period of latency, direct
the cellular machinery to reproduce the virus. The study of retroviruses led to the
discovery and development of the oncogene theory of tumourigenesis: some
retroviruses actually contained oncogenes within their genomes, while others interact
with oncogenes in either a direct or indirect way to contribute to tumour formation (3,
4).
1.1.1 Classification of retroviruses
Historically, because of their pattern of pathogenicity, the retroviruses were grouped
into three subfamilies. The subfamily Oncovirinae, the acute oncogenic retroviruses;
Lentivirinae, associated with 'slow' diseases or those with long latent periods, and the
Spumavirinae, the "foamy" viruses, named because of the pathogenic changes
observed in infected cells. Retroviruses were classified (Types A-D) according to the
electron microscopic appearance of their nucleocapsid structures (5). The most recent
classification of the Retroviridae family on the basis of sequence relatedness defines
seven genera: alpharetrovirus, such as Rous sarcoma virus (RSV), and avian leucosis
virus (ALV); betaretrovirus, such as mouse mammary tumour virus (MMTV), simian
retrovirus D-type (SRV), Jaagsiekte sheep retrovirus (JSRV), and enzootic nasal
tumour virus (ENTV); gammaretrovirus, such as murine leukaemia virus (MuL V) and
feline leukaemia virus (FeLV); deltaretrovirus, such as bovine leukaemia virus (BLV)
and human T-Iymphotropic virus (HTLV); epsilonretrovirus, such as Walleye dermal
1
sarcoma virus (WDSV); lentivirus, such as maedi-visna virus (MVV) of sheep,
caprine arthritis-encephalitis virus (CAEV), equine infectious anaemia virus (EIAV)
and the human, simian, feline and bovine immunodeficiency viruses (HIV, SIV, FIV,.
BIV) and spumavirus such as simian foamy virus (SFV). These genera can be
grouped into simple retroviruses (alpharetrovirus, betaretrovirus, gammaretrovirus)
and complex retroviruses (deltaretrovirus, lentivirus, spumavirus, and
epsilonretrovirus ).
1.1.2 General features of the retrovirus replication cycle
Retroviral virion particles contain two identical single stranded, genomic RNA
molecules of positive polarity that are replicated through a double-stranded DNA
intermediate (6, 7). The 5' end of the genomic RNA begins with the "R" (for repeat)
and "U5" (for unique 5' region) segments, followed by the viral genes gag ('group-
specific antigen'), pol ('polymerase'), env ('envelope'), which are the three major
open reading frames (orfs) (Figure 1-1). However, this is not the basic structure
because many retroviruses contain additional orfs. The 3' end of the genomic RNA
terminates with the U3 (for unique 3' region) and R (identical to the 5' region)
regions and a polyA tail. Following reverse transcription of the RNA genome into a
double strand (ds) DNA copy, this then integrates into the host cell chromosomal
DNA, where it is thereafter referred to as the "provirus". Because of the mechanism
used for reading and utilising the viral RNA template during reverse transcription (7-
9), the U3 and U5 regions are duplicated such that the 5' and 3' ends of the proviral
genome differ in structure from the ends of the RNA genome.
Each end of the proviral genome is made up of regions called long terminal repeats
(LTRs) which contain the proviral U3, R, and U5 regions. This arrangement of both
termini of the viral genome enables appropriate expression of the viral genes. The U3
region contains the enhancer and promoter sequences that drive viral RNA
transcription from the 5' LTR. In many retroviruses the viral gag and pol genes are
expressed from an unspliced gagpol transcript while, the env gene is invariably
expressed from a spliced transcript (the splice donor is located between the 3' end of
the 5' LTR and the 5' end of the gag gene, with the splice acceptor located at the 5'
end of the env gene) (10). While the genome of simple retroviruses carries the gag,
2
su
LTR
Figure 1-1. Schematic representation of the retrovirus virion depicting the
relationship of the retrovirus genes and the location of the different proteins.
LTR: long terminal repeat, PBS: primer binding site, PPT: polyurine tract. This
figure is not to scale and the regions' vary in length between different retroviruses.
Gag encodes structural viral proteins: matrix protein (MA), capsid protein (CA), and
nucleocapsid protein (NC). Pol encodes the enzymatic functions: protease (PR),
reverse transcriptase (RT), and integrase (IN). Env encodes viral glycoproteins:
surface protein (SU), and transmembrane protein (TM).
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pol, and env genes common to all retroviruses, and in some cases an extra gene such
as an oncogene or the superantigen gene of MMTV; the complex retrovirus genomes
carry regulatory genes that are involved in viral replication, or regulating viral gene
transcription such as tax and rex genes of HLTV; tat and rev of HIV; bel and bet of
spumaviruses. Moreover, the lentiviruses carry accessory genes such as the nef, vij,
and vpr for HIV; the vij, ORF A, and rev for FIV (Figure 1-2), which help them to
infect non-dividing cells such as macrophages.
Retroviral proteins are often synthesised as polyproteins, which undergo cleavage to
yield the functional products. Retroviruses are enveloped viruses and consist of an
inner core, the capsid, comprising nucleocapsid (NC) and capsid (CA) proteins that
are both encoded by the gag gene, a membrane-associated protein shell composed of
matrix protein (MA) also encoded by the gag gene, and an outer lipid bilayer derived
from cellular membranes with embedded viral transmembrane (TM) and surface (SU)
glycoproteins that are both encoded by the env gene (Figure 1-1). Moreover, the
envelope proteins are glycosylated with the exception of MuLV-related viruses in
which the TM proteins remain unglycosylated (reviewed in (11)). In additional, some
retroviruses also encode various other small proteins within the gag orf. The pol gene
encodes the viral replication enzymes: reverse transcriptase (RT), an RNA-dependent
DNA polymerase necessary for transcription of viral RNA into DNA; integrase (IN),
necessary for integrating the virus into the host cell genome; protease (PR) which is
encoded within pol for most retroviruses, is necessary for proteolytic cleavage of
primary translation products; pol also encodes an RNAse H activity that removes the
RNA strand from the hybrid RNA-DNA double strand (reviewed in (12)). Pol orf of
certain lentiviruses such as FIV, EIA V, CAEV, and visna virus encodes a
deoxyuridine triphosphatase (dUTPase, DU) (Figure 1-2), which hydrolyzes dUTP
(deoxyuridine triphosphate) to dUMP (deoxyuridine monophosphate). In fact, this
reaction not only provides a source of dUMP, an essential precursor of TTP
(thymidine triphosphate), but also maintains a low dUTP/TTP ratio that minimizes
dUTP incorporation into chromosomal DNA which leads to excision repair, DNA
breakage, and loss of viability (13, 14).
Retroviruses generally require actively dividing cells for productive infection (15).
The retroviral replication cycle (Figure 1-3) is initiated by binding of the viral
envelope glycoprotein to a specific cell surface receptor. This membrane fusion
results in release of the viral core into the cytoplasm. The viral RNA is uncoated and
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RNAse H, dUTPase (DU), and integrase (IN). Env encodes viral glycoproteins:
surface protein (SU) and transmembrane protein (TM). Y: glycosylation sites. Vif
(virion infectivity factor) controls virion release from lymphocytes. ORF A (putative.
tat, trans-activator gene) is a transcriptional activator of the LTR. Rev functions in
the stability and transport of incompletely spliced viral RNAs by binding to rev-
responsive element (Rre). PPT: Polypurine tract. SO: Splice donor. SA: splice
acceptor (SA). The arrow over the UAA gag stop codon indicates a ribosomal frame-
shift to produce the Gag-Pol polyprotein.
plasma membrane (a)I ©,.-, i_n_fe_c_tiv_e_v_i_ru_s ______.0 (b)
mRNA
~ ... ~ •• viral
'. T proteins
BL (f)
RNA
(c) +RT
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(d)
nucleus
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RNA
+ (e) provirus
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Figure 1-3. Retroviral replication cycle. Retrovirus binds to cellular receptors (a)
through virally encoded receptor binding proteins. Entry into the cell (b) is followed
by reverse transcription of the viral genome (c) to produce a DNA intermediate or
provirus. The provirus then integrates into the genome (d) and the random nature of
this process typically results in insertions into one allele of diploid genomes.
Transcription (e) and translation (f) are followed by packaging of progeny virus and
budding (g) from the host cell.
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reverse transcribed into a double-stranded, blunt-ended, linear DNA copy. This
process is catalyzed by the viral RT, resulting in a DNA molecule which is slightly
longer than the RNA molecule due to duplication of sequences from the 5' and 3'
termini. The next step in the infectious process involves import of the viral DNA into
the nucleus and insertion into a chromosome of the host genome by the viral integrase
protein, where it resides as the provirus. This process shows a strong dependence on
cell division, presumably requiring the breakdown of the nuclear membrane during
the mitosis (16, 17) in most retroviruses. However, the lentiviruses can infect non-
dividing cells.
The integration of the proviral DNA appears to be more or less random with respect
to cellular DNA sequences, showing a mild preference not only for certain regions of
the chromosome, such as those that are transcriptionally active (18, 19) or those
associated with other features, such as DNAse hypersensitivity (20-22) but also for
certain specific sites within the host DNA of unknown structure (23). Once
integration of the viral genome is complete, the provirus is maintained in the cell just
like any cellular gene.
The cis-elements required for initiation, termination and modulation of the retroviral
transcription reside within the LTRs, whereas, the factors necessary for transcription
and translation are provided by the host cell. Transcription of the provirus results in
production of copies of viral genomic RNA, which can either be translated to produce
viral proteins or packaged by viral proteins to form new core particles (10). Two
types of viral messenger RNAs from the provirus are produced in infected cells. The
major spliced RNA is the sub-genomic RNA for the env proteins, ensuring adequate
levels to populate the unit membrane that surrounds the viral particle. Splicing also
results in removal of the viral packaging signal preventing encapsidation of the sub-
genomic RNA into virions. The un spliced genomic RNAs that do carry the packaging
signal become assembled into viral cores that bud through the plasma membrane of
infected cells.
The ability of a retrovirus to propagate in a given cell type is mainly determined by
the tissue specificity of the enhancer sequences in the LTR, and by the viral envelope
gene (24).
1.1.3 Endogenous retroviruses
The ability of retroviruses to integrate in the host cell genome has provided an
opportunity for these viruses to colonise during the evolution of the genome of
virtually all vertebrates. Retroviruses usually infect somatic cells, and consequently
most retroviral genes integrated into genomic DNA are not passed on to host progeny.
However, some classes of retrovirus occasionally infect germ line cells and in this
way, the integrated DNA provirus can be passed on to the next generation without
undergoing further viral replication. Offspring that develop from infected germ cells
will carry the integrated retrovirus as part of their genomes, and these retroviruses can
therefore be subsequently transmitted vertically from one host generation to the next
in Mendelian fashion. Retroviruses that enter the germline in this way are referred to
as endogenous retroviruses (ERVs) to distinguish them from horizontally transmitted,
"exogenous" retroviruses (25). The great majority of these ERVs are truncated and
inactivated by point mutations and deletions accumulated in the course of evolution,
however some ERVs are transcriptionally active, and both detrimental and beneficial
effects to the host have been suggested and more rarely, confirmed (26-30). In
general, ERVs are proposed to contribute to shaping the genome of the host and
influencing gene expression by promoting chromosomal rearrangements through
homologous recombination between distant loci (31) and by directly influencing gene
expression (32).
Several exogenous retroviruses such as; feline leukaemia virus in cats, mouse
mammary tumour virus (MMTV) and murine leukaemia viruses (MuLVs) in mice,
and avian leukaemia viruses in chickens have endogenous counterparts in the germ
line of their host species (28). The only retroviral genera for which clear endogenous
counterparts have not been identified are lentiviruses and deltaretroviruses (33).
The draft human genome sequence shows that 8% of human DNA sequences
represent human endogenous retrovirus (HERV) and related retrotransposons (34).
1.2 Retroviral Oncogenesis
Retroviruses have been valuable tools in the study of oncogenesis. They were first
associated with malignant diseases in animals approximately one century ago. In
1908 Ellerman and Bang observed that avian erythroleukaemia could be transmitted
by cell-free filtrates and were caused by a virus (1). Years later, Rous reported that
extracts from certain poultry sarcomas were infectious and could induce these
tumours when inoculated into healthy poultry (2). These two pioneering events
marked the beginning of oncoretrovirus research. Since the 1960s retroviruses have
been shown to cause leukaemia, lymphoma, and other forms of cancer in a wide
variety of vertebrate animals.
1.2.1 Retroviral transduction of cellular genes
During replication, retroviruses can acquire cellular sequences through aberrant
recombination events. Such recombinant retroviruses (Figure 1-4) are usually
defective. They have lost parts of the viral genome and require the aid of intact
retroviruses via trans-complementation for replication or integration. If the acquired
cellular gene is a proto-oncogene (a gene involved in such functions as cellular
homeostasis, growth control, and signalling cascades), its overexpression under the
control of strong viral promoters can lead to malignant transformation. The
incorporation of a proto-oncogene within the retroviral genome can occur when
transcription from the 5'LTR reads through the packaging signal of viral RNA at the
beginning of gag and onwards, often spliced, into cellular sequences.
Such viruses with incorporated viral oncogenes (v-one) derived from cellular proto-
oncogenes (c-one) have been called 'acute transforming viruses' because they usually
induce polyc1onal tumours rapidly after a short incubation period (2-3 weeks) and are
capable of transforming cells in culture.
Transduction of an oncogene has not been observed in human cancer, however it has
proven to be very useful in experimental settings for studying the action of oncogenes
in cancer (12).
1.2.2 Retroviral cis-insertional activation of cellular genes
Insertion of a retrovirus into or nearby a cellular proto-onocogene may lead to
activation of this gene by promoters or enhancer elements in the viral LTR. Simple
retroviruses typically act oncogenically by cis-activation of host genes. In the large
majority of B-cell lymphomas in ALV-infected chickens, for example, the cellular
proto-oncogene c-mye has been found to be affected by this mechanism of provirus
integration. Hayward and colleagues demonstrated that the c-mye proto-oncogene
5' LTR Ltgag v-onc Lt env LTR 3'
Figure 1-4. Retroviral transformation by transduction of an oncogene.
Transduction of an oncogene in which the provirus contains a viral oncogene (v-onc)
originally derived from the host cell. Parts of the viral genome are deleted or
truncated, and the virus relies on help from intact viruses for replication or integration
(coinfection with a helper virus).
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could be activated by retroviral insertion (3S). Since then many genes have been
identified as common retroviral insertion sites in cancer cells (reviewed in (24, 36)).
Oncogenic retroviruses that lack viral oncogenes (e.g. ALV, MMTV, FeLV) have
been called 'slow-transforming retroviruses' because they usually induce mono- or
oligo- clonal tumours after a latent period of 3-12 months, and are usually unable to
transform cells in vitro (24). Instead, the predominant mechanism by which they
nduce tumours is a process called insertional mutagenesis.
Insertion of a provirus within or adjacent to cellular proto-oncogenes alters the normal
organisation of the locus and also introduces strong promoter and enhancer regions
into the locus. The major ways by which a proto-oncogene becomes activated by the
insertion of a retrovirus are referred to as promoter insertion and enhancer activation.
Viral promoter insertion
Gene activation by promoter insertion requires the integration of a provirus upstream
of the gene in the same transcriptional orientation. Transcription of the downstream
endogenous gene is initiated from the viral promoter sequences in either the 5' or the
3'LTR, thereby replacing the function of the normal promoter. Promoter insertions
where the transcript is initiated from the 5'LTR usually yield fusion transcripts as a
result of transcript splicing using the splice donor (SD) or cryptic SD sites within the
viral DNA toward the second exon or, in case a cryptic splice acceptor is present, the
first exon of the endogenous gene (37, 38) (Figure l-Sb). Examples of 5'LTR
insertion are the AVL integrations in the c-erbBIEGF-receptor gene in chicken-
erythroleukaemias (39, 40), Mo-MuLV integrations in c-myb found in mouse
lymphosarcomas (41, 42) and Mo-MuLV integrations activating the c-lck gene in
some murine T cell lymphomas (37). 3'LTR promoter insertion is similar to 5'
promotion except that transcription is initiated at the 3' promoter of the LTR (Figure
I-Sc). The most studied example represents AVL proviral insertions occurring
predominantly in the first intron of the c-myc gene in avian bursal lymphomas (20,43,
44). In many tumours carrying promoter insertions the 5'LTR is deleted suggesting
that the removal of the 5'LTR promotes the transcription of the endogenous gene by
the 3'LTR (4S).
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Viral enhancer activation
Proviral insertions can also stimulate transcription of genes from their authentic
promoters through the activity of the enhancers s,equences contained within the LTRs.
Enhancer insertion involves integration of a provirus either at the 5' end of a gene in
the inverse transcriptional orientation (Figure I-5d), or at the 3' end in the same
transcriptional orientation (Figure I-Se). Typical examples are the activation of c-
myc by ALVin some bursal lymphomas (46), the activation of int genes by MMTV in
murine mammary carcinomas (47, 48), and the activation of pun-Y and c-myc in
MuL V-induced T-cell lymphomas (49). The group of 3' enhancer insertions also
includes proviral insertions within the 3' untranslated region of the gene, in the same
transcriptional orientation, in which the mRNA transcription is terminated at the poly
(A), polyadenylation site present in the 5'LTR (Figure 1-5f). The result of these
insertions is often the stabilisation of mRNA transcripts by the removal of sequences
in the 3' untranslated region, which contain negative regulatory elements, such as
mRNA-destabilising motifs. Examples include pim-l and pim-2 in MuLV -induced T-
cell lymphomas (50-52), N-myc in MuLV-induced T-cell lymphomas (53).
Viral enhancer activation is the most frequent mechanism of gene activation by
insertional mutagenesis, due to the fact that activation by enhancement allows more
flexibility with respect to both proviral orientation, and the distance between proviral
integration and the target gene.
Truncation of cellular gene product
The integration of a provirus into the coding sequence of a gene can have effects on
the resulting protein, inactivating or mutating it in such a way that an aberrant gene
product is produced. Transcript truncation by proviral insertions may also produce a
functional protein with oncogenic properties by deletion of either NH2- or COOH-
terminal domains (54). This may happen in combination with enhancer or promoter
activation. Protein truncation from proviral insertions often occurs by transcription
termination using the viral polyadenylation signal. If the promoter insertion occurs in
the first intron of a gene (Figure 1-5g), transcripts arising from the endogenous
promoter may be truncated by the viral 'poly-A, while the provirus promotes
transcription of the downstream exons. If the start 'codon is located in the second
exon as is the case for c-myc or c-fms a full-length protein will be produced (55, 56),
13
Figurel-S. Mechanisms of retroviral insertional activation
TI Provirus TI Target (c-one) gene
5' LTR gag pol env 3' LTR
SA
Figure I-Sa. Proviral enhancer and promoter sequences in the U3 region of the LTR,
and the poly(A) signal in R are utilised to deregulate endogenous genes. Structural
features of a provirus, and an endogenous gene (c-onc), which in this case consists of
3 coding exons (black boxes) as well as 5' and 3' untranslated regions (open boxes).
Abreviations: TI, transcriptional initiation; pA, polyadenylation signal; SD, splice
donor; SA, splice acceptor.
Activation by promoter insertion
5'LTR promotion
SD Cryptic SD
5' LTR gag pol env 3' LTR
SA
- I
- II
- III
Figure I-Sb. Promoter insertion in which the 5'LTR promoter is used to drive
transcription of a downstream endogenous gene. In this case, the transcription results
in the formation of fusion transcripts containing both viral and cellular sequences, due
to a read through at the 3' LTR polyadenylation site and subsequent splicing using the
subgenomic mRNA splice donor (I), a cryptic splice donor (II), or a cryptic splice
acceptor site (III). The black arrow indicates the transcriptional orientation.
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3'LTR promotion
5' LTR gag pol env 3' LTR
~-
Figure I-Sc. Promoter insertion in which the 3' LTR promoter is used to drive
transcription of a downstream endogenous gene. The black arrow indicates the
transcriptional orientation.
Activation by enhancer insertion
3' LTR env pol gag 5' LTR
Figure I-Sd. Provirus integrated at the 5' end of an endogenous gene in the reverse
transcriptional orientation. The black arrows indicate the transcriptional orientation.
5' LTR gag pol env 3' LTR
~-
Figure I-Se. Provirus integrated at the 3' end of an endogenous gene in the same
transcriptional orientation. The black arrow indicates the transcriptional orientation.
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5' LTR gag pol env 3' LTR
~.::JAA ...AA
Figure I-Sf. Provirus integrated within the 3' untranslated region of the endogenous
gene and in the same transcriptional orientation. The transcript is cleaved at the
polyadenylation site of the 5' LTR. The black arrow indicates the transcriptional
orientation.
Protein truncation by transcription termination at viral poly-A site
SD Cryptic SD
5' LTR gag pol env 3' LTR
• IAA...AA II V- I
II-
- III
Figure I-Sg. Protein truncation originated from proviral insertions within a gene via
termination of the endogenous transcript using the viral poly-A, however the provirus
promotes transcription of the downstream exons (I). Protein truncation originated by
promoter insertion in which the 5'LTR promoter is used and transcription results in
the formation of fusion transcripts, due to a read through at the 3' LTR
polyadenylation site and subsequent splicing using the subgenomic mRNA splice
donor (II),. or cryptic splice donor (III) sites. The black arrow indicates the
transcriptional orientation.
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or a truncated protein using a alternative start codon may be expressed as occurs for c-
myb insertions (57). Another example of protein truncation by transcription
termination is the insertion of FIV provirus bet~een exons 3 and 4 of the LVI-l gene
in a feline B-celllymphoma (Q254). Here, the truncated trancript contains 3'LTR
and host LVI-l intron 3 sequences (58). Truncation of the encoded protein can also
occur by proviral insertions within a gene in the opposite transcriptional orientation
due to the presence of a cryptic poly-A site in the virus (Figure 1-5h). An example is
the insertion of MMTV into int-6 gene in murine mammary tumours (59).
Somatic and clonal integration of retroviruses in the genome can enhance proto-
oncogene expression or inactivate tumour suppressor genes. A cell that has such
integrations acquires a growth advantage, and is then clonally selected to grow and
may result in tumour formation. In these cases, the proviral DNA can be utilized as a
molecular tag to identify the flanking sequences of the host genome. This technique
has been referred to as retroviral tagging (60). The basic fundamentals of the gene
tagging strategy are that insertion is essentially a random process and that the
occurrence of multiple insertions within a narrow genomic domain in independently
derived tumours provides evidence of a selective advantage to cells bearing these
insertions (61).
High throughput cloning of retroviral integration sites has been accomplished by
introducing peR techniques, which have replaced the cloning of the proviral insertion
sites by generation of phage libraries of the tumour DNA, and by using the mouse
genome database (38, 62-64).
1.2.3 Retroviral trans-activation of cellular genes
Some complex retroviruses encode viral proteins (Le. not acquired through
recombination with cellular sequences) that can act oncogenic ally. Examples are the
viruses of the deltaretrovirus genera and possibly also the simple retroviruses JSRV
and ENTV (65). Deltaretroviruses such as BLV and HTLV encode a protein Tax that
acts as a transactivator of transcription (66, 67) (Figure 1-6). It primarily activates
and regulates the transcription of viral genes by activation of the viral LTR, but also
alters the transcription pattern of cellular genes, including proto-oncogenes. This can
lead to a loss of growth control and malignant transformation. A number of host
genes are up-regulated (and some down-regulated) by Tax, and its effect on the
17
Protein truncation by transcription termination at viral cryptic poly-A site
3' LTR env
•
pol gag 5' LTR
• I IAA ...AA
Figure 1-5h. Protein truncation originated from proviral insertions within a gene in
the opposite transcriptional orientation by the presence of a cryptic poly-A site in the
virus.
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LTR pol env tax
Figure 1-6. Retroviral trans-activation of an oncogene. The provirus encodes viral
proteins (eg. HTLV-Tax) that are not acquired through recombination with cellular
sequences and can activate not only the viral LTR, but also a set of cellular genes,
including proto-oncogenes. Exons of the proto-oncogene are indicated by numbered
boxes.
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overall cellular transcriptome is being elucidated using DNA arrays (68).
1.2.4 Insertional inactivation of cellular genes
Retroviral integration can also inactivate the expression of cellular genes by
interruption and/or deletion of host-cell gene sequences and production of aberrant
mRNAs. However, this is less likely to lead to cancer because it generally requires
the inactivation of both alleles (either by two integrations or by one integration
followed by transcriptional silencing or by loss of the second allele) in order to detect
a phenotype for most genes. Examples of the oncogenic effects of retroviral insertion
through inactivation of the gene activity were seen in leukaemogenesis induced by the
Friend virus complex that is composed of the Friend murine leukaemia virus (F-
MuLV) and by the Friend spleen focus-forming virus (SFFV) (Table 1-1).
Erythroleukaemic cell lines derived from spleens from mice infected with F-MuL V
were shown to have integrated proviruses into the p53 tumour suppressor gene with
resultant loss of gene expression (69-71). It initially seems unlikely that gene
inactivation would arise by two insertional events into both alleles, but independent
insertional mutations that knock out both alleles of the p53 gene were reported for one
tumour cell line (72). In some tumours, proviral integration is associated with
deletions of p53-coding sequences, while in others, integration into intronic sequences
results in the synthesis of aberrant p53 mRNAs. Therefore, p53 gene is inactivated in
almost all erythroleukaemia cell lines induced 'by polycythemia- or anaemia-inducing
strains of Friend virus (FV -P/FV -A) or F-MuL V strain due to retroviral insertions,
deletions, and point mutations (reviewed in (73, 74». Moreover, in one
erythroleukaemia cell line, CB3, induced by both FV-P and F-MuL V strains of Friend
virus the Fli-2 (Friend leukaemia integration 2) locus was identified as a common site
for retroviral integration in which the proviral insertion was associated with the loss
of the second allele, resulting in the inactivation of the erythroid cell- and
megakarocyte-specific gene p45Nfe2 (75). The transcription factor Nfe2 (nuclear
factor erythroid 2) plays a critical role in the regulation of erythroid cell specific gene
expression (76). Its large subunit, p45Nfe2 has been found to be tissue specific and
with expression restricted to erythroid cells, megakaryocytes, and mast cells (77).
In a similar way, the Neurofibromatosis-I (NFl) tumour suppressor gene, which
encodes the neurofibromin GTP-ase activating protein, has also been shown to be
20
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inactivated by provirus integration of MuLV and a murine AIDS virus-related
endogenous virus at a common viral integration site, Evi.~2(ecotropic viral integration
site 2) in myeloid leukaemia of BXH-2 mice (78, 79). This integration resulted in the
production of truncated Nf-l transcripts and no stable, full length neurofibromin,
which is involved in the development of neurofibrosarcomas and myeloid leukaemia
(80). As with p53, inactivation of the second allele can occur by integration of a
second provirus or by a non viral mechanism.
A recent study identified NFATc3 (nuclear factor of activated T cell 3) as tumour
suppressor for the development of murine T-cell lymphoma induced by the murine
lymphomagenic retrovirus SL3-3. Furthermore, only one allele of the Nfatc3 gene is
targeted by T-cell lymphomagenic retrovirus SL3-3 MuL V so the repression of
NFATc3 expression can be associated with additional transcription repression effects
at either the provirus targeted or untargeted allele (81).
1.3 Cellular genes involved in cancer
Cancer is a genetic disease due in part to the accumulation of mutations, by which the
tumour cells become insensitive to controls by the local cellular environment and the
whole organism. An attempt to summarise the various traits of cancerous cells has
been made by Hanahan and Weinberg. They suggest that most, if not all cancers
acquire the same set of functional capabilities during their development, namely self
sufficiency in growth signals, insensitivity' to growth inhibitory signals, tissue
invasion and metastasis, limitless replicative potential, sustained angiogenesis, and
evasion of programmed cell death (apoptosis) (85). This model predicts that each
individual tumour will exhibit as many mutation events, in as many genes, as are
necessary to acquire these six traits. Tumour growth by clonal expansion of a single
somatic cell is generally a slow and multistep process, in which an estimated three to
six independent genetic steps are necessary to complete tumorigenesis, and acquire
these six characterisitics (reviewed in (86». Therefore, the risk of cancer
development depends not only on mutations initiating tumorigenesis, but also on
subsequent mutations driving tumour progression (87). Unlike diseases such as cystic
fibrosis or muscular dystrophy where mutations in one gene can cause disease, no
single gene defect is sufficient to cause cancer. So, an invasive cancer develops only
When several genes are defective (88). Mutations occur randomly throughout the
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genome; among these are mutations in genes that function in normal cells to maintain
the stability of the genome and to guarantee that it is faithfully copied and transmitted
to progeny during each cell division (89).
It has been established that environmental factors, such as tobacco, diet, sunlight,
radiation, pollution, and stress can play an important role in the etiology of cancer
(reviewed in (90)). In addition, oncogenic viruses have been related to human as well
as animal cancers. Examples of human cancer viruses include the papilloma viruses
in cervical cancers (91) and the Epstein-Barr virus in Burkitt lymphoma, in
nasopharyngeal cancer (92) and in B cell lymphomas (reviewed in (93)). Moreover, it
has been suggested that multiple, low penetrance genes segregating in the human
population confer cancer susceptibility and resistance to environmental carcinogens
(94, 95). Therefore, these low penetrance genes determine cancer predisposition by
affecting processes such as carcinogen metabolism, DNA repair efficiency,
inflammation, and the immune response to provide relative degrees of tumour
resistance (96)
Although environmental and other non-genetic factors have roles in many stages of
tumorigenesis, it is widely accepted that cancer-susceptibility genes playa significant
role. Most of these genes normally function to restrict cancer development and are
thereby defined as tumour suppressor genes (TSGs) (97, 98).
1.3.1 Oncogenes
Oncogenes are genes that undergo gain-of-function alterations in cancer cells. The
study of oncogenes began with experiments on RSV, one of the acutely transforming
retroviruses (reviewed in (99)). These viruses were shown to possess, in addition to
their normal genetic content. extraneous DNA sequences, which were responsible for
acute oncogenesis. In fact, RSV is unique in having all genes necessary for viral
replication (gag, pol, env) in addition to the oncogenic v-src; all other acute
transforming retroviruses lack one or more of the structural genes, rendering them
replication incompetent. The homologous cellular genes, known as c-one' s are called
proto-oncogenes because they have served as targets for genetic transduction by
retroviruses. Proto-oncogenes were identified initially by the homology of their
nucleotide sequences to retroviral oncogenes (reviewed in (lOO)). Some retroviral
oncogenes have undergone mutation in their coding regions, altering the biochemical
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properties of the gene product. Others, however, harbour no detectable alterations
and are oncogenic by virtue of the fact that they are under the transcriptional control
of the constitutively active viral LTRs. Furthermore, oncogenes are generally
considered as dominant genes because an activating somatic mutation in one allele of
an oncogene is sufficient to confer a selective growth advantage on the cell.
The high degree of evolutionary conservation of the proto-oncogenes across all
multicellular organisms points to basic functions that these genes might have for the
cell. Proto-oncogenes generally encode a class of proteins that are selectively active
only when the proper regulatory signals allow them to be activated (Table 1-2). Their
products are elements of cell cycle positive control pathways, including growth-factor
receptors, signal transduction proteins, and transcriptional regulators. Other proto-
oncogene products function to negatively regulate apoptotic pathways. Disregulation
of these gene products will therefore result in insensitivity to antigrowth signals and
evasion of apoptosis, two of the hallmarks of cancer mentioned previously (85).
There are in fact a number of mechanisms where by proto-oncogenes can be activated
aberrantly within normal cells, resulting in transformation. Such include retroviral
transduction or integration as discussed previously, genetic modification such as point
mutation or insertion mutation, gene amplification, chromosomal rearrangement or
epigenetic modification leading to over-expression.
The products of the proto-oncogenes can act in a number of different ways, which
include phosphorylation of proteins at serine, threonine, or tyrosine residues and in
this case the role of the proto-oncogene product can be induction of phosphorylation
(as with some growth factors such as PDGF (c-sis gene product) (101», or self-
catalysis (as with the receptors for some growth factors such as c-erhB gene product
(102»; transmission of signals by GTP-binding proteins, as exemplified by the
GTPases (products of the Ras genes) (103); and the control of transcription from
DNA as in the case of the transcription factors such as Myc gene (104). Even with
differences in their normal roles, these genes all contribute to unregulated cell
division if they are present in a mutant (oncogenic) form. The mutant oncoproteins
are uncoupled from the regulatory pathway that should be controlling their activation,
leading to continuous unregulated expression or function of the oncoproteins.
The isolation of the majority of proto-oncogenes to date has been done not only by
molecular cloning of genes, which have been activated by proviral insertion, but also
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by identification of genes which have been transduced by a retrovirus (reviewed in
(24)).
1.3.2 Tumour suppressor genes: History and genetic characterisation
Failure of growth inhibition is one of the hallmarks of cancer (85). The proteins
responsible for arresting cellular proliferation are the products of TSGs. The study of
TSGs began with experiments involving somatic cell fusion (110). Harris and
colleagues observed that the growth of murine cancer cells could be suppressed by
fusion with non-tumourigenic cells. Such somatic cell hybrids tended to revert to the
malignant phenotype over time; an event that coincided with the loss of chromosomes
from the cell. Subsequent experiments using chromosome segregation showed that
the transfer of single chromosome carrying a wild type gene suppresses tumour
formation of malignant cells. Together, these studies pointed to the existence of
genes that could suppress tumourigenicity (110, 111). Indeed, these observations
supported the view that malignancy was a recessive trait, and that a particular
chromosome or a small number of genes might be responsible for the tumour
suppression.
At the same time, Knudson was conducting epidemiological investigations into the
childhood cancer retinoblastoma (112) and proposed that two hits or mutagenic events
were necessary for tumour development (98, 113-116). In inherited retinoblastoma,
he hypothesised that susceptibility was due to a mutation present in the germ line, but
that neoplastic disease required a second mutation which could occur early in life,
leading to strong penetrance and the characteristic dominant autosomal inheritance
pattern. By contrast, the sporadic form of retinoblastoma, which requires two de novo
mutational events to inactivate both alleles, is much rarer.
However, this two-hit paradigm of TSG mutation in which the inactivation of both
TSG alleles was required to develop a cancer phenotype may not be universal. There
is now considerable evidence suggesting that loss of only one allele of a TSG might
contribute to the tumourigenesis, a process known as haploinsufficiency. This has
been shown in mice carrying single, inactivated alleles of the genes encoding p27KipJ
(117), p53 (118), TGF-pl (119), and Dmpl (cyc1in D-binding Myb-like protein)
(120). In each case, the genetically deficient mice are predisposed to tumour
development, but the resulting tumours frequently retain a functional wild-type allele.
Moreover, the p27KipJ and Dmpl mutant mice show at least slightly more severe
tumour susceptibility phenotypes in the homozygous state than in the heterozygous
state for most tumours types. These observations have led to the suggestion that
haploinsufficiency effects can be strong or weak (121, 122). Whereas a strongly
haploinsufficient effect results in tumour formation in the absence of loss of the wild
type allele, in a weaker haploinsufficient effect loss of the wild type allele is required
to complete tumourigenesis, a process known as loss of heterozygosity (LOH). LOH
can occur by loss of the whole chromosome carrying the wild type allele, by mitotic
recombination, large or small chromosomal deletions, or point mutation of the wild
type allele (123).
In addition to family linkage analysis, as implied by the two hit model of Knudson, a
search for consistent LOH, which occurs in particular tumour types (and frequently in
familial cancers) is used as a tool for narrowing the region of interest by deletion
mapping, and finally for searching the intact homologous chromosomal segment for
mutated genes whose functions can be demonstrated to protect against cancer
development. However, this approach will exclude identification of genes that either
require two functional copies to adequately suppress tumour cell growth and thus will
have only one inactivated allele in tumours, or when the second allele of the target
gene is transcriptionally silenced through promoter methylation of its cytosine
phosphate guanosine rich regions (CpG islands). Indeed, there are many regions of
LOH identified in human cancer for which no TSG has been identified. One such site
is the long arm of human chromosome 7 where the DMPl resides (124). In fact, it is
the linkage method and the occasionally observed cytogenetic changes that have been
most fruitful in identifying TSGs such as WTl (Wilms Tumour), BRCA-l and -2, APC
(Adenomatous Polyposis Coli) NFl, VHL (von Hippel-Lindau), and BLM (Bloom
mutated).
Functional classification of tumour suppressor genes
According to the functional classification proposed by Kinzler and Vogel stein (97,
98), the TSGs genes belong to one of the three classes: gatekeepers, caretakers and
landscapers (Table 1-3). Defects in gatekeeper genes lead to abnormal cellular
proliferation, differentiation, and apoptosis. Caretakers, by contrast, suppress
tumourigenesis indirectly (125, 126). They may function in maintaining the genomic
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integrity of the cell and regulate DNA repair mechanisms or chromosome segregation
(126). Caretaker defects lead to genetic instabilities that contribute to the
accumulation of mutations in other genes that directly affect cell proliferation and
survival (127). An increasing number of TSGs are included in this category. The two
highly penetrant breast cancer-associated genes, BRCA-J and BRCA-2 (hereditary
breast cancer) (128) have been placed in this class of TSGs. There are fewer
examples of landscapers which are defined as genes that regulate the stromal
environment (129). The landscaper genes may contribute to the viability and
metastatic potential of tumour cells by, for example, mediating paracrine growth
stimulation. In fact, the 'caretaker and gatekeeper' model proposed by Kinzler and
Vogelstein suggest that TSGs of both types required two inactivating mutation events.
However, their model did not predict any increased genetic instability resulting from
loss of a single allele of a caretaker gene (130).
Two of the most frequent targets of mutation during tumourigenesis are the
gatekeepers:' retinoblastoma (RB) TSG and p53 TSG (reviewed in (131, 132)). Loss
of RB protein results in deregulated cell proliferation and apoptosis, whereas loss of
p53 desensitises cells to checkpoint signals, including apoptosis. Therefore, to
recognize their role in the development of most human cancer, it is important to
understand the cell cycle biology. The cell cycling process is carefully regulated and
responds to the specific needs of a certain tissue or cell type. In normal, physiological
conditions there is a balance between cell death (programmed cell death or apoptosis)
and proliferation (cell division) producing a steady state (133). Conventionally, the
cell cycle has been divided into four phases: S phase, DNA replication or synthesis;
M phase, mitosis; Gland G2, gap phases when the cell is metabolically active and
preparing for DNA replication and mitosis, respectively. Hartwell and colleagues
identified a number of genes whose products are required for the progression of the
cell cycle (reviewed in (134)). These proteins are now known as the cyclins and the
cyclin dependent kinases (cdks). Although initially identified and characterised in the
yeast Saccharomyces cerevisia, these molecules are remarkably well conserved and
appear to function similarly in all eukaryote organisms.
Retinoblastoma TSG
The Rb protein was the first TSG product to be recognised (135). Although germline
mutations in Rb are associated with rare cancers such as childhood retinoblastomas
and osteosarcomas (136), somatic mutations in RB also contribute to the development
of common human tumours, such as lung and bladder carcinomas. Rh is a member of
a gene family that includes pi07 and pi30, which collectively co-repress the
transcription of genes that regulate cell cycle progression, apoptosis, and
differentiation. The Rb family proteins exert much of their growth suppressive
control during the first gap phase (G1) of the cell cycle and entry into DNA synthesis
(S phase). In vivo phosphorylation of Rb is cell cycle dependent. The
hypophosphorylated form is present in GO/G1 where it binds and sequesters proteins
such as E2F. Phosphorylation in late G 1 allows E2F to be released and activate the
transcription of genes required for DNA synthesis (S phase) (137 -139).
Phosphorylation of Rb is mediated by cdks in complex with their cognate cyclins:
cyclin D (D 1, D2 and 03 )-cdk4/6 and cyclin E-cdk2 (132). Inhibitors of these kinase
complexes include the INK4 proteins (p16INK4a,pI5INK4b,p18INK4c,pI9INK4d)which
block the ability of cyclin D-cdk4/6 to phosphorylate and regulate Rb's growth
suppressi ve functions (140-143).
Functional inactivation of the RB protein in the absence of an RB mutation can also
lead to tumourigenesis indirectly through alterations in upstream regulatory proteins
such as cyclin 01 overexpression in breast carcinoma, head and neck tumours, and
mantle cell lymphomas; cdk4 overexpression in glioblastomas; and p16INK4aloss in
melanoma, pancreatic carcinoma and T cell lymphoma (144). Viral oncoproteins
from DNA tumour viruses, such as adenovirus EIA, simian vacuolating virus 40 large
tumour (SV40 T) antigen and the E7 proteins of human papillomaviruses interact with
the hypophosphorylated form of Rb and interrupt its function, thus facilitating viral
replication as well as promoting tumorigenesis if replication fails.
P53TSG
Another well-known TSG is the p53 gene, that was first isolated in
immunoprecipitates of large tumour antigen (large T) from SV40-transformed rodent
cells (145, 146). It was originally thought to be an oncogene, due the high levels of
expression of the p53 protein (so called because o~ its molecular weight of 53 kDa) in
transformed mouse cells, but not in normal mouse cells (147). In fact, reintroduction
of wt p53 into p53 deficient cells results in growth inhibition; with cells exhibiting
growth arrest at or near the G liS phase transition. Therefore, the wt p53 acts
negatively to block transformation, (148), so it functions as a classical TSG.
P53 TSG is mutated in more than 50% of human cancers, and mutation in other genes
that affect p53 function occur in many tumours that retain a normal p53 gene (144).
Mutations of p53 underlie the familial Li-Fraumeni cancer susceptibility syndrome
(149), which predisposes to a range of tumour types including breast cancer,
sarcomas, brain tumours and leukaemia. Unlike RB, mutation at one allele may be
sufficient to give rise to the altered cell phenotype (150). Moreover, p53 mutations
may result in genomic instability, which then permits accumulation of the multiple
mutations required for tumour development (127).
The p53 phosphoprotein is normally unstable and rapidly degraded. However,
cellular stress, including irradiation, hypoxia, drug-induced genotoxic damage, and
even oncogene activation are responsible for the activation and stabilization of p53
(151). Then, the activated p53 restricts cellular growth by inducing senescence, cell
cycle arrest (at Gland/or G2 phase) to allow repair to take place or apoptosis if the
damage is excessive (152). For these reasons, p53 has been called as 'guardian of the
genome' (153). The p53 protein functions as a transcription factor and a number of
target genes containing p53-binding sites in their promoters have been identified, one
of the most important of which is the WAF} gene product, p21 (154) also known as
Cdk-interacting protein 1 (Cipl) (155). The p21 protein binds to and inhibits Gl
cyclin-cdk complex kinase activity, preventing the phosphorylation of cdk substrates
and thereby blocking the transition from G 1 to S phase in the cell cycle (154, 155).
Therefore, the stabilisation of p53 by DNA damage results in P21WAFIICIPI induction
and arrest in G 1 (156).
A number of negative regulators of p53 have been identified, including the MDM2
(157, 158) which functions as a ubiquitin E3 ligase, targeting p53 for ubiquitination
and degradation by the proteasome. Indeed, MDM2 is the key cellular regulator of
p53 (159). However, the expression of MDM2 is itself induced by p53, for instance
following ultraviolet (UV) irradiation (160), which may serve to autoregulate p53
activity in normal cells (161). Therefore, p53 can transactivate the Mdm2 gene, thus
establishing a negative feedback loop that maintains the p53 protein at low levels in
nonstressed cells (159).
Oncogenic signals activate p53 by induction of the ARF (alternative reading frame)
tumour suppressor (human p14ARF and murine pI9ARF) encoded by an alternative
Open reading frame in the p161NK4alocus, which inhibits the E3 ligase function of
MDM2 (162, 163). However, DNA damage signals activate p53 via ARF-
independent pathways involving the regulatory kinases ATM (ataxia telangiectasia
mutated), CHK2, and ATR (ATM and Rad3-related). "In fact, DNA damage induces
phosphorylation of p53 at serine 15 by ATM and ATR and at serine 20 by CHK2,
resulting in disruption of the p53-MDM2 complex (164).
Examples of other genes that function as TSGs include the phosphatase and tensin
homologue (PTEN), VHL, and cadherins. Each of these genes is associated with well-
defined clinical syndromes in humans; in the case of PTEN (mapped to human
chromosome lOq23) deletion is associated with a high frequency of endometrial
carcinomas and glioblastomas (165). PTEN activity causes cell cycle arrest and
apoptosis as well as inhibition of cell mobility, so loss of function of this gene alone
confers three of the hallmarks of cancer (165, 166).
With VHL gene (chromosome 3p), germline mutations are associated with hereditary
renal cancers, phaeochromocytomas, haemangioblastomas of the central nervous
system, retinal angiomas and renal cysts. The main substrate for VHL gene product is
hypoxia inducible transcription factor 1 (HIF-1), which itself upregulates a number of
pathways associated with increased angiogenesis. Lack of VHL activity prevents
degradation of HIF-l and is associated with increased levels of angiogenic growth
factors (167).
Loss of cadherin (particularly E-cadherin located on chromosome 16q) is associated
with increased ability to invade tissue and metastasise. This is because the caderin
family of glycoproteins act as 'glues' between epithelial cells, so loss of cadherin
allows cells to disaggregate and move around more easily. Loss of cadherin function
is associated with many types of cancers, including those that arise in the oesophagus,
colon, breast, ovary and prostate (168).
The losses of function of the TSGs described above are due to a structural change or
germline mutation of the genes involved, however this is not the only mechanism by
which TSG function may be lost. In addition, TSGs may be silenced by epigenetic
change involving hypermethylation of promoter sequences without a change in DNA
base sequence (169). Hypermethylation can be maintained through rounds of cell
division, and examples of this phenomenon include BRCA-I in breast cancer and VHL
in renal cell arcinomas (170). Recent data demonstrating that genomic
hypermethylation causes chromosomal instability and induces tumours in mice
strengthens the evidence that epigenetic change contributes directly to tumour
development (171).
1.4 LVI-l (WDR76) locus
The LV/-i tlentivirus integration-F) locus named by the Human Genome Organisation
(HUGO) at http://www.hugo-internationaI.org as WDR76, was identified as a
target for proviral insertional mutagenesis in a case of a pre-B cell lymphoma in a cat
infected with FlY (58, 172).
Lymphoma is the most common malignancy in cats and most cases are induced by
FeLV, especially in younger cats, but lymphoma can occur independently of FeLV
infection (173, 174). Many epidemiological studies have described lympho-
proliferative malignancies in association with FlY (175-182), and an increased risk of
malignant lymphoma (lymphosarcoma) in FlV -infected cats (183-185).
The feline lentivirus, FIV, is a significant feline pathogen, with an overall infection
prevalence of approximately 11% in cats worldwide (186, 187). FIV is a T-
lymphotropic virus and studies have been centred on the alteration of T-cell subsets,
especially the T helper cells (CD4) (188). However, despite these defects in T-cell
function, infection induces a marked activation and expansion of B cells. In fact, with
increased time post infection, the major reservoir for proviral DNA appears to be
CD21+ cells (B cells) and CD8+ T cells (189, 190). In the early stages of the FlY
infection there is a generalized lymphadenopathy characterized by hyperplasia of B-
cell areas with prominent and irregular expansion of lymphoid follicles (191) and a
persistent polyclonal activation of B cells with the production of antibodies to a
variety of non-viral antigens including self-antigens (192) similar to that described in
HIV-infected patients (193,194).
The clinical course of FlY infection parallels that seen in HIY infection. At 4-6
weeks after experimental infection with FlY, cats develop an acute clinical syndrome
similar to that seen in HIV -1 infection, including mild pyrexia and lymphadenopathy
(195) that usually disappears after 2-3 months (186). This is followed by a long
asymptomatic period of latent infection lasting at least 3-5 years (196-198)) in which
the CD4+: CD8+ T cell ratio declines because a gradual decrease in CD4+ cells (188,
199, 200) and in some cases, an increase in CD8+ cells as well (188, 199, 201). In
naturally infected cats, the asymptomatic period is followed by the development of a
variety of disorders associated with a progressive immune dysfunction which
eventually becomes manifest clinically as feline" acquired immune deficiency
syndrome (FAIDS) (202-204).
The majority of FIV associated lymphomas have been high-grade B cell lineage (178,
205, 206). The characteristics of FIV-associated lymphomas, thus, parallel those of
the lymphomas arising in HIV -1 infection of humans (207, 208) and SIV infection of
non-human primates (209, 210).
In contrast to the directly oncogenic retroviruses such as murine and feline leukaemia
viruses, lentiviruses are generally considered to play an indirect role in tumour
development. Most HIV -associated lymphomas are believed to develop secondary to
one or a combination of factors, including immunodeficiency, polyclonal B-cell
activation, and the involvement of other infectious agents, notably Epstein-Barr virus
or HHV-8 (211). Between 40% and 50% of HIV-l related non-Hodgkin's
lymphomas are associated with the y-herpesvirus Epstein-Barr virus (EBV) (212). It
is possible that a similar virus may be involved in the aetiopathogenesis of FIV-
associated lymphoma (213).
Tumours associated with HIV and related lentiviruses have generally been found to
lack viral sequences, suggesting that the tumour predisposition conferred by this
genus of retroviruses is due to an indirect mechanism. The demonstration of
integrated sequences in only one of several FIV -associated tumours examined by
restriction fragment analysis to date (213, 214) suggests that, consistent with the
current knowledge of the other lentiviruses, FIV facilitates tumour development by
indirect mechanisms in the majority of the cases. It has been suggested that
lymphomas may emerge secondary to the immune dysfunction which accompanies
FIV infection (214).
Despite these generally negative observations, a number of studies have suggested
that there may be exceptions to this rule. The apparent capacity of HIV to transform
non-immortalised B lymphocytes in vitro (215) and the detection of traces of HIV
nucleic acids in AIDS lymphomas by PCR have led to speculation that HIV plays an
initiating role in lymphomagenesis in at least some cases (216). A single copy,
clonally integrated HIV-l provirus was identified in a rare HIV-l associated T-cell
lymphoma. The authors speculated that the virus might have integrated near a
cellular oncogene such as c-MYC, thereby causing constitutive c-MYC expression and
cellular transformation (217). Another monoclonal integration of viral sequences in
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the tumour DNA was demonstrated for one case of HN -associated T-cell lymphoma
where viral integration was mapped to the FUR ge~e and was associated with over
expression of the nearby FPSIFES proto-oncogene (208).
A similar observation was found in a case of B-celllymphoma (Q254), which arose
six years and 3 months post infection, in a lO-month-old neutered male specific-
pathogen-free cat that had been infected with the Glasgow-8 strain of FN as part of a
long term pathogenesis study (191). The tumour was extranodal, high grade, and of
immature B-cell origin as demonstrated by immunocytochemical staining and antigen
receptor gene analysis. Moreover, the tumour cells harboured a single integrated
proviral copy detected by Southern blot analysis (172). This observation indicated
that a single infection event preceded clonal expansion of the transformed cell and
raised the possibility of a direct oncogenic role for FN (172). Further analysis
indicates that FN integration in lymphoma Q254 occurred within a conserved gene
on feline chromosome B3. RT-PCR analysis suggested that the feline gene appeared
to have been transcriptionally down-regulated in the genesis of the lymphoma.
Searches for matches to known genes by BLAST analysis revealed a highly
significant match to a human gene (FU12973IQ9H967) that maps to chromosome
15q15 (58). The human LVI-1 gene is highly conserved, as shown by its close
homology to its murine homologue on chromosome 2 (Q9CTV4 at band E5).
The structure of the human LV/-1 gene based on the draft human genome sequence
shows a gene comprising 13 exons and covering 40kb of the human genome on
chromosome 15q15. The first exon occurs within a CpG island, which also marks the
boundary with the next 5' gene (MFAP1, microfibrillar associated protein 1), which
maps in the opposite orientation. The relative position of the FN insertion in the
homOlogous feline gene is between exons 3 and 4, in the same transcriptional
orientation (Figure 1-7). RT-PCR analysis revealed a very low level of expression of
a truncated viral-host gene fusion transcript arising from the 3' viral LTR adjacent to
exon 4, but no transcripts were detected from the apparently unaffected allele.
Moreover, this position of insertion within the gene suggests the presence of a
truncated or fused mRNA species that was shown by RT-PCR analysis. However, the
presence of transcripts in the control tissue (salivary gland) from the same animal
demonstrated that this evident loss of expression was not a constitutive defect.
Therefore, integration resulted in truncation of the target gene, while the unaffected
allele appeared to have been transcriptionally down-regulated, suggesting that LVI-1
35
~ K C C I-< Ce 0 v v v,D v 0.. ~ .......0 ~ ;>~ 0 vQ c - .......~~ V ..... ;;.-. Uv "0~ v ,D ,D ('jI-< V
Q
bl) v "0 C El
~J
c v .......S ~ - 0V ~ I-< <l::eo ('j Vu "0::s rJ5 v ....... C VJ..c:: v C "0 vC =t VJK ....... ....... .g;::: 0 -~
~
"0
~ ,D c
'"' ..!:.od VJ
('j ~
"0 i.j =t
0..
C ~ .......0 0 K I-<~ - eo U,D ....... V VJ..c:: 0 ~ ~ c.. "0 "0 ('j~ "0 ('j
I:l () () Q c ..c: c - I-<0 0 () ('j 1::: v 0 ......
H 0 ()
0 ....... o::l vVJ 0 I-<
+J
~
E-< v 0
..c:
I:l E-<
"0 c v ......
H r:t:
~ ....... ..c: v :i ......rIl - ...... ('j...... .......-~ () ~ ~ VJ ..c:r:t: .c c 0 0 ......u ....... .....() 0.. ..... VJ....... C v
(!} r:t: as 1::: 0..
.....
0 ,D VJ
U E-< Q v ....... 0 v
N E-i
() ~ ;> 1::: v c eo
..- E-i c3
~ "0 v ..c: ~ bl}
U
VJ ...... =t
...... V C 0 VJ
~
E-<
I-< C ..c:
~ v
....... ....... v
..-
() "S ~
VJ I-<
(!} E-< ~
VJ
..- §-
VJ =t
(!} () ~ ~ ....... .....
(!} E-< r:t: =t
U
0
c El v 2u
~
() ~ v ......
..- u () ..c:: ;;.-. ..c: ..c:
....... ........... VJ VJ
(!}
~
.. ,D u'- VJ
(!} ~ 0
....... c
(!} E-<
"0 ..c: 0 :aQ v c ~ .......
U E-< .... ...... 0 1::: E-<u
~
E-< "0
('ju ....... tr) v
E-i () Q .......
...... VJ >........
~~
E-< () ::s "0 VJ C -
~
E-< 0 C 0
....... v
() '"'
....... 0..
~
;>
'"' v
.......
(!} E-< () v ......
U E-< 0
::s ~ ;> k; ~ u
E-i
~
r:t:
rIl ....... V..c: ...... "0 0..
U () If)
('j c vu ..... ..c: VJ
E-i
~
~ :a v ('j ~,... (!} E-< C"' I-<
......
S
(!} E-< If) ~ v
'"""-; El <UQ...
~ ~ r:t: I
~ on ..c: ~
0 .....E-< .......E-< <l:: VJ..... U E-< ~ Ce 0 ~ I-<(!} E-< K Q) "0 0
E-i () 0 c v
......
(Xl U ~
rIl V V VJ ;> 0..
U
0 ~ bl) v ....... ve ....... t:: I-< Ur-.. ~ E-< ,~ ~ v v u
CO E-i E-<
0 VJ bl} "0
('j
U 0 0 '"' v ...... ...... ...... v..c:: VJ '-E-i E-< E-< ....... C 0.. u
E-i ()
~
<:oJ I-< 0 V ....... .......
S i.j I-<
.....
LO
E-i
~
Q "0
u 0..
E-i
C VJ VJ
U
~ 0 v ~ § ~
E-i () E-< e u ~ bV') c
(!} 0 0 ::s v 0
~ r:t: qt () ..c:: c v :i c K
E-i E-< ()
v ..c: 0 v
~ (!}
~
I:l E-< ~
bl} ...... 0 .......
-= Cd ~
VJ v
E-i 0 ()
'"""-; ..2 ..c:
(\') (!} ~ 0
I
s= ......E-i I"iI 0 ~ "0 C "0 ~0 C vu _~I ~ ('j ('j ..c: § 00
E-i ~ ..... ;;.-. ...... V')
~ () () '"'
. VJ '- '-'-- ....... ,D vE-i () 0 ::s ::s 0 u ......
(!} E-< E-< ... "0 (j "0 C C
~
() ()
<:oJ 0.. v v v v::s ~ U Cd u =t El()
~ ~E-< '"' u C cr' v.. rIl ('j ....... V V .....
E-i E-< () rIl <:oJ "0 =t
v
(!} E-< E-< ::s '-
VJ
<:oJ 0 C cr' 0::: I-<p:: U E-< 0 ·s ~ ....... v v
" E-i U E-<
E-< e c VJ VJ E-< ~
...:I U () E-<
0 ....... ....:l
0
c. 0 0
....... V El
o. ..
~
r:t: ~
Q
...... ~ "0
fI) 0
Q ('j ....... ~
0~ ~ u C ...... I-<
I E-< () ~ 0 0 0 0..:> E-i ~ ~
- K v ~..... 0:::
H E-i r..: v v u vIZ. ~ () ..c: "0 =t ..c: E-<I ...... Z ..... ....:l~ VJ § ......v C -~ ...... ~ V t"r)
'"' ('j rJ5 VJ::s u c v v v~ ....... 0 K I-< ..c:"0 0.. .......... K 0~ c ~ '-....... v ,D 0
36
was inactivated in the course of lymphomagenesis by a combination of viral insertion
and another as yet undetermined mechanism (58).
1.5 LVI-J gene as a member of the WD-40 gene family
Human LVI-J locus is predicted to encode a protein of 626 amino acid residues.
Analysis of LVI-1 for known protein family domains revealed a series of five tandem
WD-40 repeats in a 250 amino acid C-terminal domain (58). WD-40 repeats (also
referred to as WD or beta-transducin repeats) are approximately 40 amino acid long
motifs, which often terminate in a tryptophan-aspartic acid (W-D) dipeptide. WD-
containing proteins often contain this WD motif at the C-terminus, and consist of 4-16
repeating units in a 'beta-propeller structure.' In addition a glycine-histidine (GH)
dipeptide is typically found 11 to 24 residues from the N-terminus. WD-repeat
proteins are a large family found in all eukaryotes but not in prokaryotes (218) and are
implicated in a variety of cellular functions such as signal transduction, RNA
synthesis/processing, chromatin assembly, vesicular trafficking, cytoskeletal
assembly, cell cycle control, or apoptosis (219). WD-40 repeats are found in a wide
range of proteins with functions of potential relevance to cancer, including
transcription factors (Gro/Tl.E, Groucho /transducin-like enhancers), ubiquitin ligases
(COPl, constitutively photo morphogenic 1), apoptotic regulators (Apaf-1, apoptotic
protease activating factor-I), and G-protein p-subunits, presenting many alternative
mechanisms for possible tumour growth regulation (219). The WD repeat protein
encode by the LV/-J gene has a structural similarity to DDB2 (58), the small subunit
of a damaged DNA-binding (DDB) protein complex which is defective in xeroderma
pigmentosum (XP) patients of complementation group E (220). Indeed, DNA repair
defects are commonly observed in lymphomas, and this class of gene has also been
shown to be subject to epigenetic regulation (221), suggesting that such an event
could mediate tumour initiation, especially in a B-cell population under proliferative
stress, as seen in -FIV infection (192). However, as mentioned above, the WD-40
domain protein families execute many regulatory functions, and thus other loss-of
function effects relevant to oncogenesis should not be excluded (58).
The DNA damage binding protein known as DBB or UV -DDB (222) is constituted by
the 127 kDa DDB1 protein and the 48 kDa DDB2 protein (220, 223, 224). The DDB
subunits are also found in a protein complex that includes components of a Cullin 4A
(CuI4A )-based ubiquitin E3 ligase as well as the COf,9/signalosome (225).
In contrast to human tissues, in rodent tissues DDB is absent or present at very low
levels. Rodent genomes contain the DDB 1 and DDB2 genes, but expression of DDB
is suppressed in many tissues. In the mouse, DDB2 mRNA levels are relatively low
in skin, brain, lung, muscle and heart, but relatively high in testes, liver and kidney
(_
(226). It was been suggested that rodents may not have as great a need for DDB as
humans because their skin is protected by fur and additionally because they are
nocturnal animals exposure to UV is kept to a minimum (222).
Despite the ability of the DDB protein complex to bind UV light-irradiated DNA
(227), the specific role of DDB in nucleotide excision repair (NER) is uncertain
because NER can be reconstituted with purified components and damaged naked
DNA in the absence of DDB (228-230). However, DDB has been shown to stimulate
binding of the repair factors, XPA and RPA to damaged DNA (231), suggesting that
DDB stimulates NER by recruiting core NER factors to damaged DNA via interaction
with XPA and RPA.
NER recognises a variety of helix-distorting DNA lesions, including the cyclobutane
pyrimidine dimers (CPDs) and the 6-4 pyrimidine-pyrimidone photoproducts (6-4PP)
induced by UV irradiation (232). It is the only pathway in humans that removes UV-
induced photoproducts (233). NER can operate via two pathways: global genomic
repair (GGR) and transcription-coupled repair (TCR). GGR repairs the DNA damage
over the entire genome (232), while TCR. that preferentially removes DNA lesions
from the transcribed strand of active genes (234).
As mentioned above, mutations in the DDB2 gene, which encodes a WD-40 repeat
containing protein, have been found in XP-E cell lines that are lacking the damaged
DNA binding activity (235), suggesting that DDB2 might contribute to NER process.
In fact, in vivo studies showed that XP-E cells and rodent cells lacking DDB activity
are selectively defective in GGR of CPDs, and transfection of the DDB2 gene into the
rodent cells complements the deficiencies (236, 237), suggesting that DDB may be
involved in GGR especially for CPDs.
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1.6 Aims of the project
By virtue of their ability to integrate into host "DNA, the immunosuppressive
lentiviruses have the potential to act as direct agents in carcinogenesis. Therefore it is
important to monitor the sites of the integration of these agents in vivo and to examine
their capacity to silence as well as activate host cell genes. The aims of this project
were to carry out a comprehensive characterization of the LVI-1 gene. However, the
research was restricted to the human and murine homologues because of the
limitations of the cat genome sequence information.
1. LVI-1 gene expression studies
The first aim was to carry out an analysis of human and murine LVI -1 gene expression
in vivo and in cell lines in vitro. In view of limited knowledge of the murine gene,
cDNA cloning was undertaken to establish the full sequence and coding potential of
the Lvi-I transcripts in representative murine tissues.
2. LVI-l gene product(s) studies
The aims were to identify and determine the localization of the gene product(s) as a
clue to protein function. Specific antisera were raised to the human and murine gene
product(s) and these were tested by immunofluorescence and analysis of cell fractions
by western blotting.
3. Clues to LVI-l function
The similarity of LVI-l to DDB2 indicates a possible role for this gene in DNA repair
pathways. In addition, as many UV damage repair genes show a direct response to
induced damage by increased transcription, post-translational modification or
intracellular translocation, the effects of the UV irradiation were assessed using
several different types of human and murine cell lines of known p53 status.
The following chapters will describe the experimental techniques used to achieve
these objectives and the results that were obtained.
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Chapter II
Materials and methods
2.1 Materials
Materials in regular use such as equipment and general solutions are detailed in this
Section.
2.1.1 Cell culture materials
Sources of cell lines
WI-38: The WI-38 human diploid cell line derived from normal embryonic (3
months gestation) lung tissue (238).
CEM: Human T lymphoblastoid cell line derived from peripheral buffy coat of a case
of acute lymphoblastic leukaemia (239).
U-937: Human histiocytic lymphoblastoid cell line derived from pleural effusion in a
case of diffuse histiocytic lymphoma (240).
KG-la: Human acute myeloid lymphoblastoid cell line derived from bone marrow of
a case of erythroleukemia that developed into acute myeloid leukaemia (241).
K-562: Human chronic myeloid lymphoblastoid cell line derived from pleural
effusion in a case of chronic myeloid leukemia (CML) in blast crisis (242).
Jurkat: The Jurkat E61 clone is a human acute T cell leukaemia cell line (243).
Kasumi-l: Human acute myeloid lymphoblastoid cell line derived from a case of
with acute myeloid leukaemia (244).
SW480: Human colon adenocarcinoma cell line derived from tumour of a case of
colon adenocarcinoma (grade 4, Duke class B) (245).
P/mi (p/m16i, p/m32i and p/m47i): The p/mi mouse cell lines were derived from
Moloney Murine Leukemia virus (Mo-MuLV) induced thymic lymhomas in p53-null
CD2-MYC mice (246).
BW5147: Mouse T lymphoblastoid cell line derived from a spontaneous AKRlJ
thymoma (247).
3T3: Mouse fibroblast cell line derived from disaggregated Swiss albino mouse
embryos (248).
H/3T3: Mouse fibroblast cell line H-ras transformed 3T3 cells (H-3T3 cells were
provided by Prof. Alan Balmain previously of Beatson Institute for Cancer Research,
University of Glasgow).
Plasticware
Tissue culture flasks, pipettes (5, 10, and 25 ml), 100 mm cell culture dish and cell
scraper were supplied by Costar (Corning Incorporated, Netherlands). Cryotubes
l.8 ml were supplied by Nunc (DK 400, Roskilde, Denmark). Falcon conical
centrifuge tubes (15 and 50 ml) were supplied by Becton Dickinson Labware Europe.
Chamber Slide System-2 well glass slide was supplied by Lab- Tek (Nalge Nunc
International, Rochester, New York).
Solutions, media and supplements
All solutions and media for cell culture were supplied by Invitrogen Life
Technologies, unless otherwise stated.
Media
Dulbecco's Minimum Essential Medium (DMEM) with 4500 mg/L glucose, L-
Glutamine and pyruvate.
RPMI 1640 medium with L-glutamine.
Supplements
Foetal Bovine Serum (FBS), HyClone, Perbio: virus 'and mycoplasma screened. FBS
was heat inactivated at 56°C for 30 minutes, then stored in 50 rnl aliquots at -20°C
until use.
L-glutamine: supplied as a 200 mM (lOOx) stock solution, and stored at -20°C in
5 ml aliquots. This was routinely added to culture media prior to use.
Penicillin/streptomycin (P/S): supplied as a lOOx stock solution of 10,000 units
penicillin and 10,000 units streptomycin per millilitre and stored in 5 rnl aliquots at
-20°C.
Trypsin-EDTA: supplied as lOx liquid, stored at -20°C. This was diluted 1:10 in
sterile PBS prior to use and stored at 4°C.
2-Mercaptoethanol (2-ME): supplied as 50 mM solution in Dulbecco's PBS.
N-2-Hydroxyethylpiperazine-N' -2-ethanesulfonic acid (Hepes): supplied as 1 M
solution in dH20.
2.1.2 Bacterial strains
E.coli One Shot® TOPIO
E. coli TOPlO: One Shot Chemically Competent E.coli cells (-1 x 109 colony
forming units/ug) (Invitrogen). Genotype: F mcrA Mmrr-hsdRMS-mcrBC)<D80
lacZ~M15 ~lacX74 deaR recAl araD139 Mara-leu)7697 galU galK rpsL (StrR)
endAI nupG. The genotype <l>80IacZ~M15 marker enables blue-white screening by
a-complementatiO.n of ~-galactosidase encoded by vector DNA (e.g. pCRTMII).
E.coli BL21
E. coli BL21: A protease-deficient E. coli host strain. for optimal expression of
recombinant proteins (Amersham Pharmacia Biotech). Genotype: E. coli B F, ompT,
hsdS (rB-,mg), gal, dcm.
2.1.3 Complete kits
5'/3' RACE Kit, 2nd Generation (Roche Applied Science)
Big Dye® Terminator Version 1.1 Cycle Sequencing Kit (Applied Biosystems)
Bulk GST Purification Module (Amersham Biosciences)
ECL™ Western Blotting Detection Reagents (Amersham Biosciences)
Endof'ree'" Plasmid Maxi Kit (Qiagen)
GST Detection Module (Amersham Biosciences)
High Pure PCR Product Purification Kit (Roche Applied Science)
High Pure Plasmid Isolation Kit (Roche Applied Science)
Improm-II™ Reverse Transcription System (Promega)
QtAquick" PCR Purification Kit (Qiagen)
Qlaquick" Gel Extraction kit (Qiagen)
Rad Prime DNA Labeling System (Invitrogen Life Technologies)
RNA 6000 Nano LabChip® Kit (Agilent Technologies)
TOPO TA Cloning" (Invitrogen Life Technologies)
2.1.4 DNA
Plasmid, molecular weight markers and oligonucleotide DNAs were stored at -20°C.
Plasmid vectors
pCR® 2.1-TOPO vector (Invitrogen): lacZ+, amp", kan'; T7 promoter and priming
site, M13 forward and reverse primer annealing sites. Plasmid designed for direct
cloning of PCR products with 3' deoxyadenonosine residues (A - overhangs),
generated by the non-template dependent activity of Taq polymerase. The vector is
supplied as linearised DNA with single 3' deoxythymidine (T) residues allowing for
efficient ligation of target sequence to vector.
pCR®II-TOPO (Invitrogen): As above but also has SP6 promoter and priming sites.
pUC 19 (Invitrogen): Plasmid supplied with TA cloning kit for use as positive control
for verifying the transformation efficiency of competent bacteria; concentration of
O.If..lg/ml.
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Glutathione S-transferase fusion vectors, pGEX-5X-l and pGEX-5X-2 (Amersham
Pharmacia Biotech): The vectors contain the Glutathione S-Transferase (GST) gene
(with an ATG and ribosome-binding site, and is under the control of the tac
promoter), an expanded multiple cloning site (MCS) that contains six restriction sites
and provides all three translational reading frames beginning with the EcoRI
restriction site, and an internal lac _rl gene for use in any E. coli host (Figure 2-1).
pGEX-5X-l: Glutathione S-transferase gene region: tac promoter: -10: 205-211; -
35: 183-188; lac operator: 217-237; Ribosome binding site for GST: 244; Start
codon (ATG) for GST: 258; Coding region for factor Xa cleavage: 921-932. MCS:
934-969. Beta-lactamase gene region: Promoter: -10: 1333-1338; -35: 1310-1315;
Start codon (ATG): l380; Stop codon (TAA): 2238. lacIq gene region: Start codon
(GTG): 3321; Stop codon (TGA): 4401. Plasmid replication region: Site of
replication initiation: 2998; Region necessary for replication: 2305-3001. Sequencing
primers: 5' pGEX Sequencing Primer binds nucleotides 869-891; 3' pGEX
Sequencing Primer binds nucleotides 1044-1022.
pGEX-5X-2: Glutathione S-transferase gene region: tac promoter: -10: 205-211; -
35: 183-188; lac operator: 217-237; Ribosome binding site for GST: 244; Start codon
(ATG) for GST: 258; Coding region for factor Xa cleavage: 921-932. MCS: 934-
970. Beta-lactamase gene region: Promoter: -10: 1334-1339; -35: 1311-1316; Start
codon (ATG): 1381; Stop codon (TAA): 2239. lacIq gene region: Start codon
(GTG): 3322; Stop codon (TGA): 4402. Plasmid replication region: Site of
replication initiation: 2999; Region necessary for replication: 2306-3002. Sequencing
primers: 5' pGEX Sequencing Primer binds nucleotides 869-891; 3' pGEX
Sequencing Primer binds nucleotides 1045-1023.
Molecular size standards'
Molecular size standards used include <l>X174RF DNA/HaeIII fragments (size range
72 bp to 1,353 bp), A DNA/HindIII fragments (size range 125 bp to 23,l30 bp), and
Low DNA Mass™ Ladder (size range: 100-2000.,bp) all supplied by Invitrogen Life
Technologies.
Oligonucleotide primers
Oligonucleotides for polymerase chain reaction (PCR) and cycle sequencing were
MUltiple cloning site of pGEX-5X-l
Factor xa ..
I tie .Glu Gty· Arg'~GIY lie Pro 'Glu PI'll! Pro Gly Arg Leu Gill Argr Pro His Arg i\$p
ATe GM GGTCGTGGGATC CCC,GAAn;C,CCG G~lCGAle!c GA~,CGGeCG C,ATCGIGAC 1M:
BamHI iEcoRI S;na I Sail Xh:oI ~IotI stop CodOIlS
Multiple cloning site of pGEX-5X-2
~ Factor Xa
Ille Glu Giv ArglLeti Ire Pto Gly lie Plo GI~ ~r Thr Ar~ Ma 11.14Ala SOl
ATC GM Gm CG;r GflG ATe C,CCGrill. AYr, cpc G~I TCG ~C1CG5~IG GCe GCt\ TCG rGA
BamH I EooR I Sma I sail XhO I Noll Stop cooon
e~pMI
pGEX-5X-1
41H2 bp
pGEX-5X-2
4013bp
Mlu I
Figure 2-1. Organization of pGEX-SX-l and pGEX-SX-2 vectors (GST gene
fusion system), Plasmid map: Glutathione-S-transferse gene region (tac promoter,
lac operator); multiple cloning site (MCS); Amp', ampicillin resistance; ori, pBR322
origin of replication. Coding sequences of the MCS of both vectors are indicated
above, in which the stop codon(s) is located at 3' of the Not I site.
synthesised by MWG Biotech, and delivered as high purity salt free lyophilised DNA.
Primers were reconstituted at 100 pmol/ul in distilled water (dH20) and stored at
-20°C.
2.1.5 Enzymes
All enzymes were stored at -20°C and were removed from storage immediately
before use.
Restriction enzymes
All enzymes and their associated buffers were supplied by Invitrogen Life
Technologies (UK).
Details of restriction enzymes, their restriction sites and reaction conditions are shown
in Table 2-1.
T4 DNA Ligase
T4 DNA ligase (Invitrogen, UK) supplied with 5x ligation buffer (used at a final
concentration of 50 mM Tris-HCI (pH 7.6), 10 mM MgCh, 1 mM DTT and 1 mM
ATP).
Alkaline Phosphatase, Calf Intestinal (ClAP)
Calf Intestinal Alkaline Phosphatase (CLAP) (Promega, UK) supplied with lOx
reaction buffer (used at a final concentration of 0.05 mM Tris-HCI (pH 9.3 at 25°C),
1mM MgCh, 0.1 mM ZnCh and 1mM Spermidine)
2x ReddyMix™ PCR Master Mix
2x ReddyMix ™ PCR Master Mix (1.5 mM MgCh) (Abgene, UK). Standard PCR
reactions were performed in a final volume of 25 ul using 12.5 ul of 2x ReddyMix ™
PCR Master Mix and 12.5 ul of a mixture of template.. primers and dH20. Each
reaction contains Taq DNA Polymerase (1.25 units), 75 mM Tris-HCI (pH 8.8 at
25°C), 20 mM (NH4)2S04, 1.5 mM MgCh, 200 f!M of each dNTP, precipitant, and
-
red dye for electrophoresis.
Table 2-1. Restriction enzymes.
Restriction Restriction site Buffer Temperature of
enzyme incubation (OC)
EcoRI [5'-GtAATTC-3 '] REACT@3 37
v
BamHI [5'-GtGATC-3'] REACT@3 37
SstI [5'-GAGCT tC-3'] REACT@2 37
EcoRV [5'-GAT tATC-3'] REACT@2 37
XbaI [5'-T tCTAGA-3'] REACT@2 37
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Extensor Hi-Fidelity rcu Master Mix, Buffer 1, ReddyMixTM
Extensor Hi-Fidelity PCR Master Mix, Buffer 1," ReddyMix ™ (Abgene, UK).
Standard PCR reactions were performed in a final volume of 25 ul using 12.5 ul of
Extensor Hi-Fidelity PCR Master Mix, Buffer 1, ReddyMix ™ and 12.5 ul of a
mixture of template, primers and dH20. Each reaction contains Taq DNA Polymerase
(1.25 ~units), 2.25 mM MgClz, 350 !!M of each dNTP, buffer 1 (used for
amplifications up to 12 kb), precipitant, and red dye for electrophoresis.
Ribonuclease A Type IlI-A
Ribonuclease A Type III-A (Sigma, UK) was used to purify DNA from contaminating
RNA.
2.1.6RNA
Molecular size standards
Molecular size standards (5 ug/lane) include a 0.24 kb to 9.5 kb RNA ladder and a 0.5
kb to 10 kb RNA ladder all supplied by Invitrogen Life Technologies. RNA ladders
were stored at -70°C.
2.1.7 Radiochemicals
a_32p dCTP, specific activity 3000 Ci/mmol, for DNA labelling was supplied by
Amersham Life Science.
2.1.8 Protein SDS-PAGE-standards
Prestained SDS-PAGE (Sodium Dodecyl Sulphate - Polyacrylamide Gel
Electrophoresis) standard was the Precision Plus Protein™ Standards, supplied by
Biorad. This standard contains ten highly purified recombinant proteins ranging from
"
10 kDa to 250 kDa. The stock was aliquoted and stored at -20°C. Each aliquot was
heated to 95°C for 3 minutes prior to use to dissolve any precipitated solids.
2.1.9 General chemicals
..
Chemicals used were of analytic, ultrapure or molecular grade quality and were
supplied by Sigma Chemical Company (Dorset, England), Fisher Scientific UK
Limited (Leicestershire, UK), Invitrogen Life Technologies, unless stated otherwise.
Bacterial agar, and tryptone, and phosphate buffered saline (DulbeccoA): Oxoid.
2.1.10 Equipment
Major Equipment
Automatic Sequencing Apparatus: ABI Prism 3100 Genetic Analyzer (Applied
Biosystems, Foster City, USA)
Flow cytometer: Coulter Epics XL MCL (Beckman Coulter Company, Florida, USA)
Gel cast: AE-6210 Slab Gel Cast (Atto Incorporation, Japan); casting stand and
casting frames from Mini-Protean 3 Cell and Systems, and gel caster from Sub-Cell
Systems (Bio-Rad Hertfordshire, UK)
Gel drier: Easy Breeze Gel Dryer (Hoeter Scientific Instruments, San Francisco,
USA)
Gel electrophoresis systems: Biomax QS710 Horizontal Unit (Scientific Imaging
Systems - Eastman Kodak Company, New York, USA); Sub-Cell GT Submerged
Horizontal Agarose Gel Electrophoresis System, and MiniProteanU™ (Bio-Rad,
Hertfordshire, UK); AE-6200 Slab EP Chamber, and AE-6220 Slab EP Chamber, for
two gels (Atto Incorporation, Japan)
Hybridisation oven: Mini Oven MKU, Hybaid Limited
PCR Machines: PCR Express Thermal Cycler (Hybaid Limited, Middlesex, UK),
DNA Thermal Cycler (Perkin Elmer, Boston Ma, USA), and PTC-220 DNA Engine
Dyad® Cycler (MJ Research Incorporated, Massachusetts, USA)
Phosphoimager: Molecular Dynamics Storm 840 equipped with ImageQuant
software (Amersham Pharmacia Biotech, Sunnyvale, USA)
Power packs: Electrophoresis Power Supply, EPS 500/400 (Pharmacia Fine
Chemicals, Uppsala, Sweden), and Power PAC 300 (Bio-Rad, Hertfordshire, UK)
Semi-dry electrophoretic transfer: Trans-blot® SD Semi-Dry Transfer Cell (Bio-Rad
Hertfordshire, UK)
Sonicator: Soniprep 150 MSS l50.CX 3.5 (Sanyo Gallenkamp PLC, Leicester, UK)
Spectrophotometer: DU® 640 Spectrophotometer (Beckman, California, USA),
Agilent 2100 Bioanalyzer (Agilent Technologies, Germany)
Ultraviolet trans-illuminator: High Performance Ultraviolet Transluminator (UVP-
Ultra Violet Products, San Gabriel, CA), and Geneflash Syngene Bio Imaging (Fisher
Scientific- Synoptics Ltd, UK)
UV Cross Linker: Spectrolinkerl'" XL-I500 UV Crosslinker (Spectrotronics
Corporation, New York, USA)
Consumables
21G sterile syringe needles were supplied by Becton Dickinson S. A. (Fraga, Spain)
Acrodisc syringe filters (0.2 urn and 0.45 urn) were supplied by Sartorius (Hannover,
Germany); used for sterilising of filtering small volumes of solutions
Centrifugal filters: Microcon and Centricon YM-30 (Millipore Corporation, Bedford
USA)
Eppendorf tubes: Flip-top 0.5 ml and 1.5 ml, and screw-top 1.5 ml (Elbkay
Laboratory Products, Hampshire, UK), and Rnase-free Microfuge Tubes (Ambion,
Cambridgeshire, UK)
Film: Hyperfilm MP, and Hyperfilm ECL (Amersham Biosciences,
Buckingshamshire, UK)
Filter paper: Qualitative Circles 185 mm 0 (Whatman", Kent, England)
Filter tip pipette tips: A range of capacities '(10, 20, 200, 1000) III supplied by Rainin
Instrument Co (Woburn, MA); for use in setting up PCR reactions
Fine Tip Pastette Sterile were supplied by Alpha Laboratories (Hampshire, UK)
Flat ended gel loading tips were supplied by Sorenson Bioscience Inc (Utah, USA)
Hybridisation buffer: Rapid-hyb buffer (Amersham Pharmacia Biotech,
Buckingshamshire, UK)
Gel exclusion column: NiceM columns (Amersham Biosciences, Uppsala, Sweden)
Membranes: Hybond™-N nylon membrane and Hybond™ -ECL nitrocellulose
membrane (Amersham Biosciences, Buckingshamshire, UK)
Parafilm was supplied by Pechiney Plastic Packaging (Menasha WI)
Petri dishes were supplied by Sterilin (Staffordshire, UK)
Pipette tips were supplied by Sarstedt (Numbrecht, Germany)
Pipette tips RNAse free: 1000 u.l and 200 ul supplied by Starlab (Ahrensburg,
Germany), and 1 ul to 20 [.ll supplied by Elkay Labo.ratory Products Ltd (Hampshire,
England)
Scalpel blades: Sterile disposable scalpels (Schwann-Morton , Sheffield, UK)
Spreaders, L shaped were supplied by VWR International (Lutterworth, UK)
SteriLe plastic containers: Bijoux and Universals (Greiner Bio-One, Gloucestershire,
UK)
Syringes (2, 5, 10,20,50) ml were supplied by Becton Dickinson
2.1.11 Buffers, solutions and growth media
Water
Diethylpyrocarbonate (DEPC) treated RNAse free water was supplied by Ambion,
Cambridgeshire, UK. Tissue culture grade distilled water was supplied by Invitrogen
Life Technologies. Ultrapure water (for procedures involving recombinant DNA,
PCR etc.) was provided by a Milli Q® ultrapure water purification system (Millipore
Ltd., Watford, UK). An Elix® purification system (Millipore Ltd., Watford, UK) was
used to supply water for preparation of general solutions and media.
Antibiotics
Ampicillin (Sigma): 100 mg/ml in ddH20. Filtered through a 0.22 urn filter,
aliquotted and stored at -20 QCuntil use.
Buffers and solutions
19x Dry Blot Buffer: 0.5 M Tris base, 0.4 M Glycine, 12.8 mM SDS. Working stock
Was prepared prior to use at a 1:10 dilution with 20% (v/v) Methanol.
lOx MOPS (3-N-Moroholino-propanesulfonic acid) Buffer: 200 mM MOPS, 50 mM
NaOAc (3H20), 10 mM Na2EDTA, adjusted to pH 7.0 using either NaOH if free acid
MOPS or HCI if Na salt MOPS. Stored at 4 QCin the dark.
19x SDS-PAGE Running Buffer: 0.25 M Tris base, 1.92 M Glycine, 34.7 mM SDS
lOx TBE (Tris-borate-EDTA) Buffer Solution: 0.9 M Tris base, 0.9 M Boric acid,
23 mM Na2EDTA. pH 8.2/8.3. Stored at room temperature.
10x TBST CTris-buffered-saline-tween) Buffer Solution: 0.1 M Tris base, 1.5 M
NaCI, 0.5% Tween-20, adjusted to pH 8.0.
lOx Tris-glycine buffer for electrotransfer of proteins onto membranes (transfer
buffer): 0.25 M Tris base, 1.92 M Glycine. Working stock was prepared prior to use
at a 1:10 dilution with 15% (v/v) Methanol.
1M Tris HCI: 121 g Tris base, 800 ml dH20. Adjusted to desired pH with
concentrated HCl and made up to 1L.
Ix Phosphate buffered saline (PBS): 140 mM NaCl, 2.7 mM KC1, 10 mM Na2HP04,
1.8 mM KH2P04 (pH 7.3)
2.5x RadPrime Buffer: 125 mM Tris-HCL, pH 6.8; 12.5 mM Magnesium chloride;
25 mM 2-Mercaptoethanol; 150 ug/ml Oligodeoxyribonucleotide primers
2..0xPropidium iodide (pn stock solution: made to a working solution of 1 mg/ml
with ddH20 in a fume cupboard. This wa~ filtered through a 0.22 urn syringe filter,
and stored at 4 QCin the dark.
2..0x SSC: 3 M NaCl, 0.3 M Sodium citrate, pH 7.0 in dH20. Stored at room
temperature.
lOx TAE CTris-acetate-EDTA) Buffer Solution: 2 M Tris base, 50 mM Na2EDTA,
1M Glacial acetic acid.
Acrylamide elution buffer: 500 mM Ammoniumacetate, 10 mM Magnesium acetate,
0.1 mM Na2EDTA, 0.1% (w/v) SDS)
Ammonium persulphate: 10% (w/v) stock solution in ddH20, freshly made.
Denaturation buffer: 1.5 M NaCI, 0.5 M NaOH 10 dH20. Stored at room
temperature.
Destain solution for protein gels: 5% Methanol, 7.5% Acetic acid in ddH20.
Ethidium bromide: made to a working solution of 3 mg/ml with ddH20 in a fume
'-
cupboard. Stored at room temperature in the dark.
Gel loading buffers:
1. DNA- 30% Glycerol, 0.25% (w/v) Bromophenol blue, 0.25% (w/v) Xylene cyanol,
in ddH20. Stored at room temperature and used at a 1:5 dilution.
2. RNA- 50% (v/v) Formamide, 2.2 M Formaldehyde, Ix MOPS, in nuclease-free
water. Made fresh. Immediately prior to loading on the gel add RNA running dye:
50% Glycerol, l x MOPS buffer, 0.5% (w/v) Bromophenol blue, in nuclease-free
water (stored at -20 DC).
3. Protein- SDS-PAGE Protein 2x Sample Loading Buffer: 120 mM Tris-HCl, pH
6.8,20% (v/v) Glycerol, 5% SDS, 7.4% p-mercaptoethanol, 0.5% (w/v) Bromophenol
blue in ddH20. Stored in aliquots at -20 DC. Sample diluted at least 1:2 with buffer
and heated at 100 DCfor 5 minutes prior to loading gel.
glutathione elution buffer 1: 10 mM glutathione, 50 mM Tris-HCI, pH 8.0
glutathione elution buffer 2: 75 mM Hepes pH 7.4, 150 mM NaCl, 10 mM reduced
glutathione, 5 mM DTT, 2% N-octyl glucoside
LYsis buffer for immunoprecipitation: 50 mM Tris pH 8.0, 150 mM NaCl, 0.5% (v/v)
Nonidet P 40, 5 mM Na2EDTA, 1 mM Dithiethreitol (DTT). Stored in aliquots at
-20 DC. Working Lysis buffer was prepared prior to use by addition of 0.2 mM
Na2V04, and protease inhibitors as follows: 10 ug/rnl Aprotinin, 10 ug/ml Leupeptin,
2.5 ug/rnl Pepstatin A, 10 mM p-glycerophosphate, 1 mM Phenylmethanesulfonyl
fluoride (PMSF).
Neutralisation buffer: 1.5 M NaCI, 0.5 M Tris-HCI pH 8.0, in dH20. Stored at room
temperature.
PI Staining solution: 50 ug/ml 20x Propidium Iodide (PI) stock solution, 100 Uzml
Rnase A in sample buffer (1 gil Glucose in PBS. This was filtered through a 0.22 11m
syrin~e filter, and stored at 4 QC).
SDS-PAGE Protein Gel Fix-Stain Solution: 0.25% (w/v) Coomassie Brilliant Blue
R-250, 50% (v/v) Methanol, 10% (v/v) Acetic acid in ddH20.
STE buffer: 10 mM Tris pH 8.0,150 mM NaCI, 1 mM EDTA
TE Buffer: 10 mM Tris-HCI, 1 mM Na2EDTA adjusted to pH 8.0. Autoclaved and
stored at room temperature.
Whole Cell Extract Buffer: 20 mM Hepes pH 7.0, 5 mM EDTA, 10 mM EGTA,
5 mM NaF, 1 mM DTT, 0.4 M KCI, 0.4% (v/v) Triton X-lOO, 10% (v/v) Glycerol.
Stored in aliquots at -20 QC. Working Whole Cell Extract buffer was prepared prior
to use by addition of 0.1 ug/ml Okadaic acid, and protease inhibitors as follows:
5 ug/ml Aprotinin, 5 ug/rnl Leupeptin, 5 ug/rnl Pepstatin A, 1 mM Benzamidine,
50 ug/ml PMSF.
X-Gal (5-bromo-4-chloro-3-indolyl-Bgalactoside) solution: prepared as 40 mg/rnl
stock in dimethylformamide; stored in aliquots at -20 QCin the dark.
Bacteriological media
Media was sterilised by autoclaving at 121 QCfor 15 minutes, unless otherwise stated .
.f..X YTA medium: 1.6% (w/v) Tryptone, 1% (w/v) Yeast extract, 0.5% (w/v) NaCI in
dH20. pH then adjusted to 7.0 with NaOH.
1.B (Luria Bertani) medium: 1% (w/v) Tryptone, 0.5% (w/v) Yeast extract, 1% (w/v)
NaCl in dH20. pH then adjusted to 7.0 with NaOH.
LB-agar: as for LB medium but also containing 1.5% (w/v) agar.
LBG medium: 1% (w/v) Tryptone, 0.5% (w/v) Yeast extract, 0.5% (w/v) NaCl in
dH20. After the medium has cooled to (50 to 60) QC,20 mM Glucose was added.
LBG-agar: as for LBG medium but also containing 1.5% (w/v) agar.
\..
SOC medium: 2% Tryptone, 0.5% Yeast extract, 10 mM NaCl, 2.5 mM KCI, 10 mM
MgCh, 10 mM MgS04, and 20 mM Glucose. (Invitrogen Life Technologies, UK).
TSS (Transformation and Storage Solution): 1% (w/v) Tryptone, 0.5% (w/v) Yeast
extract, 0.5% NaCl, 10% (w/v) Polyethylene glycol (Mr 3350),5% Dimethylsulfoxide
(DMSO), 0.05 mM MgCh in dH20. pH then adjusted to 6.5. Sterilised by filtering
through a 0.22 urn syringe filter, and stored at 4 "C. Stable for up to 6 months.
2.2 Methods
Methods used commonly throughout the thesis are detailed in this Section whilst more
specific methods are dealt with in the relevant chapter. Many of the methods
described here are based on standard protocols, which are detailed in several
laboratory manuals (249, 250).
2.2.1 Growth and manipulation of mammalian cells
All procedures involving mammalian cells were carried out in a laminar flow hood
using standard aseptic procedures.
Cryopreservation of cells
Stocks of cells for long-term storage were preserved over liquid nitrogen. Cells to be
frozen were grown to mid-log phase (as described below) and removed into a sterile
50 ml centrifuge tube (using l x trypsin-EDTA solution where necessary). Cells were
centrifuged at 1000 rpm for 5 minutes and the supernatant discarded. The cells were
then re-suspended in freeze medium at a concentration of approximately
3 x 106 cells/rnl. Freeze medium consisted of the appropriate culture medium
supplemented with FBS to 20% and 10% dimethylsulphoxide (DMSO, Sigma
Aldrich) as a cryoprotectant. The cell suspension was transferred in one millilitre
aliquots, to labelled cryovials (Nunc cryotubes vials, Nunc) and brought to -70 QCat
a controlled rate of -1 QC per minute using a NALGENETM Cryo 1 QC Freezing
Container (NALGENE, USA). The vials were then transferred to a liquid nitrogen
freezer for long-term storage. Cell stocks were revived by rapid thawing in a 37 QC
water bath and maintained following standard techniques (described below).
Cell counting
Cells were counted in a haemocytometer (Bright-Line Hemacytometer, Sigma) as
follows. Cell pellets were suspended in an appropriate volume of media to allow ease
of counting in the haemocytometer chamber. A 10 III volume of the cell suspension
Was then diluted 1:1 in trypan blue stain 0.4% (Invitrogen Life Technologies) and
incubated at room temperature for 1 minute. The suspension was then introduced to
the haemocytometer chamber and cell counts made using an inverted microscope with
a 4x or lOx objective. Cells lying on the top and right hand perimeter of each large
square (l mm) were included; those on the bottom or left hand perimeters were
excluded. Cell concentrations (cells/ml) were calculated by multiplying the mean
numbers of cells per large marked square by 2 x 104 to account for the volume of the
haem5:>cytometer chamber and to correct for the dilution factor. Dead cells were
differentiated by uptake of the trypan blue stain and appear blue.
Maintenance of mammalian adherent cell lines
WI-38, SW480, 3T3, and H/3T3, (Section 2.1.1). All cell lines form an adherent
monolayer in culture, and were cultured in 75 crrr' tissue culture flasks kept at 37 QC
in a humidified incubator containing 5% (v/v) C02. Cells were cultured in 20 ml
DMEM (Section 2.1.1) supplemented with 10% FBS, 100 international units (IU)/ml
penicillin, 100 ug/ml streptomycin, and 2 mM glutamine. Cultures were split
typically 1:3, every 2 to 3 days, when sub-confluent and maintained at densities of 106
cells/nil. The medium was decanted from the cell monolayer and cells washed with
10 ml of warm PBS. Then, 3 ml to 5 ml of Ix trypsin-EDTA solution was added,
cells were incubated at 37 QC for 5 to 15 minutes and observed by microscopy to
ensure cell layer dispersal. The detached cells were then washed in fresh medium,
pelleted by centrifugation at 1000 rpm for 5 minutes, prior to resuspending in fresh
medium and seeding new tissue culture flasks.
Maintenance of mammalian suspension cell lines
CEM, U-937, KG-la, K-562, Jurkat, Kasumi-l, p/rni, and BW5147 (Section 2.1.1).
Cells were cultured in suspension in RPMI 1640 medium (Section 2.1.1)
supplemented with 10% FBS, 100 IU/ml penicillin, 100 ug/rnl streptomycin, 2 mM
glutamine, and 5x 10-5 M ~-mercaptoethanol with the exception of KG-l a cell line
which was maintained in DMEM supplemented ~ith 10% FBS, 100 IU/ml penicillin,
100 ug/ml streptomycin, and 2 mM glutamine. Cultures were maintained at 37 QCin
a humidified incubator with 5% CO2 in upright 75 cm
2 tissue culture flasks. Cells
Were split every two to three days, typically 1:5 to 1:7, and maintained at densities of
between 5 x 105 cells/ml and 5 x 106 cells/ml. The suspension cells were pelleted by
centrifugation at 1000 rpm for 5 minutes, prior to resuspending in fresh medium and
seeding new tissue culture flasks.
2.2.2 Recombinant DNA techniques
Storage and growth of bacteria
Plasmid DNA was maintained and stored in the E.coli strain One Shot Chemically
Competent cells". Glycerol stocks were prepared from transformed bacteria and their
long-term storage as outlined below.
The desired bacterial culture was streaked onto a 1.5% LB agar plate (Section 2.1.11);
as the plasmid conferred ampicillin resistance the medium was supplemented with
100 ug/ml ampicillin. The plate was then incubated overnight at 37 QC and the
following day single colonies were picked using a sterile pipette tip into a sterile
universal containing 5 ml LB medium supplemented with 100 ug/ml ampicillin.
Cultures were incubated at 37 QCovernight in a horizontal orbital incubator at 220
rpm. Confirmation that overnight cultures were derived from bacteria containing the
correct plasmid was achieved by DNA isolation and restriction digestion. Glycerol
stocks were prepared by addition of 150 ",,1of glycerol to 850 ",,1of culture broth to
produce a 15% glycerol mixture. Glycerol stocks were then stored at -20 QCand -70
QC. Bacterial stocks were revived for subsequent work by using a sterile platinum
wire to scratch the surface of the glycerol stock, and streaking this onto an agar plate
as outlined above.
Extraction and purification of plasmid DNA
Plasmid DNA was isolated using a modification of the alkali lysis technique described
by Birnboim and Doly (1979) (251).
Large-scale plasmid preparation
Large quantities of highly pure, endotoxin free plasmid were prepared using the
EndoFree® Plasmid Maxi Kit (Qiagen,UK). 50 ul of glycerol stock from the desired
transformant was used to seed an overnight multiplier culture in 100 ml of LB
medium incubated at 37 QCwith shaking at 220 rpm. These exponentially growing
bacteria were harvested by centrifugation of the culture in 50 rnl sterile centrifuge
tubes at 4000 g for 20 minutes at 4 "C. The remainder of the protocol was performed
according to the manufacturer's instructions. DNA was stored at -20°C.
Small-scale plasmid preparation
RequIrements for small amounts of plasmid DNA, such as sequencing, were met
using the High Pure Plasmid Isolation Kit (Roche Applied Science, Germany). This
kit allows isolation of plasmid DNA from 2 rnl to 3 ml LB broth cultures of
exponentially growing bacteria. Bacteria were harvested by centrifugation
(13,000 rpm for 1 minute), and DNA isolated following the manufacturer's protocol.
The method involved lysis of the bacterial cells to release plasmid DNA, which was
then purified by centrifugation, filtration using spin columns, washing and final
elution into 100 fA.I of elution buffer (10 mM Tris-HCl, pH 8.5). DNA storage was at
-20°C.
Determination of nucleic acid concentration and quality
Determination by spectrophotometry
Nucleic acid samples were diluted either at 1:20 by addition of 25 fA.I of resuspended
nucleic acid in 475 fA.I of dH20, or 1:100 by addition of 5 fA.I of the resuspended
nucleic acid in 495 fA.I of dH20. Optical density readings were taken at 260 nm and
280 nm, using dH20 as a blank. An optical density reading of 1.0 at 260 nm
corresponds to an approximate nucleic acid concentration of 50 ug/rnl for double
stranded (ds) DNA and 40 ug/ml for single stranded (ss) RNA. The ratio of the
readings taken at 260 nm and 280 nm (OD26oI0D28o) was used to give an estimate of
the purity of the nucleic acid. Pure preparations of DNA and RNA have an
OD26ofOD28o of 1.8 and 2.0 respectively; a lower value suggests contamination,
typically with protein or phenol.
Estimation of double stranded DNA concentration and quality by agarose gel
electrophoresis
This method was used when there were insufficient amounts of dsDNA for
spectrophotometry, or when purity of a particular DNA fragment needed to be
investigated. The concentration of dsDNA was determined by running the sample on
an agarose gel electrophoresis as described below, and the intensity of the
fluorescence of the unknown DNA was compared to that of a known quantity of the
appropriate size marker (ex 174 RF DNA/HaeIII fragments or A DNA/HindIII
fragments) following staining with ethidium bromide and visualisation by UV
transilluminarlon. Smearing of a DNA band indicated degradation of the sample and
resulted in exclusion of that DNA from further analysis.
Restriction endonuclease digestion
Typically, 1 ug of miniprep DNA was digested in a 20 ul reaction mix containing the
appropriate buffer for the restriction endonuclease(s), 2 mM spermidine and 10 units
of the desired restriction enzyme. The reactions were incubated at 37 QC for a
minimum of 1 hour. Where the isolation of restriction fragments was required, larger
quantities of DNA, generally 20 ug, were digested with 100 units of enzyme, and the
reaction volume and others components increased proportionally. In this case,
reactions were incubated at 37 QCfor 12 to18 hours.
Electrophoresis of DNA
Agarose gel electrophoresis
DNA fragments of 1.0 kb to 10 kb were' separated by agarose gel electrophoresis
using a Biomax QS710 Horizontal Unit (Scientific Imaging Systems - Eastman
Kodak Company, New York, USA) or Sub-Cell GT Submerged Horizontal Agarose
Gel Electrophoresis Systems (Bio-Rad, Hertfordshire, UK). Typically, 0.6 g to 0.9 g
or 2 g to 3 g agarose was added to 60 ml or 200 ml of l x TBE or Ix TAE buffer,
respectively; melted in a microwave for 1 minute to 2 minutes and mixed to produce a
1% to 1.5% gel (w/v). Once the gel mix had cooled to 55 QC,the gel was poured into
a 100 mm x 65 mm or 150 mm x 200 mm gel support in its casting tray and an
appropriate gel comb (eight, twelve or twenty wells) inserted. The gel was allowed to
solidify before transferring to an electrophoresis tank; the gel was immersed in l x
TBE or l x TAE buffer and the comb carefully removed. Gel loading buffer (Section
2.1.11) was added to DNA samples at a final concentration of l x and samples loaded
into the wells using a micropipette. Known concentrations of DNA size markers were
prepared similarly and run alongside the samples in order to gauge both product size
and yield. Gels were run at 100 volts for 60 to 120 minutes or overnight at 20 volts,
then removed from the gel apparatus and stained in buffer solution containing 0.5
ug/ml ethidium bromide for 30 minutes. Following destaining for 30 minutes in
dH20, gels were visualised on a medium wave UV transilluminator (UVP Inc. and
Geneflash Syngene Bio Imaging) and photographed using black and white Video
Graphic Printer Sony UP-895MD (Fisher Scientific- Synoptics Ltd, UK).
Polyacrylamide gel electrophoresis
In order to separate, visualise and determine the size of DNA fragments under
approximately 1.2 kb (including PCR products and small products of restriction
digests), non-denaturing polyacrylamide gel electrophoresis was employed. Glass
plates of 16 cm x 16 cm size were assembled with a 0.75 mm spacer in a casting stand
(Atta, Atto Corporation). 4% gel was prepared with 3.3 ml of 30%: 1.579%
acrylamidelbisacrylamide solution (Severn Biotech Ltd, Kidderminster, UK), 2.5 ml
of lOx TBE buffer (Section 2.1.11) and ddH20 added to 25 ml total volume.
Following the addition of 32 III of TEMED (Sigma) and 200 III 10% APS (Section
2.1.11), the gel solution was poured between the assembled gel plates and a comb (12
wells) inserted. After polymerisation, the gel plates were removed from the casting
apparatus, the spacer removed and the plates transferred to the gel electrophoresis
apparatus. The apparatus was filled with l'x TBE buffer, the gel comb removed and
the wells flushed with buffer. Samples were prepared as described above and loaded
onto the gel using 0.4 mm flat ended gel loading tips; <j>X174RF DNA/Hae III
fragments and Low DNA Mass Ladder were loaded as molecular size standards. Gels
were electrophoresed at 250 volts for 45 minutes then removed and stained in buffer
solution containing 0.5 ug/ml ethidium bromide for 30 minutes. Following destaining
for 30 minutes in dH20, gels were visualised on a UV transilluminator (UVP Inc. and
Geneflash Syngene Bio Imaging) and photographed using black and white Video
Graphic Printer Sony UP-895MD (Fisher Scientific- Synoptics Ltd, UK).
Purification of restriction enzyme fragments
When purification of DNA fragments was required 'for construction of recombinant
plasmids, the DNA was purified from agarose gels using the QIAquick® Gel
Extraction Kit (Qiagen). DNA fragments of interest were cut from an agarose gel
using a clean scalpel blade and the protocol was then performed according to the
manufacturer's instructions.
Cloning of hybrid DNA molecules
Ligation of vector and insert DNA
The quantity of vector and insert DNA used in ligations was calculated to produce a
molar ratio between 1:1 and 1:5 using the equation:
X ng of vector x Y kb of insert x insert: vector ratio = ng of insert required
Z kb of vector
Vector DNA was linearised using appropriate restriction enzyme(s). To prevent re-
circularisation of the vector DNA following digestion with a single enzyme, both 5'-
phosphate groups were hydrolysed twice with 0.01 units of CIAP (Promega) at 37 QC
for 30 minutes. Generally, 50 ng of vector DNA and a three fold molar excess of
insert DNA were ligated, with an appropriate volume of ligation buffer and 4 units T4
DNA ligase (Invitrogen), in a final volume of 20 ul. A control ligation, omitting
insert DNA was generally set up in parallel to the above, in order to check for
'background' when performing subsequent bacterial transformations. Ligations of
DNA fragments generated by PCR were carried out according to the manufacturer's
instructions with t e TOPO TA Cloning Kit (Invitrogen Life Technologies). TOPO
TA Cloning provides a highly efficient, 5 minute, one step cloning strategy for the
direct insertion of Taq polymerase-amplified PCR products into a plasmid vector.
Taq-polymerase has a nontemplate-dependent terminal transferase activity that adds a..
single deoxyadenosine (A) to the 3' ends of PCR products. The linearized vector
supplied in the kit has single, overhanging 3'deoxythymidine (T) residues. This
allows PCR inserts to ligate efficiently with the vector. Ligations were carried out
overnight at 14 QCexcept when using the TA-TOPO Cloning kit where ligations
')
were carried out at room temperature for 5 minutes. Stored thereafter at -20 QCif not
used immediately.
Transformation of bacteria with plasmid DNA
All transformations included a positive control using supercoiled plasmid DNA (eg
pUCl'9 10 pg/ml) to monitor the efficiency of the transforming bacteria and a ligation
control (vector DNA, no insert) to monitor the background rate of transformation due
to recircularisation of vector DNA.
Transformation of commercially prepared competent bacteria
2 III of a 1:5 dilution of ligation mix, 2 III of neat ligation mix or 2 III of TA ligation
mix were added to 50 III of One Shot@TOPlO Chemically Competent E. coli cells
(Invitrogen Life Technologies). Cells and DNA were mixed by gentle tapping to
avoid damage to the bacterial cells. In all cases the reactions were then incubated on
ice for 30 minutes. Cells transformed with ligation mix and TA ligation mix were
subsequently heat shocked at 42 QC for exactly 40 seconds and 30 seconds
respectively, and then returned to ice. 250 III of SOC medium (Invitrogen) was then
added and incubated at 37 QCfor 1 hour with shaking at 220 rpm. Cells (50 ~l and
200 ~l) were plated onto LB plates containing 100 ug/ml ampicillin and 1.6 mg X-Gal
(Section 2.1.11). Plates were incubated overnight at 37 QC.
Preparation offreshly competent bacteria and subsequent transformation
E.coli host strain: BL21 cells (Amersham Pharmacia Biotech), used for procedures
involving the pGEX plasmid were made competent using a modification of the
procedure described by Chung et al. (252). A single colony was picked from an LB
agar plate after overnight growth and used to inoculate 50 ml of LB broth. Bacteria
were grown at 37 QC,with shaking at 250 rpm, to an OD6ooof 0.4 to 0.5. The cells
Were then sedimented at 2500 g for 15 minutes at 4 QC,the supernatant discarded, and
then resuspended in 5 ml of ice-cold TSS buffer. Cells were kept on ice until used for
transformations, within 2 to 3 hours of preparation. Then, 1 ng or 5 ng of pGEX
plasmid DNA was added to 1 ml of freshly competent E.coli host strain: BL21 cells.
The mixture was incubated on ice for 45 minutes followed by heat shock at 42 QCfor
exactly 2 minutes and returned to ice. 100 III of the transformed cells were added to
900 III of LBG medium (Section 2.1.11) and incubated with shaking at 250 rpm for 60
minutes. Cells (50 j.ll and 200 ul) were plated onto LBAG plates (LB plates
containing 100 ug/rnl ampicillin; 20 mM glucose) and were incubated overnight at
37°C.
Screening of transformants for desired recombinant plasmids
All plasmid strains used in this project conferred ampicillin resistance upon host
bacteria, allowing selection and maintenance of transformed bacteria with ampicillin
supplemented media.
The pCR@n plasmid contains genes encoding the lacZa fragment of ~-galactosidase
and the lac promoter and is thus capable of complementation with the <p fragment
encoded by the E.coli host strains, giving active ~-galactosidase. The incorporation
of X-gal into LB agar plates allows the selection of transformants based on blue-white
screening. Disruption of lacZa expression occurs with the cloning of fragments into
the multiple cloning site of this vector, hence recombinants with plasmid containing
insert DNA appear white whilst non-recombinants, expressing a functional ~-
galactosidase, appear blue. White colonies were picked from plates containing X-Gal
and used to inoculate 5 ml of LB medium containing ampicillin (lOO ug/ml) and
grown overnight at 37 QCwith shaking. Alternatively, when large number of colonies
need to be screened to identify recombinants, colony hybridisation analysis was
performed using the method first described by Grunstein and Hogness (253). Briefly,
white or light blue colonies were picked, spotted not only on nitrocellulose filters over
LB agar plates containing 100 ug/ml ampicillin but also onto reference plates, and
then were incubated overnight at 37 QC. After that, the reference plate was placed at 4
QC and the filter upon which single bacterial clones had grown was treated as for
Southern blot (see 2.2.6) in order to allow identification of recombinants clones by
hybridisation with an appropriate probe (see below). Following identification of
recombinant clones, the relevant colony was picked from the reference plate and
expanded for further analysis.
Recombinant plasmid DNA, isolated by small-scale plasmid purification as described
above, was subjected to restriction digest with the appropriate enzyme(s), and the
resulting products of digestion run on a polyacrylamide or agarose gel, stained with
ethidium bromide and visualized by UV illumination. Bacteria with plasmids
containing inserts of the desired size were stored as glycerol stocks as detailed above.
2.2.3 Preparation of total RNA
" /
The unstable nature of isolated RNA and the necessity for very pure isolates for
downstream applications required that all materials used in RNA preparation be
totally free from ribonuclease (RNAse) activity. RNAse is a very stable, ubiquitous
enzyme that degrades RNA requiring no cofactors for function. All plasticware used
were RNAse free and all solutions were prepared using DEPC treated dH20. Gloves
were worn and changed frequently.
RNA extraction using RNA-Bee™
Various methods have been described for the isolation of undegraded RNA, and
progress in the field have led to the development of single step methods for the
procedure (254, 255). RNA-Bee ™ (Biogenesis) is a monophase solution containing
phenol and quanidine thiocyanate. This RNA isolation reagent is a complete and
ready-to-use reagent for isolation of total RNA from samples of human, animal, plant,
bacterial and viral origin. The samples used for RNA isolation in this project were
cell pellets harvested from tissue culture experiments. These were homogenised
directly in RNA-Bee™ by simply plpening-vigorously several times. 2 ml of RNA-
Bee™ was used per 107 cells. The homogenate was then incubated on ice for 5
minutes to allow dissociation of nucleoproteins from the nucleic acids. Chloroform
was then added (0.2x starting volume), and thorough mixing was carried out by
shaking the tube vigorously for approximately 30 seconds. The mixture was then
centrifuged at 12000 g for 15 minutes at 4 °C to allow separation of the mixture into
three distinct phases, an upper aqueous phase containing the RNA, a semi-solid
interphase containing most of the DNA, and a lower organic phase. The upper
aqueous phase was removed by careful pipetting and transferred to a clean 1.5 ml
RNAse-free microfuge tube. This was followed by addition of an equal volume of
isopropanol, mixing, and incubation of the sample on ice for 1 hour. The RNA was
then pelleted by centrifugation at 12000 g for 15 minutes at 4°C. The supernatant was
decanted, and a wash step using 75% ethanol was carried out, followed by
centrifugation at 7500 g for 5 minutes. The supernatant was decanted and the pellets
air dried for no longer than 10 minutes (complete drying of the pellet makes
resuspension difficult) and resuspended in 50 !!l of DEPC treated dHzO. RNA was
stored at -70 QC and its concentration determined either by spectrophotometry
(SectiBn 2.2.2) or using the RNA 6000 Nano LabChip Kit (see below).
Assessment of RNA
Assessment of RNA using RNA 6000 Nano LabChip Kit
RNA 6000 Nano LabChip Kit (Agilent Technologies) allows the characterisation of
total RNA samples and their concentration, with only nanograms of sample. Each
RNA LabChip contains an interconnected set of rnicrochannels that is used for
separation of nucleic acids fragments based on their size as they are driven through it
electrophoretically. For determination of RNA concentration, total RNA in sample
must be between 25 ng/uI to 250 ng/ul. The manufacturer's instructions were
followed using 1 ul of RNA sample either neat or 1:10 dilution with DEPC treated
dH20. All procedures were performed using RNase-free rnicrocentrifuge tubes and
pipette tips.
Assessment of RNA using agarose gel electrophoresis
Iug of each RNA sample was run on a 1% agarose TBE gel. Assessment of RNA
quality was carried out by checking the integrity of the I8S and 28S ribosomal
subunit bands, and examining their rate of migration in comparison to a A
DNAlHindIII fragments molecular weight standard (Invitrogen Life Technologies).
2.2.4 Amplification of DNA by polymerase chain reaction
The polymerase chain reaction (PCR) is a technique that allows the amplification of
DNA sequences between two specific oligonucleotides using very little starting
material.
Primer design
Primers were designed manually according to a protocol defined by QIAGEN (256).
Briefly, the guidelines for designing PCR primers followed are in terms of primer
sequence, to avoid running 3 or more G or C bases at the 3' -terminal sequence since it
may stabilize non-specific annealing of the primer. A thymidine at the 3' end should
also b~avoided, since it is more prone to mispriming than other nucleotides (257).
Mismatches between template and primer DNA at the 3'end should be avoided, as
DNA polymerase will be acting in a 5' to 3' direction, thus it is best if these are
located close to the 5' end of the primer. Moreover the formation of primer-dimers
can be avoided by not using primers with complementary sequences in the 3' region;
design of primers in this respect was aided by the Primer express software program
(Version 2.0 - Applied Biosystems).
Primer length should be between 18 and 30 nucleotides; any increase in size beyond
this is unlikely to improve primer specificity significantly and this size of primer is
sufficient for sequence as complex as the human genome. Other potential features of
the primer sequence, such as restriction enzyme sites or promoter elements should be
engineered onto the 5' end of the primer, because bases located at the 5' end of the
primer are less critical for primer annealing. Such additions can have a detrimental
effect on primer specificity at low temperatures, and so are best used when amplifying
from a single template vector.
Primer GC content of 40 - 60% is recommended.
The optimal annealing temperature was obtained from the estimated melting
temperature (Tm= 2 x (A+T) + 4 x (C+G».
Preparation of peR reactions
The sensitive nature of PCR means that very stringent steps must be taken if
contamination is to,be avoided. First, physical separation of the PCR area from bench
space used for other work is recommended. In the case of PCRs carried out in this
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project, a dedicated PCR suite isolated from the main laboratory was used (PCR 6
Vertical Laminar Airflow Cabinet with UV Sterilisation). In addition, a set of
instruments used to aliquot reagents (micropipettes and their tips) were kept within
the PCR suite and restricted to PCR use. Filter tip pipette tips were used to reduce the
chance of carryover of reaction components from one tube to the next and master
mixes of reagents were used whenever possible to reduce the number of pipetting
steps required per reaction. Reaction components including primers were aliquoted
prior to use and stored at -20°C.
Reaction conditions
Standard PCRs were carried out using 2x ReddyMix TMpCR Master Mix (ABgene),
which contains the Taq DNA polymerase isolated from Thermus aquaticus. Standard
reaction mixes were set up in either 50 !1-1 or 25 !1-1 in 0.2 ml reaction tubes containing
0.2 mM each dNTP, 75 mM Tris-HCl, pH 8.8, 20 mM (NH4hS04, l.5 mM MgCh,
0.01 % (v/v) Tween 20, l.25 units Taq DNA polymerase, 2.0 11Meach primer and
10 ng to 1 ug of template (genomic DNA or cDNA). Thermal cycling were carried
out in two programmable thermal cyclers; PCR Express Thermal Cycler (Hybaid
Limited, Middlesex, UK) and PTC-220 DNA Engine Dyad® Cycler (MJ Research
Incorporated, Massachusetts, USA). The exact parameters of the reactions varied, but
generally consisted of an initial denaturation at 94°C for 5 minutes (genomic DNA
template), followed by 20 to 35 cycles of: denaturation at 94 QC, for 1 minute;
annealing at 50°C to 60 °C for 1 minute; and extension at 72°C for 1 minute.
Reaction products were separated by polyacrylamide or agarose gel electrophoresis as
detailed in 2.2.2, using 5 !1-1 or 10 !1-1 of reaction product per well.
Purification and assessment of peR products
Single PCR products were excised either from polyacrylamide or from agarose gels.
Small PCR products were excised from 4% polyacrylamide gel and eluted using
acrylamide elution uffer (Section 2.1.11) at 37°C overnight. Eluate solution (13000
rpm for 1 minute) was precipitated using 2.5x volume of 100% ethanol at -70°C for
30 minutes. Pelleted DNA (13000 rpm for 20 minutes) was dried by centrifugation
under vacuum. The pellet was then resuspended in 25 !1-1 of ddH20 and highly
purified DNA was obtained using the QIAquick® PCR purification Kit (Qiagen)
according to the manufacturer's protocol. Long PCR products were excised from
agarose gel and highly purified DNA was obtained using the QfAquick'" Gel
Extraction Kit (Qiagen) according to the manufacturer's protocol. Then, 1/10 of
eluted DNA from polyacrylamide and agarose gels were assessed by 4%
polyacrylamide and 1% TBE agarose gels electrophoresis against a <1>X174RF
DNAlHaeIII fragments and a A DNA/HindIII fragments molecular weight standard
(Invitrogen Life Technologies), respectively and an estimation of quantity obtained.
First 'hrand DNA synthesis for reverse transcriptase (RT)-PCR
Analysis of gene expression requires accurate determination of mRNA levels, but as
PCR is based on amplification of DNA, the process of amplifying RNA sequence
requires an initial step of conversion of the RNA to cDNA by reverse transcription.
In order to maximise the likelihood of obtaining full-length cDNA copies of mRNA, a
commercial cDNA synthesis kit was employed (ImProm-II™ Reverse Transcription
System, Promega).
Typically, 1ug of total RNA was placed in a RNAse free microcentrifuge tube with
O.S ug Oligotd'Tj., primer and brought to S J.lIwith nuclease-free water. The mixture
was denatured at 70QC for S minutes then chilled on ice. A reverse transcription
reaction mix was assembled on ice containing lx RT buffer, S mM MgCh, O.S mM
dNTP mix, 1 U/[!1 Recombinant Rnasin® Ribonuclease Inhibitor, and 1 ul Improm-
IITMRT. The template-primer combination was added to the reaction mix on ice.
Following an initial annealing at 25 QCfor 5,minutes, the reaction was incubated at 42
QCfor up to 1 hour. The reverse transcriptase was thermally inactivated at 70 QCfor
IS minutes prior to amplification by PCR using primers specific for the gene of
interest. Freshly synthesised cDNA was kept at -20 QCfor long-term storage.
2.2.5 DNA sequenc analysis
Automated sequencing
Sample preparation
DNA sequencing was carried out using the Big Dye®Terminator Version 1.1 Cycle
Sequencing Kit (Applied Biosystems). Generally, 200 ng to 500 ng of highly purified
DNA template was added into the cycle sequencing reaction containing 3.2 pmol of
sequencing primers (Table 2-2), O.Sx sequencing buffer (80 mM Tris-HCI, 2 mM
MgClz) and 4 [!l of cycle sequencing mix (Big Dye® Terminator Version 1.1 Cycle
Sequencing Kit, Applied Biosystems). Samples were prepared in the PCR Express
Thermal Cycler (Hybaid Limited) incorporating 25 cycles of amplification, each cycle
consisting of a denaturing step at 96 QC for 30 seconds followed by an annealing
temperature of 50 QCfor 15 seconds, and an elongation step of 60 QCfor 4 minutes.
Sequencing products were purified by precipitation using ethanol (80%) at room
temperature for 15 minutes. Pelleted DNA (14000 rpm for 20 minutes) was washed
in ethanol (70%) and repelleted (14000 rpm for 10 minutes) before all ethanol was
removed and the pellet dried at 90 QCfor 1 minute. The pellet was then resuspended
in 25 !AI of Hi-Di Formamide (Applied Biosystems).
Sample sequencing and evaluation
Samples were loaded into 96 well plates and run on the ABI PRISM@ 3100 Genetic
Analyzer (PE Applied Biosystems, UK) under standard sequencing conditions for
generation of automated sequence data. Electrophoresis on the ABI PRISM@ 3100
Genetic Analyzer was performed using 36 em and 80 cm capillaries which reads up to
500 nucleotides and 950 nucleotides respectively, with 98.5% base calling accuracy
with less than 2% ambiguity. A series of different computational software were
utilised for sequence analysis including the 'Blast' search engine within the NCBI
database (http://www.ncbi.nlm.nih.gov/), and the 'Blat' search engine within the
UCSC Genome Browser Home (http://www:genome.ucsc.edu/).
Table 2·2. Sequencing primers.
Primer
name
Primer sequence Description
Universal 5'd[GTAAAACGACGGCCAG]3'
M13 (-20)
Forward
Universal
M13
Reverse
pGEX5'
pGEX 3'
Forward cycle sequencing
primer from pCR@II-TOPO
vector
5' d[CAGGAAACAGCT ATGAC]3' Reverse cycle sequencing
primer from pCR@II-TOPO
vector
5' d[GGGCTGGCAAGCCACGTTTGGTG]3' Forward sequencing primer
from pGEX series
5'd[CCGGGAGCTGCATGTGTCAGAGG]3' Reverse sequencing primer
from pGEX series
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2.2.6 DNA and RNA hybridisation analysis
Southern blot transfer of DNA
This was carried out essentially as described by Southern (258). Generally, 20 ug of
high molecular weight genomic DNA was digested with 100 units of the desired
restriction enzyme, in the appropriate restriction enzyme buffer and 2 mM
spermidine. The reactions were incubated overnight at 37°C. Digestion products
were then precipitated with half volume of 7.5 M ammonium acetate and two
volumes of 100% ethanol. Pelleted DNA (14000 rpm for 20 minutes) was washed
with 70% ethanol and repelleted (14000 rpm for 20 minutes) before all ethanol was
removed and the pellet dried by centrifugation under vacuum for 10 minutes and
resuspended in TB pH 8.0 for several hours at 37°C. DNA samples were
electrophoresed as described in the Section 2.2.2 on a 0.8% agarose gel in lx TAB
buffer overnight at 23 volts. 5 x 103 counts per minute of 32P_end labelled marker (1
!!g of A. DNNHindIII fragments) together with 1 ug of unlabeled marker were also
loaded on the gel. Following electrophoresis, the gels were stained in buffer solution
containing 0.5 ug/ml ethidium bromide for 30 minutes, viewed by UV
transillumination and photographed as described above; submerged in denaturation
buffer for 30 minutes, followed by submersion in neutralisation buffer for 30 minutes.
The gel was equilibrated in 20x SSC and the DNA was transferred onto Hybond™_N
nylon membrane (Amersham Biosciences) by capillary blotting overnight in 20x SSC
as described by Sambrook et al., 1989 (249). The membrane was removed and the
DNA crosslinked to the membrane (Spectrolinker XL-1500 UV Crosslinker,
Spectronics Corporation).
Northern blot transfer of RNA
20 ug of total cellular RNA was lyophilised (VR-l Hetovac, Heto Laboratory
Equipment), then resuspended in 20 ul of RNA loading buffer and denatured for 15
minutes at 65°C. Subsequently.fi ul of RNA running dye was added and RNAs were
separated on 1% agarose gel containing 2.2 M formaldehyde. Electrophoresis was
carried out for 3 to 5 hours at 100 volts in lx MOPS, with buffer recirculation (302S,
Watson Marlow Pumps). Moreover, 5 ug of RNA ladder (Invitrogen Life
Technologies), treated in the same way as the RNA samples, were used as molecular
weight markers. Following electrophoresis, the gel was stained in ddH20 containing
3 Ilg/ ml ethidium bromide for 10 minutes, then destained twice in ddH20 for 30
minutes, viewed by UV transillumination and photographed to confirm the presence
and integrity of RNA. The marker lanes were removed using a clean scapel,
destained overnight in ddH20 and photographed. The rest of the gel was equilibrated
in lOx SSC for 30 minutes, and then transferred overnight onto Hybond™ -N nylon
membrane (Amersham Biosciences) by capillary blotting in lOx SSC as described by
Sambrook et al., 1989 (249). The membrane was removed and the RNA crosslinked
to the membrane (Spectrolinker XL-1500 UV Crosslinker, Spectronics Corporation).
Preparation of radiolabelled DNA probes
PCR or restriction fragment DNA probes were gel purified from non-specific or
vector sequence (Section 2.2.4) and radioactively labelled using the RadPrime DNA
Labeling System (Invitrogen Life Technologies), and a_32p dCTP, specific activity
3000 Cilmmol (Amersham Life Science). Briefly, 25 ng of DNA fragment was made
up to 21 III with ddH20, boiled for 5 minutes and chilled on ice. Then, the heat
denatured DNA was radio labeled using 20 III of 2.5x RadPrime Buffer (Section
2.1.11), 10 pmol/ul of each three nucleoside triphosphates (dATP, dGTP, and dTTP),
1 III of Klenow fragment (Large Fragment of DNA Polymerase I) and 1.85 Mbq of a-
32p dCTP in a final volume of 50 III and incubated at 37°C for 10 minutes.
Unincorporated 32p_ labelled nucleotides 'were removed by gel-filtration through
Sephadex-G50 beads (Nick™Columns, Pharmacia Biotech) and labelled fragments
were eluted in 400 III of TE buffer and specific activity was determined by liquid
scintillation analysis (MicroBeta Jet Liquid Scintillation and Luminescence Counter,
Perkin Elmer Life Sciences). Probes were labelled to specific activities of 108
cpm/ug or greater. ""
Hybridisation of labelled probes to membrane bound nucleic acids
..
Membranes which had been pre-wetted in 2x SSC and rolled into Hybaid
hybridisation bottles were pre-hybridised in 15 ml of pre-warmed hybridisation buffer
(Rapid-hyb buffer, Amersham Pharmacia Biotech) at 65°C for 1 hour in a
hybridisation oven (Mini Oven MKII, Hybaid Limited) with continuous rotation.
Freshly, radiolabelled dsDNA probe was boiled for 5 minutes and chilled on ice prior
to addition to the pre-hybridisation solution: 106 ..cpmlml was used for genomic
Southerns and northerns and 105 cpmlml was used for plasmid DNA Southern blots.
Filters were hybridised at 65°C for 2 hours in a hybridisation oven with continuous
rotation. After rinsing briefly with 2x sse, the membrane was washed for 20 minutes
with _three changes of 0.1 x sse, 0.5% SDS at 60 DC, unless otherwise stated.
Membranes were then sealed in polythene and exposed either to X-ray film
(Hyperfilm MP, Amersham Biosciences) at -70°C or the Molecular Dynamics
Storage phosphor screen (Molecular Dynamics, Amersham Pharmacia Biotech) at
room temperature. In order to reprobe with an alternative probe, filters were stripped
of existing probe by continuous shaking in boiling ddH20 containing 0.1 % SDS until
the solution has cooled to room temperature.
2.2.7 Protein analysis
Protein extraction
Whole cell extracts, from cells grown in tissue culture were prepared for western blot
analysis essentially according to the method of Marais et al., (259). All procedures
were performed at 4 cc. Typically, cells were washed twice with ice-cold PBS,
drained throughly, lysed in 100 ",,1working whole cell lysis buffer (Section 2.1.11) per
106 cells or 60 mm dish and rotated for 10 minutes. The crude extract was cleared in
a bench top centrifuge at 14000 rpm for 30 minutes and the supernatant transferred to
a fresh pre-cooled eppendorf. Extracts were quantitated as described below, and
stored at -70°C.
Estimation of protein concentration
In order to estimate protein yields, a Bio-Rad Protein Assay (Bio-Rad), based on the
method of Bradford was used, in which a differential colour change of a dye occurs in
response to various concentrations of protein (260).
A protein standard (bovine serum albumin, BSA) was diluted with ddH20 to
concentrations ranging from 0.025 to 0.8 mg/ml to allow the production of a standard
curve each time the assay was performed. Aliquots of protein for quantification were
diluted in order to give a concentration in the above range. The dye reagent was
prepared by addition of 4 volumes of ddH20 to 1 volume of Dye Reagent Concentrate
(Bio-Rad) and filtration through a Whatman #1 to remove particulates. Samples were
diluted 11500 in diluted dye reagent, and incubated in sterile polystyrene cuvettes at
room temperature for 5 minutes to 1 hour. OD595was determined against the reagent
blank. The absorbance of the protein standards was used to construct a standard curve
from which an approximate concentration of the unknown samples could be read.
SDS - PAGE of proteins
The separation and analysis of proteins was facilitated by one dimensional denaturing
discontinuous gel electrophoresis, as originally described by Laemmli (1970) (261).
Mini SDS-PAGE gels (8.0 cm x 7.3 cm) were formed and run using the Mini-
PROTEAN II electrophoresis system (Bio-Rad) as recommended by the
manufacturer. Glass plates were assembled with 0.75 mm spacers in a casting stand.
The separating gel was poured to a depth of approximately 5 cm; consisting of 4 ml
30%: 0.8% w/v acrylamide/bisacrylamide (giving a 12% gel), 2.05 ml ddH20, 3.75
ml 1 M Tris-HCI (pH 8.8), 100 III 10% SDS, 100 III 10% APS and 4 III TEMED.
This was overlain with ddH20-saturated butanol and allowed to polymerise. The
butanol was then poured off, the surface of the separating gel rinsed with ddH20 and
the stacking gel poured; consisting of 830 III 30%: 0.8% w/v
acrylamide/bisacrylamide, 3.4 ml dH20, 630 III 1 M Tris-HCI (pH 6.8), 50 III 10%
SDS, 50 III 10% APS and 5 III TEMED. A 10 well comb was inserted and the gel
allowed polymerising. Gels were run in l x running buffer. Equal volumes of protein
sample and SDS-PAGE Protein 2x Sample Loading Buffer (Section 2.1.11) were
vortexed, heated to 95 QC for 5 minutes and chilled on ice prior to loading on gel.
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Wells were flushed and samples loaded using 0.2 mm flat-ended gel loading tips
(Sorenson Bioscience Inc). Moreover, 7 III of a protein molecular weight standard
(Precision Plus Protein™ Standards, Bio-Rad) was loaded in one or both outer wells
to allow size estimation of sample proteins.
Standard SDS-PAGE gels (13.8 cm x 13 cm) were formed and run using the AE-62oo
Slab EP Chamber, and AE-6220 Slab EP Chamber, for two gels (Atto Incorporation).
The separating gel was poured to a depth of approximately 10 cm; consisting of 16.7
ml 30%: 0.8% w/v acrylamide/bisacrylamide (giving a 10% gel), 13.4 ml dH20,
18.75 ml 1 M Tris-HCI (pH 8.8), 500 ul 10% SOS, 375 ul 10% APS and 20 JlI
TEMEO. This was overlain with ddH20-saturated butanol and allowed to
polymerise. The butanol was then poured off and the surface of the separating gel
rinsed with ddH20. Excess water was removed with a sheet of 3mm Whatman filter
paper! and the stacking gel poured; consisting of 3.4 ml 30%: 0.8% w/v
acrylamidelbisacrylamide, 13.6 ml ddH20, 2.5 ml 1M Tris-HCl (pH 6.8), 200 ul 10%
SOS, 200!-t1 10% APS and 20 JlI TEMEO. A 14 well comb was inserted and the gel
allowed polymerising. Gels were run in lx running buffer, and samples were treated
as for mini SOS-PAGE gels (see above). Moreover, 14 JlI of a protein molecular
weight standard (Precision Plus Protein ™ Standards, Bio-Rad) was loaded in one or
both outer wells to allow estimation of the size of sample proteins.
Mini SOS-PAGE gels were electrophoresed at 110 volts to 150 volts for 55 to 90
minutes, and standard SOS-PAGE gels at 230 volts to 250 volts for 2 hours until the
bromophenol blue dye reached the bottom of the separating gel. The gel was then
removed from the glass plates, the stacking gel discarded, and the protein bands
detected either by staining with SOS-PAGE Protein Gel Fix-Stain Solution (Section
2.1.11) or by immunodetection as described below. Visualisation of protein bands
with Coomassie Brilliant Blue involved staining for one hour in four to five gel
volumes of protein fix-stain solution followed by destaining for approximately 4 to 24
hours in destain solution (Section 2.1.11), with four to five changes of solution. Gels
were then removed and preserved by drying for two to six hours, sandwiched between
prewetted cellulose film (Amersham Bioscience), in a gel drying apparatus (Easy
Breeze Air Gel Dryer - Hoefer Scientific Instruments).
Electroblotting
Electroblotting was necessary for the transfer of protein after polyacrylamide
resolving gel electrophoresis to a nitrocellulose membrane.
Following electrophoresis:
Mini SOS-PAGE gels were removed from the glass plates, and the resolving gel
equilibrated in lx transfer buffer with 15% methanol (Section 2.1.11) for 5 minutes at
room temperature. Two Scotch-Brite pads and a further 4 pieces of 3MM Whatmann
filter paper of the same size as the gel were presoaked for 10 minutes in l x transfer
buffer, carefully removing air pockets from the Scotch-Brite pads by repeated
squeezing and agitation. These pieces were necessary for building up a sandwich
around the gel for electroblotting. One piece of Hybond ECL nitrocellulose
membrane (Amersham Biosciences) was presoaked for 1 minute in Ix transfer buffer.
Electroblotting experiments were carried out using the Mini-PROTEAN® II cell (Bio-
Rad). The electroblot apparatus contains a gel holder consisting of hinged white and
black clamps on which the components of the sandwich are built up on the black
clamp as follows; Scotch Brite pad, 2x filter papers, gel, nitrocellulose membrane,
followed by the remaining 2 pieces of filter paper and the second Scotch Brite pad.
At each stage any air bubbles are carefully removed from between the layers. The gel
holder is then closed and placed in the transfer cell with the black clamp facing the
cathode. An ice block is included to prevent overheating of the transfer buffer. The
cell is thenfilled with lx transfer buffer and electroblotted for 45 minutes at 80 volts
in the cold room (4°C). Molecular weight marker positions were highlighted and the
membrane stored at 4 "C.
Standard SDS-PAGE gels were removed from the glass plates, and the resolving gel
equilibrated in 1x dry blot buffer with 20% methanol (Section 2.1.11) for 15 minutes
at room temperature. The gel was covered in pre-wetted nitrocellulose membrane (Ix
dry blot buffer) and sandwiched between 12 pieces of Whatman 3MM rinsed in lx
dry blot buffer. The sandwich was turned over and placed on the semi dry blotter
(Trans-blot" SD Semi-Dry Transfer Cell, Bio-Rad). Air bubbles were removed and
transfer effected at 20 volts for 2 hours. Molecular weight marker positions were
highlighted and the membrane stored at 4 "C....
EeL detection
The detection of proteins by immunoblotting (western blotting) is a rapid and
sensitive technique that exploits the inherent specificity of antigen recognition by
antibodies (262).
Hybond-ECL nitrocellulose membrane (Amersham Biosciences) was immersed in lx
TBST buffer (Section 2.1.11) containing 5% low fat dried milk (Marvel - Premier
Beverages, Stafford, UK) overnight at 4°C, to block non-specific binding sites, rinsed
briefly with Ix TBST buffer, washed once for 15 minutes, and then twice for 10
minutes, with shaking at room temperature in Ix TBST buffer. The membrane was
then incubated with the primary antibody, at a pre-determined dilution in blocking
buffer (either 5% low fat dried milk, TBST or, 5% BSA, TBST), with shaking. This
was followed by washing three times in Ix TBST buffer for 10 minutes, with shaking
at room temperature, prior to incubating with the secondary antibody (HRP labelled),
appropriately diluted in 5% low fat dried milk, TBST, for I hour, at room
temperature, with shaking. The membrane was washed as above before detection
using the ECL™ Western Blotting Detection Reagents (Amersham Biosciences).
Enhanced Chemiluminescence (ECL) is a light-emitting-non-radioactive method for
detecting immobilized specific primary antibodies conjugated with horseradish
peroxidase (HPR)-linked secondary antibodies. Light emission is generated by the
HPRlhydrogen peroxide catalysis of luminal to an excited oxidated state, and it is
dramatically enhanced in the ECL system by chemical enhancers such as phenol
(263). Briefly, an equal volume of detection reagent A was mixed with reagent B
(typically 4 ml each). Excess buffer was drained from the membrane and the
detection solution was pipetted onto the surface of the membrane carrying the protein.
After incubation for one minute at room temperature, excess reagent was drained
from the membrane, which was then wrapped in plastic film. The membrane was
exposed to blue-light sensitive autoradiography film (Hyperfilm ECL, Amersham
Biosciences) for seconds or minutes, before developing in an automated processor
(SRX-IOIA Compact X4, Xograph Imaging Systems).
Unless otherwise stated, membranes were stripped for subsequent analysis in 200 ml
of 0.2 M Glycine, pH 2.5, 1% SDS, for I hour at room temperature. The membranes
were washed three times at room temperature in Ix TBST buffer, blocked overnight
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and then probed with I: 1000 dilution of goat anti ~-actin (1-19) sc-1616 polyclonal
antibody (Santa Cruz Biotechnology) for 4 hours at room temperature. As a
secondary antibody, HRP conjugated rabbit anti-goat IgG polyclonal antibody
"
(DakoCytomation) was used at dilution of 1:2000 for 1 hour at room temperature.
Chapter III
Structure and coding potential of the human and murine L VI-1 genes
3.1 Introduction
Due to the limiting resources of feline genome and cDNA sequence information, it
was decided to focus on the human and murine orthologues of the LVI-J gene, which
could ultimately be used to model the effects of truncation or transcriptional silencing
of the gene. Previous work indicated that the transcript sizes for LVI-J were different
for the human, murine and feline genes (58). It was therefore considered important to
establish the basic transcription pattern and the coding potential of the LVI-J genes.
At the outset of my work, very little was known about the murine gene, and no full-
length cDNA had been reported. However, the available database information has
grown steadily, allowing comparison and validation of my experimentally derived
information with public domain sequence information. The chapter describes an
analysis of the structure of the human and murine LVI-J genes based on the currently
available information in 2006.
3.2 Analysis of LVI-l genomic organisation in human and murine
The mammalian LVI-J gene is highly conserved and comprises 13 exons covering 40
kb of the human genome on chromosome l5ql5 and 37 kb of the murine genome on
chromosome 2 band E5. The overall genomic organisation of the human and murine
LVI-J genes is shown in Figure 3-1. This and other figures are based on the latest
public domain releases of the human and murine genome sequences, ESTs and cDNA
clones (http://www.genome.ucsc.edu). Homology is evident over exons 2 - 13 of the
murine and humangenes. The murine gene has a longer 3'UTR (2.3 vs 0.6 kb),
which is sufficient to account for the differences in the major transcripts detected by
northern blot analysis (4.5 vs 2.8 kb) in previous studies (58). There is an obvious
difference, however, at the 5' end of the genes and the 5' exons display no obvious
homology.
Comparison of the predicted amino acid sequence of the human and murine cDNAs
shows a high degree of homology from exon 2-13, but 5' start regions show a
difference between species as a result of the utilisation of different 5' exons and
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promoters, which I have designated PI and P2. Human LVI-l transcripts III the
database appear to be derived from the proximal (F2) promoter region whereas the
murine transcripts contain sequences derived from further upstream in the PI
promoter region (Figure 3-2), close to the adjacent 5' gene (MJapl). Another
difference between the annotated human and mouse genome sequences lies in the
CpO Jsland that marks the apparent 5' end of the human LVI-l gene and is not
detected in the murine gene.
CpO islands are associated with the 5' ends of most house-keeping genes and many
regulated genes in vertebrates. Often CpO islands overlap the promoter and extend
about 1000 base pairs downstream into the transcription unit. In fact, they provide
one of the most reliable measures for promoter prediction (264, 265). Along with
other conserved features these elements inform algorithms that can be used to predict
the presence of a eukaryotic promoter. The genomic regions spanning PI and P2
were analysed for predicted promoters using the Proscan programme version 1.7
(http://thr.c"it.nih.gov/molbio/proscan/).This analysis is reported to predict pol IT
promoters with a 70% success rate and one false positive/ l-lkb (266). The
programme identifies a number of promoter elements in the human and murine L V/-l
PlIP2 regions (Figure 3-2). Notably, the PI region predicts a 5'->3' promoter activity
for the murine genomic region, but a 3' ->5' element for the equivalent human.
An obvious possibility is that the LV/-l gene has a dual promoter structure, with
alternative isoforms arising from the us~ of either element. To examine this
possibility more closely, the PI and P2 regions were examined for the presence of
conserved sequence elements, such as open reading frames and splice donor sites. As
shown in Figure 3-3, the PI region flanks the adjacent Mfap l gene and the longest
murine Lvi-l cDNA clones begin only 98 bp 3' to MJapl transcription unit. This
observation would suggest that PI promoter region of the murine Lvi-l gene is bi-
directional and capable of driving expression of both the Lvi-l and Mjapl gene. A
binding site for Sp l (stimulating protein 1), which is frequently found within CpO-
rich promoters, marks the 5' limit of the murine Lvi-l cDNAs. At the 3' end of exon
la, there is a canonical splice donor signal (sd2: AOOT) and a variant (sd l: TOOT),
which has been utilized in one of the mLvi-l cDNA clones (AK031592). The most
commonly used splice donor (sd2) is conserved in the human genomic sequence. At
the P2 region, it is clear that the mouse sequence is also rich in CpOs, although the
81
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reduced stretch of these linkages presumably explains the failure of standard
algorithms to score a CpG island in the mouse sequence. However, in contrast to PI,
the essential elements appear conserved here, including the major splice donor at the
end of exon le (sd l). A second donor, which is used in one human LV/-J cDNA
(BC025247) is not conserved in the murine sequence. Notably, a short open reading
frame that marks the predicted translational start of the hL V/-J gene is also conserved
in the murine sequence, raising the possibility that this promoter may be used in
expression of the murine gene.
In contrast, variant exon Ib in the murine gene does not appear to correspond to
predicted promoter structure and its significance is unknown at present as it has been
detected only in a single reported EST (CF172437 (Figure 3-2, exon lb)) that was
spliced to exons distal to exon 2. No experimental support was found for the use of
this exon (data not shown).
The PI/P2 promoter regions were also subjected to analysis for transcription factor
binding sites using the programme TFSEARCH, which is available in the public
domain (http://www.cbrc.jp/research/dbITFSEARCH.html) (267).
Relatively few conserved sites were identified, but some of the potentially significant
motifs are indicated in Figure 3-3. These include sites for ETS (E26-Transformation-
Specific) and GATA factors, which may account for the relatively high expression of
this gene in haematopoietic cells. Another conserved feature is a heat shock
transcription factor binding site at the 3' end of exon la. The two known transcription
factors that can bind to this site are the heat shock transcription factor HSTF-I and
HSTF-2; members of the heat shock factor (HSF) protein family involved in heat
shock protein (HSP) gene regulation; a regulation that is critical for the ability of cells
to survive exposure to stress conditions. Also of note is the occurrence of adjacent
Spl sites at the human LV/-J P2 promoter, which is not precisely conserved in the
murine gene. Sp I sites also have a high predictive value for transcriptional initiation.
3.3 Coding potential of the LVI-l genes
At the outset of this project there was limited sequence information about the
mammalian LV/-J genes and no full-length cDNA had been cloned for the murine
gene. However, a number of cDNA sequences have subsequently been submitted to
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the databases. An alignment of these sequences is presented in Figure 3-4. The
largest predicted gene product of the human cDNAs 'CAK023035, BC051855) encode
a product of 626 amino acids with a predicted molecular weight of 69.75 kDa, while
the longest murine open reading encodes a protein of 57.96 kDa. However, as will be
seen from the sequence alignment, the principal difference between the human and
murine products lies in the N-terminal domain, which is derived from exon lc in most
of the predicted human gene products, but within exon 2 in the mouse products. One
of the human cDNAs, which has an alternative splicing structure that places the exon
lc start out of frame has a homologous start site to the murine gene products. A more
complete list of the potential start sites in exons le and 2 is given in Figure 3-5.
These potential start sites were subjected to analysis using the programme TIS Miner
(http://research.i2La-staLedu.sg/DNAFSMiner), which predicts the probability of
utilisation of each AUO in mammalian mRNAs based on match to consensus
sequences and an algorithm based on a large dataset of several thousand eukaryotic
mRNAs (268). This analysis suggested that the first ATO of the murine cDNA
sequence (MKALS) is the most likely translational initiation site in this mRNA.
However, a similar analysis of the human cDNA sequences suggested that the second
ATO (MKVNE) was more likely to be utilised than the first (MSRSO), while the use
of the next in-frame start, which matches to the murine start site (MKNTS) was only
slightly less likely to be utilised. The second site (MKVNE) has no equivalent in the
hypothetical murine exon 1c cDNA. However, analysis of this theoretical structure
strongly suggests that the first initiator will be used (MSOSK, 0.955) although the
next in-frame start is also quite strongly predicted (MKALS, 0.815). These results do
not provide a strong prediction with regard to the most likely initiation site, and
highlight the need for experimental test of these predictions.
3.4 Predicted LVI-1 gene products and their properties
The most striking feature of the LVI-l gene products is the C-terminal 250 amino
acids which consists of a series of WD-40 repeats (see Chapter I). No other
recognised protein motifs are found, although domain architecture programmes such
as SMART (Simple Modular Architecture Research Tool) available online at
(http://smart.embl-heidelberg.de/) define low complexity regions in the variable N-
terminal domains.. This outline structure is depicted In Figure 3-6.
85
BC025247
AK023035
BC051855
CR595259
Human consensus
BC094676
AK031592
AK162181
AK051037
AK020004
Mouse consensus
BC025247
AK023035
BC051855
CR595259
Human consensus
BC094676
AK031592
AK162181
AK051037
AK020004
Mouse consensus
BC025247
AK023035
BC051855
CR595259
Human consensus
BC094676
AK031592
AK162181
AK051037
AK020004
Mouse consensus
BC025247
AK023035
BC051855
CR595259
Human consensus
BC094676
AK031592
AK162181
AK051037
AK020004
Mouse consensus
BC025247
AK023035
BC051855
CR595259
Human consensus
BC094676
AK031592
AK162181
AK051037
AK020004
Mouse consensus
BC025247
AK023035
BC051855
CR595259
Human consensus
BC094676
AK031592
AK162181
AK051037
AK020004
Mouse consensus
--------~~~~-=~----~--~~~~-~--------------------------------}MSRSGAAAEKADSRQRPQMKVNEYKENQNIAYVSLRPAQTTVLIKTAKVYLAPFSLSNYQ
MSRSGAAAEKADSRQRPQMKVNEYKENQNI~YVSLRPAQTTVLIKTAKVYLAPFSLSNYQ
MSRSGAAAEKADSRQRPQMKVNEYKENQNIAYVSLRPAQTTVLIKTAKVYLAPFSLSNYQ
MSRSGAAAEKADSRQRPQMKVNEYKBNQNIAYVSLRPAQTTVLIKTAKVYLAPPSLSNYQ
......~~~~..~~.: ~~~~ ~ ~..~~~J-
Human
Murine
-------------------------------------MKNTSSKAESTLQNSSSAVHTES
LDQLMCPKSLSEKNSNNEVACKKTKIKKTCRRII PPKMKNTSSKAESTLQNSSSAVHTES
LDQLMCPKSLSEKNSNNEVACKKTKIKKTCRRIIPPKMKNTSSKAESTLQNSSSAVHTES
LDQLMCPKSLSEKNSNNEVACKKTKIKKTCRRIIPPKMKNTSSKAESTLQNSSSAVHTES
-------------------------------------MKNTSSKAESTLQNSSSAVHTES
-------------------------------------MKALSSKADSLLLKSSVDAYTES
-------------------------------------MKALSSKADSLLLKSSVDAYTES
-------------------------------------MKALSSKADSLLLKSSVDAYTES
-------------------------------------MKALSSKADSLLLKSSVDAYTES
-------------------------------------MKALSSKADSLLLKSSVDAYTES
-------------------------------------MKALSSKADSLLLKSSVDAyTES
/ exon 3
NKLQPKRTADAMNLSVDVESSQDGDSDEDTTPSLD-FSGLSPYERKRLKNISENADFFAS
NKLQPKRTADAMNLSVDVESSQDGDSDEDTTPALD-FSGLSPYERKRLKNISENADFFAS
NKLQPKRTADAMNLSVDVESSQDGDSDEDTTPALD-FSGLSPYERKRLKNISENADFFAS
NKLQPKRTADAMNLSVDVESSQDGDSDEDTTPSLD-FSGLSPYERKRLKNISENADFFAS
NKLQPKRTADAMNLSVDVESSQDGDSDEDTTPSLD-PSGLSPYERKRLKNISENADPPAS
TRLGPKRTSDSATLSVDAES-----SDEDSAPGLDDFSGLSPYERKRLRNIRENANFFAS
TRLGPKRTSDSATLSVDAES-----SDEDSAPGLDDFSGLSPYERKRLRNIRENANFFAS
TRLGPKRTSDSATLSVDAES-----SDEDSAPGLDDFSGLSPYERKRLRNIRENAXFFAS
TRLGPKRTSDSATLSVDAES-----SDEDSAPGLDDFSGLSPYERKRLRNIRENANFFAS
TRLGPKRTSDSATLSVDAES-----SDEDSAPGLDDFSGLSPYERKRLRNIRENANFFAS
TRLGPKRTSDSATLSVDAES-----SDEDSAPGLDDPSGLSPYERKRLRNIRENANPPAS
(exon 3a) / exon 4 / exon 5
LQLSE----------------SAARLREMIEKRQPPKSKRKKPKR-ENGIGCRRSMRLLK
LQLSE----------------SAARLREMIEKRQPPKSKRKKPKR-ENGIGCRRSMRLLK
LQLSE----------------SAARLREMIEKRQPPKSKRKKPKR-ENGIGCRRSMRLLK
LQLSE----------------SAARLREMIEKRQPPKSKRKKPKR-ENGIGCRRSMRLLK
LQLSE----------------SAARLREMIEKRQPPKSKRKKPKR-ENGIGCRRSMRLLK
LQLAE----------------SAARLRGMIKKRESPESKRKRPKKKENEIGCRRSMRLLK
LQLAE----------------SAARLRGMIKKRESPESKRKRPKKKENEIGCRRSMRLLK
LQLAE----------------SAARLRGMIKKRESPESKRKRPKKKGDEIGCRRSMRLVK
LQLAE---------------"SAARLRGMIKKRESPESKRKRPKKKENEIGCRRSMRLLK
LQLAETLVSLLVGVACCPSLNSAARLRGMIKKRESPESKRKRPKKKENEIGCRRSMRLLK
LQLAE----------------SAARLRGMIKKRESPESKRKRPKKKENEIGCRRSMRL_K
/ exon 6 /
VDPSGVSLPAAPTPPTLVADE-TPLLPPGPLEMTSENQEDNNERFKGFLHTWAGMSKPSS
VDPSGVSLPAAPTPPTLVADE-TPLLPPGPLEMTSENQEDNNERFKGFLHTWAGMSKPSS
VDPSGVSLPAAPTPPTLVADE-TPLLPPGPLEMTSENQEDNNERFKGFLHTWAGMSKPSS
VDPSGVSLPAAPTPPTLVADE-TPLLPPGPLEMTSENQEDNNERFKGFLHTWAGMSKPSS
VDPSGVSLPAAPTPPTLVADE-TPLLPPGPLEMTSENQEDNNERPKGPLHTWAGMSKPSS
VDPLGVSLPASPTQPTLVEEEENPLLPPGPLEMIPENQDDSSELLKASLKTWAEMSQTSN
VDPLGVSLPASPTQPTLVEEEENPLLPPGPLEMIPENQDDSSELLKASLKTWAEMSQTSN
VDPLGVSLPASPTQPTLVEEEGNPLLPPGPLEMIPGNQDDSSELLKASLKTWAEMSQTSN
VDPLGVSLPASPTQPTLVEEEENPLLPPGPLEMIPENQDDSSELLKASLKTWAEMSQTSN
VDPLGVSLPASPTQPTLVEEEENPLLPPGPLEMIPENQDDSSELLKASLKTWAEMSQTSN
VDPLGVSLPASPTQPTLVEEEENPLLPPGPLBMIPENQDDSSELLKASLKTWAEMSQTSN
exon 7 / exon 8 WD-40 repeat
KNTEKGLSSIKSYKANLNGMVISEDTVYKVTTGPIFSMALHPSETRTLVAVGAKFGQVGL
KNTEKGLSSI KSYKANLNGMVISEDTVYKVTTGPI FSMALHPSETRTLVAVGAKFGQVGL
KNTEKGLSSIKSYKANLNGMVISEDTVYKVTTGPIFSMALHPSETRTLVAVGAKFGQVGL
KNTEKGLSSIKSYKANLNGMVISEDTVYKVTTGPIFSMALHPSETRTLVAVGAKFGQVGL
KNTEKGLSSIKSYKANLNGMVISEDTVYKVTTGPIPSMALHPSETRTLVAVGAKPGQVGL
EKTKKGLSSIKSYKANLSGMVISEATVRKVTKGAISSVALHPSEVRTLVAAGAKSGQIGL
EKTKKGLSSIKSYKANLSGMVISEATVRKVTKGAISSVALHPSEVRTLVAAGAKSGQIGL
EKTKKGLSSIKSYKANLSGMVISEATVRKVTKGAMLLRGPPPIRSENL---GSSWGQV--
EKTKKGLSSIKSYKANLSGMVISEATVRKVTKGAISSVALHPSEVRTLVAAGAKSGQIGL
EKTKKGLSSIKSYKANLSGMVISEATVRKVTKGAISSVALHPSEVRTLVAAGAKYGQIGL
EKTKKGLSSIKSYKANLSGMVISEATVRKVTKGAISSVALHPSEVRTL---G---GQ---
/ exon 9 WD-40 repeat /
BC025247 CDLTQQPKEDGVYVFHPHSQPVSCLYFSPANPAHILSLSYDGTLRCGDFSRAIFEEVYRN
AK023035 CDLTQQPKEDGVYVFHPHSQPVSCLYFSPANPAHILSLSYDGTLRCGDFSRAIFEEVYRN
BC051855 CDLTQQPKEDGVYVFHPHSQPVSCLYFSP~PAHILSLSYDGTLRCGDFSRAIFEEVYRN
CR595259 CDLTQQPKEDGVYVFHPHSQPVSCLYFSPANPAHILSLSYDGTLRCGDFSRAIFEEVYRN
Human consensus CDLTQQPKEDGVYVPHPHSQPVSCLYPSPANPAHILSLSYDGTLRCGDFSRAIFEEVYRN
BC094676 WDLTQQ-SEDAMYVFYAHSRYVSCLSFSPTNPAHLLSLSYDGTLRCGDFSSAVFEEVYRN
AK031592 WDLTQQ-SEDAMYVFYAHSRYVSCLSFSPTNPAHLLSLSYDGTLRCGDFSSAVFEEVYRN
AK162181 ------------------------------------------------------------
AK051037 WDLTQQ-SEDAMYVFYAHSRYVSCLSFSPTNPAHLLSLSYDGTLRCGDFSSAVFEEVIMQ
AK020004 WDLTQQ-SEDAMYVFYAHSRYVSCLSFSPTNPAHLLSLSYDGTLRCGDFSSAVFEEVGSD
Mouse consensus WDLTQQ-SEDAMYVFYAHSRYVSCLSPSPTNPAHLLSLSYDGTLRCGDFSSAVPEEVYRN
exon 10 WD-40 repeat
BC025247 ERSSFSSFDFLAEDASTLIVGHWDGNMSLVDRRTPGTSYEKLTSSSMGKIRTVHVHPVHR
AK023035 ERSSFSSFDFLAEDASTLIVGHWDGNMSLVDRRTPGTSYEKLTSSSMGKIRTVHVHPVHR
BC051855 ERSSFSSFDFLAEDASTLIVGHWDGNMSLVDRRTPGTSYEKLTSSSMGKIRTVHVHPVHR
CR595259 ERSSFSSFDFLAEDASTLIVGHWDGNMSLVDRRTPGTSYEKLTSSSMGKIRTVHVHPVHR
Human consensus ERSSPSSFDPLAEDASTLIVGHWDGNMSLVDRRTPGTSYEKLTSSSMGKIRTVHVHPVHR
BC094676 EGNSPSSFDFL-NDSSSLLVGHWDGHLSLVDRRTPGTSYEKFFNSSLEKIRTVHVHPLSR
AK031592 EGNSPSSFDFL-NDSSSLLVGHWDGHLSLVDRRTPGTSYEKFFNSSLEKIRTVHVHPLSR
AK162181 ------------------------------------------------------------
AK051037 MYLRPDIR----------------------------------------------------
AK020004 QEA---------------------------------------------------------
Mouse consensus EGNSPSSPDFL-NDSSSLLVGHWDGHLSLVDRRTPGTSYEKPFNSSLEKIRTVHVHPLSR
/ exon 11 WD-40 repeat /
BC025247 QYFITAGLRDTHIYDARRLNSRRSQPLISLTEHTKSIASAYFSPLTGNRVVTTCADCNLR
AK023035 QYFITAGLRDTHIYDARRLNSRRSQPLISLTEHTKSIASAYFSPLTGNRVVTTCADCNLR
BC051855 QYFITAGLRDTHIYDARRLNSRRSQPLISLTEHTKSIASAYFSPLTGNRVVTTCADCNLR
CR595259 QYFITAGLRDTHIYDARRLNSRRSQPLISLTEHTKSIASAYFSPLTGNRVVTTCADCNLR
Human consensus QYPITAGLRDTHIYDARRLNSRRSQPLISLTEHTKSIASAYPSPLTGNRVVTTCADCNLR
BC094676 QYFVTAGLRDVHVYDARFLKSRGSQPLISLTEHSKSIASAYFSPVTGNRVVTTCADCKLR
AK031592 QYFVTAGLRDVHVYDARFLKSRGSQPLISLTEHSKSIASAYFSPVTGNRVVTTCADCKLR
AK162181 ------------------------------------------------------------
AK051037 ------------------------------------------------------------
AK020004 ------------------------------------------------------------
Mouse consensus QYPVTAGLRDVHVYDARPLKSRGSQPLISLTEHSKSIASAYPSPVTGNRVVTTCADCKLR
BC025247
AK023035
BC051855
CR595259
Human consensus
BC094676
AK031592
AK162181
AK051037
AK020004
exon 12 / exon 13
IFDSSCISSKIPLLTTIRHNTFTGRWLTRFQAMWDPKQEDCVIVGSMAHPRRVEIFHETG
IFDSSCISSKIPLLTTIRHNTFTGRWLTRFQAMWDPKQEDCVIVGSMAHPRRVEIFHETG
IFDSSCISSKIPLLTTIRHNTFTGRWLTRFQAMWDPKQEDCVIVGSMAHPRRVEIFHETG
IFDSSCISSKIPLLTT----------------------------------------- _
IPDSSCISSKIPLLTTIRHNTPTGRWLTRPQAMWDPKQEDCVIVGSMAHPRRVEIFHETG
VFDSSSISSQLPLLSTIRHNTVTGRWLTRFQAVWDPKQEDCFIVGSMDHPRRVEVFHESG
VFDSSSISSQLPLLSTIRHNTVTGRWLTRFQAVWDPKQEDCFIVGSMDHPRRVEVFHESG
------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------
Mouse consensus VPDSSSISSQLPLLSTIRHNTVTGRWLTRFQAVWDPKQEDCPIVGSMDHPRRVEVPHESG
BC025247
AK023035
BC051855
CR595259
WD-40 repeat
KRVHSFGGEYLVSVCSINAMHPTRYlLAGGNSSGKIHVFMNEKSC
KRVHSFGGEYLVSVCSINAMHPTRYlLAGGNSSGKIHVFMNEKSC
KRVHSFGGEYLVSVCSINAMHPTRYlLAGGNSSGKIHVFMNEKSC
Human consensus
BC094676
KRVHSFGGEYLVSVCSINAMHPTRYlLAGGNSSGKIHVPMNEKSC
KNVHSLWGECLVSVCSLSAVHPTRYlLAGGNSSGKLHVFMHQET-
KNVHSLWGECLVSVCSLSAVHPTRYlLAGGNSSGKLHVFMHQET--- WTKLDFGI_AK031592AK162181
AK051037
AK020004
Mouse consensus KNVHSLWGECLVSVCSLSAVHPTRYlLAGGNSSGKLHVFMHQET-
Figure 3·4. Predicted amino acid sequence comparison of human and murine
LVI·1 cDNAs. Published human (BC025247, AK023035, BC051855, and
CR595259) and murine (BC094676, AK031592, AK162181, AK051037, AK020004)
cDNA is shown. Bold text indicates the human and mouse consensus sequences.
Underlined text represents theWD-40 repeats.
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The predicted proteins were also examined for physicochemical properties (Chapter
VI) and likely subcellular location using the online-programme pTARGET available
on the web page (http://bioinformatics.albany.edu) (269), which lists nine potential
subcellular locations and assigns proteins to these on the basis of known motifs and
N- and C-terminal amino acid composition which are characteristic of proteins found
at each site. pTARGET also provides us with a confidence value for each prediction
which is calculated as the ratio of calculated score to the total score required,
expressed as percentage (100% means that the calculated score is the same as the
Score required to be a true prediction). This programme strongly predicts a nuclear
location for all of the LV/-J gene products with 88 - 100% confidence (see Table 3-
1).
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Table 3·1. Predicted location of predicted LVI·l gene products. Analysed by
pTARGET programme available online at: http://biQinformatics.albany.edul-ptargetJ
(269).
cDNA Localisation Confidence
Murine BC094676 Nuclear 87.6%
Murine AK031592 Nuclear 87.6%
Murine AK162181 Nuclear 93.9%
Murine AK00204 Nuclear 93.9%
Hypothetical exon 1c mRNA Nuclear 100%
Human BC025247 Nuclear 100%
Human AK023035 Nuclear 100%
Human BC051855 Nuclear 100%
Human CR595259 Nuclear 100%
3.5 Discussion
Analysis of the human and murine LVI-I genes and known transcripts reveals a
difference in 3'UTR length, which presumably accounts for the differences in mRNA
size detected on northern blot analysis from a previous study (58). The most
significant difference, however, is seen at the 5' end where the human and murine
genes appear to use alternative promoters. Based on the evidence of the available
cDNAs and numerous ESTs, the murine gene is transcribed from the distal PI
promoter, which appears to be a bi-directional element shared with the adjacent
MJapI gene. In contrast, the human gene transcripts are derived from the proximal P2
promoter. Analysis of gene structure in the PI and P2 regions provides some
theoretical support for this species differences.
Promoter prediction algorithms score the forward PI promoter only for the murine
gene. The P2 promoter adjacent to exon le is more strongly predicted in the human
genome and it is conceivable that the use of the distal P I promoter by the murine gene
would suppress transcription here by the phenomenon of promoter interference (270).
However, it is notable that the basic architecture of exon le is conserved in the murine
including with its open reading frame and splice donor sites. The possibility remains,
therefore, that the P2 promoter might be used by the murine gene in some
circumstances.
The issue of LVI-I gene promoter use is important, as there are implications for the
encoded gene products. Use of P2 and exon le would result in mRNA encoding a
protein with close to 100 additional amino acids, compared to the use of the next
common ATG. However, in view of the relative uncertainty of translational initiation
predictions, it is clear that direct experimental analysis will be necessary to determine
which proteins are actually generated. The significance of variant proteins encoded
by rare alternatively spliced mRNAs are unclear and may be artefactual.
Structural analysis of the LVI-I proteins reveals only a single specific feature, which
is the presence of multiple WD-40 repeats at the C-terminus. However, it is notable
that a composition-based prediction programme strongly suggests a nuclear location
for the LVI-I gene products. A caveat with this programme is that it is poor at
predicting the location of proteins that shuttle between compartments e.g. nucleus -
cytoplasm (269).
Chapter IV
Expression of the human and murine LVI-l genes
4.1 Introduction
At the outset of this study, there was little information on transcripts from the murine
Lvi-T gene and no full-length cDNAs were evident from the database. One of the first
priorities, therefore, was to generate a probe to allow detection of Lvi-I transcripts
containing the 3' exons. Also, it has become clear that most of the human LVI-I
transcripts are derived from the use of the P2 promoter, with exon le as the 5' exon,
While the murine Lvi-I transcripts are derived from the PI promoter, with exon la as
the 5' exon. However, as will be seen from the comparative sequence analysis in
Chapter III, it is conceivable that the gene has a dual promoter structure and that these
promoters are differentially regulated. The potential for use of these alternative
promoters. was assessed by 5'RACE and RT-PCR analyses. These studies are
important as they have implications for the structure of the LV/-I gene products as
well as regulation of expression of the gene.
4.2 Materials and methods
Variations from previous chapter only are included.
4.2.1 Genomic PCR
1 ug of murine genomic DNA (p/m 23i cell line) was used to amplify exon 13 of the
murine Lvi-l gene using 100 pmol of each of the gene-specific primers. Primer
sequences and PCR conditions are detailed in Tables 4-1, 4-2 and Section 2.2.4. The
463 bp amplified product was gel purified (Section 2.2.4), cloned (Section 2.2.2), and
"-its identity verified by sequencing (Section 2.2.5).
4.2.2 Generation of a human LVI-l and fJ-actin probes
Miniprep DNA from the human pGEX-LVI-I fusion plasmid (Section 5.3.14) was
used to amplify the exon 13 of the human LVI-I gene with 50 pmol of the specific
primers. For primer sequence and PCR conditions see Table 4-1, Table 4-2, and also
Table 4-1. Primer sequences (by hand)
Number of Primer Strand Sequenee (5'-+3')
primer
1 mExon13F Forward ggt gge taa ega ggt tee a
2 mExon13R Reverse eat gaa aae aee egt tte tge
3 mFLJexon IFa Forward geg get get tea tga gtg e
4 mFLJexon2F Forward gag aee gat aea gat tae aae
5 mFLJexon5R Reverse gea tgg aee tte gae ate e
6 mFLJexon5F Forward tgg atg teg aag gte eat g
7 mFLJexonllR Reverse etg age tta eag tea gea e
8 mouseFLJexon2RSP 1 Reverse tgg tge aet gte tte gte
9 mouseFUexon2RSP2 Reverse eae aet gag agt ege tga
10 mouseFLJexon2RSP3 Reverse eaa eeg ggg att tgg aea
11 mFLJexonlaF Forward get taa agg get agg gtg ag
12 mFLJexonleF Forward atg tet ggg tee aag get g
13 mFLJexon2R Reverse eag gee tgg tge aet gte
14 mHPRT5 Forward ggg gge tat aag tte ttt ge
15 mHPRT3 Reverse tee aae aet teg aga ggt ee
16 huHPRT5 Forward ggg gge tat aaa tte ttt ge
17 huHPRT3 Reverse tee aae aet teg aga ggt ee
18 humanFLJexon2RSPl Reverse gge tgg tgt ggt ate tte
19 humanFLJexon2RSP2 Reverse gat tea teg eat etg eeg
20 humanFLJexon2RSP3 Reverse age gtg gat tet gee ttg
21 humanFLJexon 1aF Forward ggg ett tge tgt tag gae te
22 hUiDanFUexonleF Forward gaa gee gaa aga tgt eea g
23 HumanFUEXON 13F Forward eae ttt eae tgg geg atg g
24 HumanFLJEXON13R Reverse aea tgt ate tte eeg etg ga
Table 4·2. Primer combinations, peR annealing conditions, and applications.
Primer Product size Annealing Application
combination temperature (OC)
1+2 463 bp 60 Genomic PCR
3+2 2383 bp 62 Analysis of transcript(s)
2+4 1985 bp 62 Analysis of transcript(s)
4+5 590bp 55 Analysis of transcript(s)
6+7 924 bp 60 Analysis of transcript(s)
11 + 13 513 bp 55 Analysis of PI promoter
12 +9 461 bp 55 Analysis of P2 promoter
14 + 15 294 bp 55 HPRT control
16 + 17 313 bp 55 HPRT control
21 + 19 373 bp 55 Analysis of PI promoter
22 + 19 411 bp 55 Analysis of P2 promoter
23 +24 234 bp 60 Plasmid PCR
Section 2.2.4. The PCR product was then purified as described in Section 2.2.4 and
radioactively labelled with a_32p dCTP as detailed in Section 2.2.6.
Human B-actin cDNA control probe (Clontech Laboratories, Palo Alto, USA) was
radioactively labelled with a_32p dCTP as detailed in Section 2.2.6.
4.2.3Reverse transcription-polymerase chain reaction (RT -PflR)
lug of total mouse RNA (thymus (Arnbion, Inc), brain, lung, testis, liver, kidney,
muscle, spleen and heart), and human RNA (Jurkat, CEM, KG-la, and K-562 cell
lines) were reverse transcribed using the ImProm-II Reverse Transcription System
(Promega) (Section 2.2.4). PCR was carried out using 2.5 ul of freshly synthesised
cDNA and 50 pmol of each forward and reverse specific primers (see Tables 4-1, 4-2,
and Section 2.2.4 for primer sequence, primer combination, and PCR conditions). 5
ul aliquots of each reaction were separated on 4% polyacrylamide gels, stained with
ethidium bromide and visualized by UV illumination. Amplification of the long
fragments (murine Lvi-l exons 1-13, 2-13, and 5-11) was performed using Extensor
PCR Master Mix, Buffer 1, ReddyMix ™version (ABgene) (Section 2.1.5) and 2.5 I-tl
aliquots of mouse thymus cDNA with 5 pmol of the specific primers (see Table 4-1
and Table 4-2 for primer sequence, primer combination and annealing temperatures).
Cycling conditions were 94 DC 2 minutes, followed by 94 DC 10 seconds, 60-62 DC 30
seconds, 68 DC 3 minutes for 10 cycles, th~n 94 DC 20 seconds, 60-62 DC 30 seconds,
68 DC 9 minutes for 20 cycles and finally 68 DC for 7 minutes. 15l-t1aliquots of each
reaction were separated on 1% agarose gels, stained with ethidium bromide and
visualized by UV illumination.
4.2.4 5'Rapid Amglification of cDNA Ends Assay (5'RACE)
5'RACE was performed on 2 ug of total RNA (human and murine) using the 5'RACE
Kit 2nd Generation (Roche) according to the manufacturer's instructions. First-strand
cDNA was synthesized using a gene-specific primer SPI (12.5 ~M) (Table 4-1,
primers 8 and 18). The first-strand cDNA was purified from unincorporated
nucleotides and primers using the QIAquick PCR Purification Kit (Qiagen) according
to the manufacture's protocol. Then, terminal transferase was used to add a
homopolymeric A-tail to the 3'end of the cDNA. The tailed cDNA was amplified by
PCR using a gene-specific primer SP2 (12.5 IlM) (Table 4-1, primers 9 and 19) and
the oligo dT-anchor primer. The oligo dT -anchor primer is a mixture of primers with
one non T (A, C or G) nucleotide at the 3'end, so that the oligo dT-anchor primer is
forced to bind to the inner end of the poly(A)-tail. Therefore, the actual length of the
added poly(A)-tail is unimportant. The obtained cDNA was further amplified by a
second PCR using a nested specific primer SP3 (12.5 Ill) (Table 4-1, primers 10 and
20), and the PCR anchor primer (supplied in 5'RACE Kit 2nd Generation, Roche).
The PCR conditions were 94 QCfor 2 minutes, followed by 10 cycles of 30 seconds
denaturation at 94 QC, 30 seconds annealing at 55 QC,40 seconds elongation at 72 QC
and then 25 cycles of 30 seconds denaturation at 94 QC, 30 seconds annealing at 55
QC, 40 seconds (plus 20 seconds for each cycle) elongation at 72 QC with a final
elongation at 72 QCfor 7 minutes. The resulting RACE products were cloned into the
pCR@2.l-TOPO vector (Section 2.2.2), and the identity of the amplified fragments
verified by sequencing (Section 2.2.5).
4.3 Lvi-I gene expression
4.3.1 Generation of a murine specific Lvi-I probe
BLAST analysis of murine cDNA and EST databases using the full-length human
LV/-l cDNA sequence (AK023035, derived from the teratocarcinoma cell line NT2
and comprising 13 exons) identified a murine cDNA AK020004 (derived from adult
male thymus) that showed a high degree of homology across exons 2 to 9. This
murine cDNA appeared to lack exons 10 to 13. However, further BLAST searching
using the human LVI-l sequence coding for exons 10 through to 13 identified
homologous murine sequences on murine chromosome 2. Murine Lvi-l exon 13
specific primers were designed (mExonI3F, mExon13R, see Table 4-1) and used to
""
amplify an exon 13 specific fragment from normal murine genomic DNA. In addition
to the expected 463 bp PCR product, a number of other products were observed, most
probably due to non-specific amplification of genomic sequences (Figure 4-1). The
"
putative exon 13 specific fragment was gel purified, cloned, and several clones
isolated, and sequenced. Sequence analysis revealed 82% homology with the
equivalent human sequence confirming that the fragment amplified indeed represents
exon 13 of the murine Lvi-l gene (Figure 4-2). Comparison of the predicted amino
acid sequence of both human and murine exon 13 also revealed a high degree of
MI M2 2
603 bp
500 bp
310 bp
Figure 4-1. Amplification of murine Lvi-I exon 13. Murine Lvi-I exon 13
amplified by DNA PCR using the primers mExon13F and mExon13R (Table 4-1).
PCR products were separated on a 4% polyacrylamide gel (lanes 1 and 2), stained
with ethidium bromide and visualized by UV illumination. Ml: <I>XI74RFDNA size
marker, M2: 25 bp DNA ladder size marker. The black arrow indicates the 463 bp,
amplified fragment of murine Lvi-I exon 13.
98
conservation. 78% of amino acids were identical with only 3 of the remaining 19
amino acids demonstrating non-conservative changes-G'igure 4-2).
To confirm that this exon 13 probe could be used to detect a unique sequence in
murine DNA, Southern blot analysis was carried out on normal murine genomic DNA
digested with EcoRI, BamHI and Sst! (Figure 4-3). Following washing at high
stringency, a single band (Sst!) or doublet (EcoRI and BamHI) was observed. The
doublets probably reflect the presence of restriction fragment length polymorphisms
(RFLPs) in the mouse genomic DNA (purified from laboratory mice with a mixed
genetic background, C57lBalbc, NIH, 129SV). This analysis clearly demonstrates
that the murine Lvi-l exon 13 DNA probe acts as a single copy probe and since it
spans an exon it can be used to detect murine Lvi-l transcripts.
4.3.2 Analysis of murine Lvi-I gene expression
The expression pattern of the murine Lvi-l gene was explored by northern blot
analysis of total RNA isolated from a range of normal murine tissues including brain,
kidney, thymus, spleen, mesenteric lymph node, testis, heart, liver, and muscle
(Figure 4-4). Following hybridisation and washing at high stringency, a single RNA
species of 4.5 kb was identified with the a,_32P-Iabeled murine Lvi-l exon 13 DNA
probe (Figure 4-4a) and with an alternative Lvi-l probe which spans the coding region
from exon 3 through to exon 5 (Figure 4-4b). This probe fragment was generated in
the same way as the exon 13 specific probe described in Section 4.3.1 (A. Terry,
unpublished results). The highest levels of expression were detected in lymphoid-
derived tissues especially murine thymus. However, low level expression was
observed across the range of tissues examined. A similar ubiquitous expression
pattern was observed across a range of normal human tissues with the highest
expression observed in human thymus RNA. However, in contrast to the single
murine Lvi-l transcript, the human LV/-l gene appears to be expressed in the form of
2 transcripts: a major species of 2.8 kb and a less abundant RNA of 4.5 kb (146).
These findings were also confirmed in a panel of 6 murine cell lines (4 T
lymphoblastoid cell lines and 2 fibroblast cell lines) and 6 human lymphoblastoid cell
lines. Thus, using the a-32P-Iabeled murine Lvi-l exon 13 DNA probe, a single
murine Lvi-l transcript of 4.5 kb was also differentially expressed in the cell lines
examined with the highest level of expression in p/mI6i, then p/m47i, and BW5147
Human
H N T F T G R W" L T R F Q A M W D
CCATCAGGCACAACACTTTCACTGGGCGATGGCTGACCAGGTTCCAAGCCATGTGGGATC
***************** ******** * ***** ** ******** ** ******* *
Murine CCATCAGGCACAACACTGTCACTGGGAGGTGGCTAACGAGGTTCCAGGCTGTGTGGGACC
H N T V T G R W L T R F Q A V W D
Human
P K QED C V I V G S M A H P R R V E I
CTAAACAAGAAGACTGTGTCATAGTTGGCAGCATGGCCCATCCACGACGGGTAGAAATCT
************* ** ********** ******* *** *********** *** ***
Murine CTAAACAAGAAGATTGCTTCATAGTTGGTAGCATGGACCACCCACGACGGGTGGAAGTCT
P K QED C F I V G S M D H P R R V E V
Human
F HET G K R V H S F G G E Y L V S V C
TCCATGAGACAGGAAAGAGGGTGCATTCGTTTGGTGGAGAATACCTTGTCTCTGTGTGTT
**** *** * ******* ******** ** * ******* ***** **********
Murine TCCACGAGTCGGGAAAGAATGTGCATTCTCTTTGGGGAGAATGTCTTGTATCTGTGTGTT
F H E S G K N V H S L W GEe L V S V C
Human
SIN A M H P TRY I LAG G N SSG K
CCATCAATGCCATGCACCCAACTCGGTATATTTTGGCTGGAGGTAATTCCAGCGGGAAGA
** *** *** **** ** ** ** ***** ******************* ** ***
Murine CCCTCAGTGCTGTGCATCCTACGCGATATATCCTGGCTGGAGGTAATTCCAGTGGCAAGT
S L S A V H P TRY I LAG G N SSG K
Human
I H V F M N E K S C
TACATGTTTTTATGAATGAAAAAAGCTGCTGA
************** ** ** *** ***
Murine TACATGTTTTTATGCATCAAGAAACCTGAGTC
L H V F M H Q E T V
Figure 4-2. Conservation of the nucleotide sequence and coding potential of exon
13 of the human and murine LVI-1 gene. Identical nuc1eotides are indicated by *.
Conservative amino acid changes are indicated in blue bold and non-conservative
changes in red bold,
100
kb M 1 2 3
23.1
9.4
6.6
4.4
0.56
2.3
2.0
Figure 4-3. Validation of murine exon 13 fragment as a single copy gene probe.
Murine genomic DNA was digested with EcoRI (lane 1), BamHI (lane 2) and SstI
(lane 3), separated on a 0.8% agarose TAE gel and transferred to Hybond N
membrane. The blot was hybridized with a-32P-Iabeled murine Lvi-l exon 13 DNA
probe. Doublets identified in lanes 1 and 2 reflect the RFLPs due the genomic
parental DNA (th ,e breeders: C57lBalbc, NIH and 129SV). M: A DNAlHindIII
fragments labeled with 32P-d CTP.
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Figure 4-4. Expression of Lvi-I gene transcripts in normal murine tissues. a. 20
ug samples of total mouse RNA from various tissues sources were separated on 1%
agarose-forrnaldehyde gels and transferred to Hybond-N membrane blot. The blot
was probed with radiolabeled a-32P-labeled murine Lvi-I exon 13 DNA probe and
then reprobed with a radiolabeled a-32P-GAPDH fragment, to control for RNA
loading and integnty. b. The same blot was stripped and then reprobed with a
radiolabeled a-32P-murine Lvi-I exon 3-5 DNA probe. MLN, mesenteric lymph
nodes.
102
(Figure 4-5a). Similarly, using the a-32P-labeled human LV/-l exon 13 DNA probe,
two human LVI-l transcripts (a major at around 2.8'kb and a less abundant RNA of
4.5 kb) were differentially expressed in the cell lines examined with the highest level
of expression in U937, then CEM and Jurkat, (Figure 4-5b). This finding suggests
that the full coding sequence of the human LVI-l gene can be accommodated by the
smaller 2.8 kb transcript but it is possible that the larger transcripts code for variable
length 5' and 3' untranslated sequences. A similar analysis of feline RNAs
demonstrated expression of a single 3.5 kb RNA species (A. Terry, unpublished
results).
4.3.3 Coding potential of the murine Lvi-I gene
At the time this study was initiated little was known about the coding potential of the
murine Lvi-l gene. The only available published sequence (cDNA AK020004)
showed a high degree of homology to the human sequence across exons 2-9 but this
cDNA appeared to lack exons 10-13 despite the existence of homologous sequences
in the murine genome (Figure 4-6a). In addition the 5' start of the murine cDNA
differed significantly from the human equivalent (Chapter III).
In order to establish the 5' start and sequence of the major 4.5 kb transcript of the
murine Lvi-l gene, cDNA was prepared (Section 4.2.3) using total RNA from normal
murine thymus (the highest expresser of the 4.5 kb Lvi-l transcript). Subsequent PCR
was performed on aliquots of thymus cDNA using a variety of combinations of
murine Lvi-l primers (Table 4-1).
Careful analysis of the murine genomic sequence on chromosome 2 spanning the
potential start site of the Lvi-/ gene was carried out and a primer designed
mFUexonIFa (Table 4-1). This forward primer lies upstream of the predicted
~
promoter region of the murine Lvi-/ gene (see Chapter III) and is upstream of the
sequences contained in the published murine cDNA clones (AK020004, AK05I037
and AK03I592). It was hoped that amplification in combination with an exon 13
specific reverse primer would generate full-length PI-derived cDNA. PCR was
carried out using mFLlexonIFa in combination with mExonI3R (Table 4-1) and a
2.383 kb fragment was generated (Figure 4-6b, lane 1). Additional PCRs included
combination of mFUexon2F and mExonI3R (Figure 4-6b, lane 3; 1.985 kb
amplimer), mFUexon5F and mFUexonllR (Figure 4-6c, lane 1; 898 bp amplimer),
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1 2 34 5 6 7 8 9 10 11 12 13
Human
)NAs AK02303
Murine
AK0200(
IFa~ ~5R .....11R .....13R2F~ 5F~
b. c. M 2M 2 3 4
2.027 kb
564 bp
Primer
'mbinations
IFA+13R 2F+13R
2.3 kb 1.98 kb
5F+IIR
924 bp
d. MI M2 I 2
2F+5R
590 bp
Figure 4-6. Analysis of murine Lvi-I transcripts structure. a. Exon structure of
the human AK023035 cDNA and murine AK020004 cDNA showing position and
direction of the primers. Black boxes and arrowheads represent the coding exons and
the forward and reverse primers, respectively. The grey box between exons 3 and 4
indicates an extra exon found only in AK020004. The red boxes represent the coding
exons not present in AK020004 but found in BC094676 and AK031592 (see Figure
3-4). b., c., and d. RT-PCR products are shown following separation by 1% agarose
gel (b. and c.) and by 4% polyacrylamide gel (d.). Lanes 1 and 3 indicate
amplification with primer combinations as shown. Lanes 2 and 4 represent the
corresponding PCR primer only controls. M, Ml, and M2 are the marker A
DNAHindIII, the marker 25bp DNA Ladder, and the marker <I>X174RF DNA,
respectively.
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and mFLFexon2F and mFLJexon5R (Figure 4-6d, lane 1; 590 bp amplimer). The
2.38 kb PCR product was gel purified, cloned and 'a number of clones isolated and
sequenced (Section 2.2.2, 2.2.4, and 2.2.5). The sizes of the PCR products obtained
for primer combinations mFLJexon2F and mExon13R, mFLJexon5F and
mFLJexon llR and mFLFexon2F and mFLJexon5R were exactly as predicted from
the available Lvi-l cDNA sequences. Products were cloned and sequenced (as
above), and DNA sequence analysis (Section 2.2.5) confirmed the specificity of the
amplified products. The consensus sequence and predicted open reading frame of the
putative full-length murine thymus-derived Lvi-l cDNA is illustrated in Figure 4-7.
The mFLJexonIFa forward primer used to generate the full-length cDNA lies in the
bi-directional PI promoter region of the Lvi-l gene (Section 3.2) and examination of
the murine Lvi-l cDNA sequence reveals that the first 116 bp represent the start of the
adjacent Mfap-I gene which is transcribed in the opposite direction to the Lvi-I gene.
In addition, alignment of this sequence with other murine cDNAs revealed the
following nucleotide changes: EXIa l07T---+C, EX8 76C---+T, EX8 88C---+T, EX9
IlIC---+T, EX9 l29T ---+C,EXlO 192G---+A,and EX12 50A---+G. However, only the
nucleotide change in exon 12 causes an amino acid change (I437V). Indeed,
isoleucine is frequently substituted by valine in homologous proteins due to the high
degree of similarity between both amino acids. The longest open reading frame is 524
amino acids coding for a protein with a predicted size of 57.96 kDa. The first in-
frame ATG is located in exon 2. This methionine is the first start codon conserved
across species (Figure 4-8 and 3-5). Moreover, murine cDNAs share homology in the
5' start region, but no in-frame start codon is present in the upstream exon la.
Although the human cDNAs contain two additional in-frame ATG codons in exonIc
and exon 2 (Figure 3-2), these are not conserved in the mouse gene and it is unclear if
these are utilised. The possibility exists that the human exon lc represents a 5'
untranslated sequence. This analysis demonstrates that at least some murine Lvi-l
cDNAs are initiated upstream of the PI promoter region of the Lvi-l gene and
matches the other murine and human cDNAs do.~nstream of exon 2, but the precise
transcription initiation site remains to be established.
4.3.4 Identification of the transcription initiation site of the murine Lvi-I gene
In order to identify 'the transcriptional start site of the murine Lvi-l gene, 5'RACE
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Exonla
----------------TGCGAGCAAGTTT----CCCGCCTTCGACATTTTCCAGAACTGG
GGAGATTTGCGCGCCTTTCGAGCAAGTTC----CCCGCCTTCGACATTTTCCAGAACTGG
--------------------------------GCCCGCCTTCGACATTTTCCAGAACTGG
TGAGATTTGCGCGCCTTTCGAGCAAGTTT----CCCGCCTTCGACATTTTCCAGAACTGG_________________________________ CCCGCCTTCGACATTTTCCAGAACTGG
_____________________________ A __GCCGGCCG_CTA_AGAAGCC_GAA--AG
_________________________________ CCGGCCG_CTA_AGAAGCC_GAA--AG
______________________________ GCGCCGGCCG_CTA_AGAAGCC_GAA--AG
_________________________________ CCGGCCG_CTA_AGAAGCC_GAA--AG
Exonlc
AAGGTCCT--CCTGTC-TGACAGTTGTTTCTTTTGGTTTTTGGTAAG-GTCC----AAGA
AAGGTCCT--CCTGTC-TGACAGTTGTTTCTTTTGGTTTTTGGTAAG-GTCC----AAGA
AAGGTCCT--CCTGTC-TGACAGTTGTTTCTTTTGGTTTTTGGT----------------
AAGGTCCT--CCTGTC-TGACAGTTGTTTCTTTTGGTTTTTGGCAAG-GTCC----AAGA
AAGGTCCT __ CCTGTC_TGACAGTTGTTTCCTTTGGTTTTTGG-----------------
ATG-TCCAGGTCGGGCGCGGCGGCTGAGA-AGGCGGACTCCAGACAGCGACCCCAGATGA
ATG-TCCAGGTCGGGCGCGGCGGCTGAGA-AGGCGGACTCCAGACAGCGACCCCAGATGA
ATG-TCCAGGTCGGGCGCGGCGGCTGAGA-AGGCGGACTCCAGACAGCGACCCCAGATGA
ATG_TCCAGGTCGGGCGCGGCGGCTGAGA-AGGCGGACTCCAGACAGCGACCCCAGATGA
,J.Exon2
AGGTGA-------------------------ATGAATATAAAGAAAATGAACATATTGCT
AGGTGA-------------------------ATGAATATAAAGAAAATGAACATATTGCT
AGGTGA-------------------------ATGAATATAAAGAAAATGAACATATTGCT
AGGTGA-------------------------ATGAATATAAAGAAAATGAACATATTGCTAGGTGA ATGAATATAAAGAAAATGAACATATTGCT
AGGTAA ATGAATATAAAGAAAATCAAAACATCGCT
AGGTAA ATGAATATAAAGAAAATCAAAACATCGCT
AGGTGAGAAACGGACTGGTGCTTCCAGGTAAATGAATATAAAGAAAATCAAAACATCGCTAGGT_A ATGAATATAAAGAAAATCAAAACATCGCT
iExon2
TATACTTCTCTGAGACCGATACAGATTACAACTTTAAGGAAAACAGCTAAGGTTTATCTT
TATACTTCTCTGAGACCGATACAGATTACAACTTTAAGGAAAACAGCTAAGGTTTATCTT
TATACTTCTCTGAGACCAATACAGATTACAACTTTAAGGAAAACAGCTAAGGTTTATCTT
TATACTTCTCTGAGACCGATACAGATTACAACTTTAAGGAAAACAGCTAAGGTTTATCTT
TATACTTCTCTGAGACCGATACAGATTACAACTTTAAGGAAAACAGCTAAGGTTTATCTT
TATGTGTCTCTGAGACCAGCACAGACTACAGTTTTAATAAAAACAGCTAAGGTCTATCTT
TATGTGTCTCTGAGACCAGCACAGACTACAGTTTTAATAAAAACAGCTAAGGTCTATCTT
TATGTGTCTCTGAGACCAGCACAGACTACAGTTTTAATAAAAACAGCTAAGGTCTATCTT
TATGTGTCTCTGAGACCAGCACAGACTACAGTTTTAATAAAAACAGCTAAGGTCTATCTT
TACCCGTTTTCACTCAGCAATTCCAAGCTAGGCCTACTTAAGTTGTCCAAATCCCCGGTT
TACCCGTTTTCACTCAGCAATTCCAAGCTAGGCCTACTTAAGTTGTCCAAATCCCCGGTT
TACCCGTTTTCACTCAGCAATTCCAAG~TAGGCCTACTTAAGTTGTCCAAATCCCCGGTT
TACCCGTTTTCACTCAGCAATTCCAAGCTAGGCCTACTTAAGTTGTCCAAATCCCCGGTT
TACCCGTTTTCACTCAGCAATTCCAAGCTAGGCCTACTTAAGTTGTCCAAATCCCCGGTT
GCCCCCTTTTCACTCAGTAATTACCAGCTAGACCAGCTTATGTGCCCCAAATCCCTATCA
GCCCCCTTTTCACTCAGTAATTACCAGCTAGACCAGCTTATGTGCCCCAAATCCCTATCA
GCCCCCTTTTCACTCAGTAATTACCAGCTAGACCAGCTTATGTGCCCCAAATCCCTATCA
GCCCCCTTTTCACTCAGTAATTACCAGCTAGACCAGCTTATGTGCCCCAAATCCCTATCA
GTAAATAATTCTAGCAAATCAGTGGTCCATAAGAAGAAAGATCGGAAGAAGACTCGTAGA
GTAAATAATTCTAGCAAATCAGTGGTCCATAAGAAGAAAGATCGGAAGAAGACTCGTAGA
GTAAATAATTCTAGCAAATCAGTGGTCCATAAGAAGAAAGATCGGAAGAAGACTCGTAGA
GTAAATAATTCTAGCAAATCAGTGGTCCATAAGAAGAAAGATCGGAAGAAGACTCGTAGA
GT~~TAATTCTAGCAAATCAGTGGTCCATAAGAAGAAAGATCGGAAGAAGACTCGTAGA
GAAAAGAATTCTAACAATGAAGTGGCGTGTAAGAAGACTAAAATAAAGAAAACTTGCAGA
GAAAAGAATTCTAACAATGAAGTGGCGTGTAAGAAGACTAAAATAAAGAAAACTTGCAGA
GAAAAGAATTCTAACAATGAAGTGGCGTGTAAGAAGACTAAAATAAAGAAAACTTGCAGA
GAAAAGAATTCTAACAATGAAGTGGCGTGTAAGAAGACTAAAATAAAGAAAACTTGCAGA
M
AAGGTTTTAACTTCAAAAATGAAGGCCTTATCTTCCAAGGCAGATTCCCTTCTGCTGAAA
AAGGTTTTAACTTCAAAAATGAAGGCCTTATCTTCCAAGGCAGATTCCCTTCTGCTGAAA
AAGGTTTTAACTTCAAAAATGAAGGCCTTATCTTCCAAGGCAGATTCCCTTCTGCTGAAA
AAGGTTTTAACTTCAAAAATGAAGGCCTTATCTTCCAAGGCAGATTCCCTTCTGCTGAAA
AAGGTTTTAACTTCAAAAATGAAGGCCTTATCTTCCAAGGCAGATTCCCTTCTGCTGAAA
AGGATTATACCTCCAAAGATGAAAAACACATCTTCCAAGGCAGAATCCACGCTGCAAAAT
AGGATTATACCTCCAAAGATGAAAAACACATCTTCCAAGGCAGAATCCACGCTGCAAAAT
AGGATTATACCTCCAAAGATGAAAAACACATCTTCCAAGGCAGAATCCACGCTGCAAAAT
AGGATTATACCTCCAAAGATGAAAAACACATCTTCCAAGGCAGAATCCACGCTGCAAAAT
Murine
Human
108
Figure 4·8. Nucleotide sequence comparison of the 5'start of murine and human
LVI.1 cDNAs. Published murine (AK020004, AK051037, AK03I592), human
(AK023035, BC05I85, BC025247) and consensus sequence for murine thymus Lvi-l
(mLvi-l) cDNAs is shown. Bold text indicates the mouse and human consensus
sequences. Red text: first conserved in frame ATG start codon. Blue text: exonIc
ATQ present in all human cDNAs.
was performed using reverse primers complementary to murine Lvi-l exon 2. First-
strand cDNA was synthesised from total mouse thymus RNA (Ambion) using the
mouseFLJexon2RSPl (Table 4-1). The amplification of the dA-tailed cDNA was
carried out using the mouseFLJexon2RSP2 (Table 4-1) and the oligo dT anchor
primer (Figure 4-9, lane 1); followed by a nested PCR with the specific primer 3
(SP3) mouseFUexon2RSP3 (Table 4-1) (Figure 4-9, lane 2). Amplified fragments
following the nested PCR were recovered by ligation into pCR2.I-TOPO vector, and
15 clones sequenced. The sequences were compared with the consensus sequence for
murine thymus Lvi- J (mLvi- J, see Figure 4-7) and seven presumptive transcriptional
initiation sites were identified. One out of the fifteen 5'RACE clones (clone 23),
revealed sequence which extended back to -358 nucleotides from the conserved
translation initiation codon ATG in exon 2 (Figure 4-10). Seven of the fifteen
sequenced 5'RACE clones revealed an alternative transcriptional start site at -323
nucleotides upstream of the translation start site ATG. Of the remaining 7 clones 4
showed an alternative transcriptional start site located at position -327 or -316; the
remaining 3 showed an alternative transcriptional start site located at position -352, -
312, and -295. This analysis would indicate that the major transcriptional start site is
located at position -358, however 47% of the clones sequenced revealed a
transcriptional start site located at position -323.
No RACE clones were found to contain sequences derived from either exon 1b or
exonlc (Figure 3-2) demonstrating that expression of the murine Lvi-J gene is driven
predominantly by the PI promoter.
4.3.5 Identification of the transcription initiation site of the human LVI-] gene
The presumptive 5'exon of human LVI-J is conserved in mammalian genomes
""(human, chimp, mouse, rat) and contains the N-terminus favoured by gene prediction
algorithms. However, a 5'RACE was performed using reverse primers
complementary to human LVI-J exon 2. First-strand cDNA was synthesised from
total RNA isolated from the Jurkat cell line using the humanFUexon2RSPI (Table 4-
1). Amplification of the dA-tailed cDNA was carried out using the
humanFLJexon2RSP2 (Table 4-1) and the oligo dT anchor primer (Figure 4-11, lane
1); followed by a nested PCR with the gene-specific primer 3 (SP3)
M 1 M 2
603
310 2713J?271,281
234 b 234
194 194
118 118
Primary peR Nested rca
Figure 4-9. Determination of the murine Lvi-I transcription start site. cDNA was
prepared using total RNA from normal' mouse thymus. Primary and nested peR
products are shown following separation by 4% polyacrylamide gel. Lane 1: primary
peR product using the oligo dT -anchor primer and mouseFLJexon2RSP2 primer.
Lane 2: nested peR using peR anchor primer and mouseFLJexon2RSP3. M is the
<I>XI74RFDNA size marker.
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TGACAGAAACAACTTCCGGTAGGGGGTAGAGGAACCAGAAGTACATAACACATAACAGAG
-358
~~~~~~~~~~~'T~T~T~TRTgT~TfT~T~T~T~T~T~TT~T~C.GCTTAAAGGGCTAGGGTGA
GATTGTGGGTAATCGGAGGGCGGCTGAGCGC-----GGATCGCTTAAAGGGCTAGGGTGA
~ ~ ~ ~ ~
GATTTGCGCGCCTTTCGAGCAAGTTTCCCGCCTTCGACATTTTCCAGAACTGGAAGGTCC
GATTTGCGCGCCTTTCGAGCAAGTTTCCCGCCTTCGACATTTTCCAGAACTGGAAGGTCC
J-exon2
TCCTGTCTGACAGTTGTTTCTTTTGGTTTTTGGCAAGGTCCAAGAAGGTGAATGAATATA
TCCTGTCTGACAGTTGTTTCTTTTGGTTTTTGGCAAGGTCCAAGAAGGTGAATGAATATA
GAAGGTAAATGAATATA
AAGAAAATGAACATATTGCTTATACTTCTCTGAGACCGATACAGATTACAACTTTAAGGA
AAGAAAATGAACATATTGCTTATACTTCTCTGAGACCGATACAGATTACAACTTTAAGGA
AAGAAAATCAAAACATCGCTTATGTGTCTCTGAGACCAGCACAGACTACAGTTTTAATAA
AAACAGCTAAGGTTTATCTTTACCCGTTTTCACTCAGCAATTCCAAGCTAGGCCTACTTA
AAACAGCTAAGGTTTATCTTTACCCGTTTTCACTCAGCAATTCCAAGCTAGGCCTACTTA
AAACAGCTAAGGTCTATCTTGCCCCCTTTTCACTCAGTAATTACCAGCTAGACCAGCTTA
AGTTGTCCAAATCCCCGGTTG---------------------------------------
AGTTGTCCAAATCCCCGGTTGTAAATAATTCTAGCAAATCAGTGGTCCATAAGAAGAAAG
TGTGCCCCAAATCCCTATCAGAAAAGAATTCTAACAATGAAGTGGCGTGTAAGAAGACTA
+1~
ATCGGAAGAAGACTCGTAGAAAGGTTTTAACTTCAAAAATGAAGGCCTTATCTTCCAAGG
AAATAAAGAAAACTTGCAGAAGGATTATACCTCCAAAGATGAAAAACACATCTTCCAAGG
CAGATTCCCTTCTGCTGAAATCATCCGTGGATGCTTATACTGAAAGTACCAGGCTGGGAC
CAGAATCCACGCTGCAAAATTCATCCTCAGCTGTTCATACTGAAAGTAACAAGCTACAAC
CCAAGAGGACCTCGGATTCAGCGACTCTCAGTGTGGACGCGGAAAGCAGC---GACGAAG
CCAAGAGAACGGCAGATGCGATGAATCTCAGTGTTGATGTGGAAAGTAGTCAGGATGGAG
ACAGTG CACCAGGCCTG
ACAGTGATGAAGATACCACACCAGCCCTG
Figure 4-10. Nucleotide sequence of the murine Lvi-I RACE clones. The most
upstream and downstream transcription start sites are indicated by red and black
arrows, respective . Underline letter: first nucleotide of MJapJ gene. Blue text: first
nucleotide of each transcriptional start site. Red text: first conserved in frame ATG
start codon. +1 and -128 indicate the coding start and transcription initiation site,
respectively. The grey and yeIJow highlighted regions are the peR anchor primer and
mouseFLJexon2RSP3 primer. The underlined region represents the Oligo dT-anchor
primer. The human sequence hLV/-J is the human cDNA AK023035.
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humanFLJexon2RSP3 (Table 3-1) (Figure 4-11, lane 3). Amplified fragments
following the nested PCR were recovered by ligation into pCR2.1- TOPO vector, and
4 clones sequenced. The sequences were compared with the human cDNA
AK023035 and 4 presumptive transcriptional initiation sites were identified. One out
of these four 5'RACE clone revealed sequence which extended back to -356
nucleotides from the conserved translation initiation codon ATG in exon 2 (Figure 4-
12). The remaining 3 clones showed an alternative transcriptional start site located at
positions -331, -313, or -305. This analysis would indicate that the major
transcriptional start site is located at position -356. Interestingly, one of the clones
showed the same transcriptional initiation site found in the published human
BC051855 cDNA. Moreover, like the human cDNAs AK023035 and BC051855, all
RACE clones lack the additional sequence observed only in the published human
BC025247 cDNA. This sequence appears to be derived from the use of an alternative
splice donor (see Figure 3-3).
In conclusion, 5'RACE analysis of the LVI-I gene has shown that the major
transcriptional start sites differ between human and murine genes. The major
transcription start site of the murine Lvi-I gene is located in exon 1a, under the control
of the distal PI promoter. In contrast, the proximal P2 promoter generally drives
transcription of the human L VI-I gene with transcripts initiating in exon 1c.
4.3.6 Promoter switching and alternative LV[·[ exon usage
As mentioned above, there is the possibility of two promoter regions in which, the
human LV/-I transcript(s) are mainly transcribed from P2 promoter whereas in mouse
the transcription appears to be driven by PI promoter. Moreover, the murine
homologue of the human P2 promoter appears to be a putative start site with the
'"'predicted amino acid sequence start MSGSK (Figure 3-3, exon Ic). Thus, the
potential expression of the murine Lvi- J gene from the P2 promoter was explored by
RT -PCR. Amplification was carried out on aliquots of 2.5 III of each murine cDNA
(thymus, brain, lung, testis, liver, kidney, muscle, spleen, and heart) with 50 pmol of
the primers: mFUexonlcF and mouseFLJexon2RSP2 (Table 4-1 and Table 4-2). As
a control for relative quantification of each mRNA transcripts, and in order to check
the quality of the cDNA samples used, PCR was performed using the housekeeping
M 1 2
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310
234
194
Primary peR
M 3 4
603
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194
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Figure 4-11. Determination of the human LVI-J transcription start site. cDNA
was prepared using total RNA from the Jurkat cell line. Primary and nested peR
products are shown following separation by 4% polyacrylamide gel. Lane 1: primary
peR product using the oligo dT-anchor primer and human FLJexon 2RSP2 primer.
Lane 3: nested peR using peR anchor primer and humanFLJexon2RSP3. Lanes 2
and 4: negative controls (Pf.R primers only). M: <I>X174RFDNA size marker.
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-356
GACCACGCGTATCGATGTCGAaTTTTTTTT~TTTTTTTCCCGCCCCTCCCGGCCTCCCG
CCGCAATCTTGGCGGGAAGGCGCCGGCCGCTAAGAAGCCGAAAGATGTCCAGGTCGGGC
--------------------AGCCGGCCGCTAAGAAGCCGAAAGATGTCCAGGTCGGGC
----------------------CCGGCCGCTAAGAAGCCGAAAGATGTCCAGGTCGGGC
-------------------GCGCCGGCCGCTAAGAAGCCGAAAGATGTCCAGGTCGGGC
J..exon2
GCGGCGGCTGAGAAGGCGGACTCCAGACAGCGACCCCAGATGAAGGT------------
GCGGCGGCTGAGAAGGCGGACTCCAGACAGCGACCCCAGATGAAGGT------------
GCGGCGGCTGAGAAGGCGGACTCCAGACAGCGACCCCAGATGAAGGT------------
GCGGCGGCTGAGAAGGCGGACTCCAGACAGCGACCCCAGATGAAGGT
-------------AAATGAATATAAAGAAAATCAAAACATCGCTTATGTGTCTCTGAGA
-------------AAATGAATATAAAGAAAATCAAAACATCGCTTATGTGTCTCTGAGA
-------------AAATGAATATAAAGAAAATCAAAACATCGCTTATGTGTCTCTGAGA
IIIIIIIIIIII~~·TGAATATAAAGAAAATCAAAACATCGCTTATGTGTCTCTGAGA
CCAGCACAGACTACAGTTTTAATAAAAACAGCTAAGGTCTATCTTGCCCCCTTTTCACT
CCAGCACAGACTACAGTTTTAATAAAAACAGCTAAGGTCTATCTTGCCCCCTTTTCACT
CCAGCACAGACTACAGTTTTAATAAAAACAGCTAAGGTCTATCTTGCCCCCTTTTCACT
CCAGCACAGACTACAGTTTTAATAAAAACAGCTAAGGTCTATCTTGCCCCCTTTTCACT
CAGTAATTACCAGCTAGACCAGCTTATGTGCCCCAAATCCCTATCAGAAAAGAATTCTA
CAGTAATTACCAGCTAGACCAGCTTATGTGCCCCAAATCCCTATCAGAAAAGAATTCTA
CAGTAATTACCAGCTAGACCAGCTTATGTGCCCCAAATCCCTATCAGAAAAGAATTCTA
CAGTAATTACCAGCTAGACCAGCTTATGTGCCCCAAATCCCTATCAGAAAAGAATTCTA
ACAATGAAGTGGCGTGTAAGAAGACTAAAATAAAGAAAACTTGCAGAAGGATTATACCT
ACAATGAAGTGGCGTGTAAGAAGACTAAAATAAAGAAAACTTGCAGAAGGATTATACCT
ACAATGAAGTGGCGTGTAAGAAGACTAAAATAAAGAAAACTTGCAGAAGGATTATACCT
ACAATGAAGTGGCGTGTAAGAAGACTAAAATAAAGAAAACTTGCAGAAGGATTATACCT
+1~
CCAAAGATGAAAAACACATCTTCCAAGGCAGAATCCACGCT------------------
CCAAAGATGAAAAACACATCTTCCAAGGCAGAATCCACGCTGCAAAATTCATCCTCAGC
CCAAAGATGAAAAACACATCTTCCAAGGCAGAATCCACGCTGCAAAATTCATCCTCAGC
CCAAAGATGAAAAACACATCTTCCAAGGCAGAATCCACGCTGCAAAATTCATCCTCAGC
Figure 4-12. Nucleotide sequence of human LVI-1 RACE clones. The most
upstream and downstream transcription start sites are indicated by red and black
arrows, respectively. Blue text: first nucleotide of each transcriptional start site. Red
text: first conserved in frame ATG start codon. + 1 and -356 indicate the coding start
and transcription initiation site, respectively. The grey, green and yellow highlighted
regions are the PCR anchor primer, extra nucleotide sequence from the human
BC025247 cDNA and humanFLJexon2RSP3 primer, respectively. The underlined
region represents the Oligo dT-anchor primer.
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gene hypoxanthine-guanine phosphoribosyl transferase (HPR1), that it is generally
expressed in high levels in most tissue types. HPRT was amplified using l ul of each
murine cDNA with 30 pmol of the primers HPRT5 and HPRT3 (Table 4-1 and Table
4-2). All tissues examined were positive for the presence of the alternative P2
promoter form; in addition an unspliced RT-PCR product is present and is probably
due- to genomic DNA contamination (Figure 4-13). Intriguingly, the relative
expression levels did not correspond to northern blot analysis, which showed higher
levels in lymphoid tissues, particularly thymus. Instead, brain, testis and liver showed
the highest level of expression of the spliced exon le transcript. These results suggest
that the murine Lvi-J gene may be expressed from either PI or P2 promoters in a
tissue-specific manner. In contrast, no expression was detected from the human Pl
promoter by RT-PCR using the primer combination humanFLJexonlaF and
humanFLJexon2RSP2 (Table 4-1 and Table 4-2), suggesting that the human gene is
expressed only from P2.
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4.4 Discussion
The aim of this chapter was to characterise the expression of the human and murine
LVI-l genes and to relate these findings to the gene structure analysis in Chapter III.
BLAST searches using the human cDNA AK023035 sequence coding for exons 10
through to 13 revealed homologous murine sequences on murine chromosome 2.
Based on this observation, a unique murine Lvi-l probe was generated for further
analysis of murine Lvi-I gene expression. Higher levels were detected in lymphoid
tissues, particularly thymus. Moreover, high levels of expression of Lvi-l were also
detected in a range of murine lymphoblastoid cell lines with the highest level of
expression in p/mI6i, then p/m47i, and BW5I47. A similar expression pattern was
also observed across a range of human lymphoblastoid cell lines with the highest level
of expression in U937, followed by CEM and Jurkat, In addition, the expression
patterns of murine Lvi-I gene by northern blot analysis detected the presence of one
transcript (4.5 kb), in contrast with the two transcripts (2.8 kb and 4.5 kb) detected in
a human tissue blot (58).
Sequence analysis of the murine Lvi-I cDNA confirmed that the murine gene is
expressed in a similar manner to its human orthologue, a finding which has
subsequently been confirmed by further full-length sequences lodged in the database
(human cDNA AK023035 and murine cDNA AK03I592). Furthermore, this study
shows that the genomic organization of LVI-/ is highly conserved between human and
mouse. 5'RACE confirmed the transcriptional start sites of the murine and human
genes and supported evidence from EST and cDNA clones that the murine gene is
expressed predominantly from the PI promoter while the human gene is expressed
from the P2 promoter. While RT-PCR cloning showed that some murine transcripts
may be initiated from within the adjacent MfapI gene, 5'RACE suggested that most
transcripts are inkiated 3' to this gene. In addition, direct analysis by RT-PCR
showed that the murine gene could also be expressed from the P2 promoter, while no
transcripts were detected from the human PI promoter region. Moreover, transcripts
from the murine P2 promoter were more abundant in non-lymphoid tissues, notably
brain, liver and. testis.
These observations argue that the Lvi-l gene is differentially expressed and regulated,
with expression of the murine gene mainly coming from the highly lymphoid specific
PI promoter, while the human gene is expressed from the more widely utilised P2
promoter. These findings also have significant implications for Lvi-I protein
expression as the P2 transcripts are predicted to express larger proteins with a distinct
N-terminal sequence (Figure 3-6).
All the results in this chapter are centred on the expression of human and murine LVI-
I gene. It was considered important to extend this analysis to study protein
expression, as the nature and abundance of the protein products could not be predicted
accurately from these RNA-based studies.
Chapter V
Characterisation of LVI·1 protein products
5.1 Introduction
At the outset of this study, no information was available on the protein products of the
LV/~/ gene. Analysis of human and murine LV/-/ gene cDNA clones showed that the
major human LV/-/ transcripts have an open reading frame of 626 amino acids
encoding a protein of 69.75 kDa, while the murine LV/-/ transcript has an open
reading frame of 524 amino acids encoding a protein of 57.96 kDa (Figure 3-5, 3-6).
However, I have shown that the P2 promoter of the murine gene is also active, with
the potential to encode a larger protein of 69 kDa, while the use of an internal AUG in
the human mRNA would generate a product of 58.78 kDa. To characterise the
products directly rabbit polyclonal antisera were generated using the GST gene fusion
system. The specificities of these antisera were then tested by comparison of western
blot signals before and after blocking with the homologous GST fusion protein
immobilised on glutathione sepharose beads. Further studies were carried out to
compare protein and mRNA expression levels of the LV/-/ gene in a panel of human
and murine cell lines, in which the polyclonal antisera were used to examine the LVI-
I protein expression by western blotting. It was important to generate and validate
these immunological reagents before subsequent use in studies of protein localisation
and function.
5.2 Material and methods
5.2.1 Production of recombinant expression vector
The recombinant- plasmids: mLvi-I-pGEX (pGEX-5X-2 plasmid containing the
coding sequence for the predicted immunogenic region of the murine Lvi-I gene) and
hLVI-I-pGEX (pGEX-5X-I plasmid containing the coding sequence for the predicted
immunogenic region of the human LV/-/ gene) were produced as described below.
Peptides were selected from the predicted immunogenic regions of the LVI-I proteins
that are generally hydrophilic (regions in contact with an aqueous environment). The
Protein Hydrophilicity/Hydrophobicity Search is available online at the Weizmann
Institute's Bioinformatics & Biological Computing web page
(http://www.weizmann.ac.ill) and was the computer program used to predict the
hydrophilic regions of the human and murine bVI-l proteins. Although other
domains were more hydrophilic, the Cvterminal domains were chosen based on the
laboratory's experience of the GST system and previous successes in generating
antisera to Cvterminal fusion fragments (271, 272).
Preparation of DNA encoding the hLVI-l C-terminus
1 ug of human genomic DNA from eEM cell line was used to amplify DNA
encoding amino acids 540 to 617 of the human LVI-J protein (hLVI-l) with 100
pmol of specific primers. Both primers contain an EcoRI restriction site at the 5' end
to allow cloning of the amplified peR product into the pGEX 5X-l vector as detailed
below. For primer sequence and peR conditions see Tables 5-1a, 5-1 b, and also
Section 2.2.4. The amplified fragment was then purified using the QfAquick" peR
purification Kit (Qiagen) according to the manufacturer's protocol. The EcoRI
fragment was obtained by digestion of the purified DNA with the restriction enzyme
(as detailed in Section 2.2.2.) and then purified as described above. The insert DNA
was then quantified by 4% polyacrylamide gel electrophoresis. Following staining
with ethidium bromide and inspection under UV illumination DNA was quantified by
comparison with the molecular weight standard DNA (<jlX174 RF DNA/HaeIII
fragments).
Preparation of DNA encoding the ml.vi-I C-terminus
DNA encoding amino acids 446 to 524 of the murine Lvi-I protein (mLvi-l) was
generated by digestion of the plasmid DNA containing exon 13 of the murine Lvi-I
gene (Section 4.2. ) with the restriction enzyme EcoRI (as detailed in Section 2.2.2)
followed by purification of the EcoRI fragment (as detailed in Section 2.2.2). The
purified fragment was then quantified by 1% TBE agarose gel electrophoresis as for
the hLVI-l protein.
Preparation of the pGEX vector
In order to prepare the vectors pGEX-5X-l and pGEX-5X-2 for cloning the human
and murine LVI-J DNA inserts respectively, 2 ug of each vector was digested with
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Table 5-1. Primers used for generation of hLVI-1-GST fusion constructs.
Table 5-1a. Primer sequences (by hand).
Number
of primer
Primer Strand Sequence (5'-3')
2
HumanFLJ13F
HumanFLJl3R
Forward
Reverse
get gaa ttc cac aac act ttc ac
age gaa ttc tat ctt ccc get gg
Table 5-1b. Primer combinations, peR conditions, and applications.
Primer combination Product size Annealing temperature (OC) Application
1 + 2 252 bp 50 Genomic PCR
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the restriction enzyme EcoRI (Section 2.2.2) followed by gel purification (Section
2.2.2). The purified and linearised vectors were then dephosphorylated by digestion
with ClAP (Section 2.2.2) followed by purification using the QlAquick® PCR
purification kit. Vector DNA was quantified by gel analysis of an aliquot as
described above for the insert fragments.
Cloning of the insert DNA into the pGEX vector
The human and murine LV/-J DNA inserts were ligated into the pGEX-5X-l and
pGEX-5X-2 vectors, respectively (as detailed in Section 2.2.2). The ligation mix was
then used to transform One Shot®TOPlO Chemically Competent E. coli cells (as
detailed in Section 2.2.2). The mLvi-1-pGEX and hLVI-l-pGEX recombinant
plasmids were identified by Grunstein-Hogness screening (as detailed in Section
2.2.2) using the u-32P-Iabeled human LV/-J exon 13 DNA probe (Section 4.2.2 and
2.2.6) and u-32P-Iabeled murine Lvi- J exon 13 DNA probe (Section 4.3.1 and 2.2.6),
respectively. The presence of inserts in the correct orientation was verified by
sequencing the clones containing the recombinant plasmids by using the primers
pGEX5' and pGEX3' as detailed in Section 2.2.5. Moreover, mLvi-1-pGEX
recombinant plasmids were also verified by dual restriction enzyme digestion with
XbaI and EcoRV enzymes (Section 2.2.2) followed by electrophoresis through a 1%
TAE agarose gel (Section 2.2.2).
5.2.2 Expression of LVI-l-GST fusion proteins
Transformation of E.coli BL21 cells
Competent E.coli BL21 cells were freshly prepared and transformed with the mLvi-l-
....
pGEX and hLVI-l-pGEX recombinant plasmids as described in Section 2.2.2. The
cells were also transformed with the parental pGEX plasmid for use as a control in
expression studies. Single colonies with the mLvi-l-pGEX and hLVI-l-pGEX
recombinant plasmids were picked after overnight growth at 37 DCon LBAG agar
plates and used for production of the hLVI-1-GST and mLvi-1-GST fusion proteins.
Small scale expression of LVI-I-GST fusion proteins
A small scale screening procedure was carried outto analyse protein expression of
transform ants of BL2I E. coli in combination with pGEX vectors. A single colony
expressing the pGEX-LVI-I fusion plasmids was inoculated into 5 ml of 2xYTA
medium and incubated overnight at 37 QC with vigorous shaking. The overnight
culture was diluted 1:100 into fresh pre-warmed 2xYTA medium (20 ml), and
incubated at 37 QCwith shaking until an A600of 0.8. Isopropyl ~-D-thiogalactoside
(IPTG) was added to a final concentration of 0.1 mM and cultures incubated at 37 QC
for a further 2 hours with vigorous shaking. The bacterial culture was transferred to
an appropriate centrifuge container and centrifuged at 4000 rpm for 10 minutes at
4 QC to sediment the cells. The supernatant was discarded and the bacterial pellet
resupended in 1 ml of ice-cold IxPBS. Lysozyme was added to a final concentration
of 1 mg/ml and the cells lysed by 10 cycles of alternative freezing in a dry ice liso-
propanol bath and 37 QCwarming to thaw. The supernatant was then removed to a
clean tube prior to purification of the fusion protein by affinity chromatography (see
below).
Small scale purification of L VI-I-GST fusion proteins
50% Glutathione Sepharose 4B slurry (Amersham Biosciences) was prepared
according to the manufacture's instructions. 20 III of 50% glutathione sepharose 4B
slurry was added to the cleared lysate derived from 20 ml of bacterial culture and
incubated at room temperature for 5 minutes with gentle agitation. The matrix was
then sedimented by centrifugation at 500 g for 5 minutes, the supernatant discarded
and the matrix resuspended in 100 III of l x PBS and sedimented by centrifugation at
500 g for 5 minutes. This was repeated a further two times for a total of three washes.
""Elution of the fusion protein was carried out by the addition of 10 III of glutathione
elution buffer 1 (Section 2.1.11). The sepharose beads were resuspended by gentle
agitation at room temperature for 5 minutes and then sedimented by centrifugation at
500 g for 5 minutes. The supernatant was collected to a fresh tube. The elution and
collection steps were repeated twice more for a total of three eluates.
Analytical scale preparation of insoluble LVI-I-GST fusion proteins
A single colony expressing the pGEX-LVI-l fusion plasmid was inoculated into 1 ml
of LB medium containing 100 ug/ml ampicillin and incubated overnight at 37 DC with
vigorous shaking. 30 ul of overnight culture was added to 1.5 ml of LB (1:50
dilution) containing 100 ug/rnl ampicillin and incubated at 37 DC with shaking for 90
minutes. IPTG was added to a final concentration of 0.1 mM and the culture
incubated for a further 4 hours. The bacterial culture was transferred to an
appropriate centrifuge container and centrifuged at 4000 rpm for 10 minutes at 4 DC to
sediment the cells. The supernatant was discarded and the bacterial pellet washed
once with 200 ~Iof ice-cold STE (Section 2.1.11), resuspended by repeated pipetting
in 135 ul of STE containing 100 ug/rnl of lysozyme, and incubated on ice for 15
minutes. Oithiothreitol (OTT) was then added to a final concentration of 5 mM. N-
laurylsarcosine (sarkosyl) sodium salt to a final concentration of 1.5% from a 10%
stock in SJ'E was added and the solution vortexed for 5 seconds. The cell suspension
was lysed by the freeze/thaw method as described above. The supernatant was
transferred to a clean eppendorf tube, Triton X-lOO added to a final concentration of
2% from a 10% stock in STE and the lysate vortexed for 5 seconds. 30 ul of washed
and swollen glutathione agarose beads suspension (50% v/v in PBS) was added, and
the lysate incubated at 4 DC on an Orbitron Rotator for 15 minutes. The beads were
washed 6 times with ice-cold PBS by repeated centrifugation at 500 g for 5 minutes.
The supernatant was aspirated, and Y2 volume of ice-cold glutathione elution buffer 2
(Section 2.1.11) was added. The tip of a 24-gauge needle was used to make a hole in
the bottom of the eppendorf. Applying positive pressure with air hose to the top of
the eppendorf tube and collecting drops from the bottom captured eluted protein, in
the absence of beads. Another Y2 volume of elution buffer was added to the beads, the
procedure was repeated, and the eluates pooled.
Preparative scale preparation of insoluble LVI-I-GST fusion proteins
A single colony expressing the pGEX-LVI-l fusion plasmid was inoculated into 40
ml of LB (Luria broth) medium containing 100 ug/ml ampicillin and incubated
overnight at 37 DC with vigorous shaking. 40 ml of overnight culture was added to
2000 ml of LB (1 :50 dilution) containing 100 ug/ml ampicillin and incubated at 37 DC
with shaking for 90 minutes. IPTG was added to a final concentration of 0.1 mM and
the culture incubated for a further 4 hours. The bacterial culture was transferred to an
appropriate centrifuge container and centrifuged at 7000 g for 7 minutes at 4 QC to
sediment the cells. The supernatant was discarded and the bacterial pellet washed
once with 120 ml of ice-cold STE (Section 2.1.11), resuspended by repeated pipetting
in 120 ml of STE containing 100 ug/ml of lysozyme, and incubated on ice for 15
minutes. OTT was then added to a final concentration of 5 mM. Sarkosyl was then
added to a final concentration of 1.5% from a 10% stock in STE and the solution
vortexed for 5 seconds. Cells were lysed by sonication as follows. The cell
suspension was sonicated for approximately 30 seconds to disrupt the bacteria. A
model Sonicator Ultrasonic Processor (Sonicator XL 2220 Labcaire Systems Ltd)
equipped with a standard probe was used for sonication; the sonicator was tuned prior
to use, following the manufacturer's instructions. The power level was generally set
to between five and six (where level 10 were maximal) which avoided frothing, which
may denature fusion proteins. A decrease in viscosity and slight darkening in colour
of the cell suspension indicated the degree of sonication. Cell debris was pelleted by
centrifugation at 10000 g for 10 minutes at 4 QC in a Beckman JA20 rotor. The
supernatant was then removed to a clean tube, Triton X-I DO added to a final
concentration of 2% from a 10% stock in STE and the lysate vortexed for 5 seconds.
2.4 ml of washed and swollen glutathione agarose bead suspension (50% v/v in PBS)
was added, and the lysate incubated at 4 ,QCovernight on an Orbitron Rotator. The
beads were washed 6 times with 10 ml of ice-cold PBS by repeated centrifugation at
500 g for 5 minutes. The supernatant was aspirated, and Y2 volume of ice-cold
glutathione elution buffer 2 (Section 2.1.11) was added. The beads were resuspended
by gentle agitation at room temperature for 10 minutes and then sedimented by
centrifugation at 500 g for 5 minutes. The supernatant was collected to a fresh tube .....
The elution and collection steps were repeated twice more for a total of three eluates.
Extraction of the solubilised LVI-I-GST fusionproteins from SDS-PAGE
Equal volumes of sample and SOS-PAGE Protein 2x Sample Loading Buffer (Section
2.1.11) were vortexed, heated to 95 QC for 5 minutes and chilled on ice prior to
loading on gel. All samples were separated on 10% Bis-Tris SOS-PAGE gels, stained
with Electro-Blue ™ Staining Solution from Qbiogene for 1 hour and then destained
with several ddH20 changes until a clear background was obtained. The gel slice
containing the LVI-I-GST fusion proteins was excised, transferred to a
ProteoPLUS™ tube from Qbiogene (that was previously hydrated, according to the
manufacturer's instructions) and then the tube was filled with 800 f..11of protein
running buffer (the same buffer used to run the gel). The supporting tray containing
the proteoPLUS tube was then placed in a horizontal electrophoresis tank (Biomax
QS710 Horizontal Unit) containing protein-running buffer and the protein
electroeluted from the gel slice at 100 volts for 60 minutes. To increase the amount of
protein recovered, the polarity of the electric current was reversed for 60 seconds.
The solution was transferred to a clean tube and centrifuged at 14000 rpm for 1
minute to remove gel residues. The protein-containing solution was transferred to a
clean tube.
Dialysis and concentration of the eluted LVI-I-GST fusion proteins
The dialysis of the eluted LVI-I-GST fusion proteins was carried out using a
ProteoPLUS™ tube from Qbiogene at 4 QC, overnight with two changes of the
dialysis buffer (PBS). The sample was loaded into the ProteoPLUS™ tube (that was
previously hydrated, according to the manufacturer's instructions) and placed in a
stirred beaker containing sterile PBS (1OOxthe volume of the protein sample).
The concentration of the GST fusion proteins was carried out using a Centricon
Centrifugal Filter Devices from Millipore. The sample was added to the sample
reservoir of the Centricon Centrifugal Filter Devices and centrifuged at 5000 g for 25
minutes at 4 QC. Then the filtrate vial was separated from the membrane support
base, and the retentate vial placed over sample reservoir and then centrifuged at 1000
g for 2 minutes to transfer the concentrate into the retentate vial.
5.2.3 Identification of LVI-l-GST fusion proteins
Identification on Coomassie stained gels
Recombinant proteins were identified by SDS-PAGE gels followed by staining with
Coomassie Brilliant Blue, as outlined in Section 2.2.7. Typically 10 f..11of each
sample was loaded into each well of a mini 12% SDS-PAGE gel. This was used to
estimate the molecular size, yield and purity of the recombinant protein.
Identification by western blot analysis
In order to confirm the identity of the protein bandsseen on Coomassie stained gels as
an hLVI-I-GST and mLvi-l-GST fusion proteins, western blotting was performed by
the protocol of EeL detection system (Section 2.2.7). Briefly, 1 ul aliquots of the gel
purified sarkosyl solubilised mLvi-l-GST and hLVI-I-GST fusion proteins were
separated on a standard 10% SDS-PAGE gel and transferred to a nitrocellulose EeL
membrane. The membrane was blocked overnight, incubated with 1:1000 goat anti-
GST antibody (Amersham Pharmacia Biotech) for 1 hour at room temperature,
washed 3-4 times in lx TBST then incubated with 1:2000 HRP conjugated rabbit
anti-goat IgG polyclonal antibody (DakoCytomation) for 1 hour at room temperature,
prior to immunodetection.
5.2.4 Mass spectrometry analysis
LVI-I-GST fusion proteins aliquots equivalent to 185 ng were resolved on NuPAGE@
Novex 4-12% Bis-Tris gel (Invitrogen Life Technologies) as described in Section
5.2.5, and stained with the SimplyBlue Safe Stain (Invitrogen Life technologies)
according to the manufacturer's protocol. Bands corresponding to the LVI-I-GST
fusion proteins were excised from the gel, placed into a 1.5 ml eppendorf tube and
sent to Sir Henry Wellcome Functional Genomics Facility (SHWFGF) in the
University of Glasgow for mass spectro~etry by MALDI-TOF (matrix assisted laser
desorption ionisation-time of flight) using the mass spectrometer, Voyager-De PRO
Worksation from Applied Biosystems. Briefly, protein identification by mass
spectrometry requires the digestion of the protein of interest with trypsin, a serine
protease that specifically cleaves at the carboxylic side of lysine and arginine
residues. The resultant mixture of peptides displays a mixture of distinct molecular
weights that after elution can be accurately measured by MALDI-TOF. In fact, the
MALDI produces a peak list in which each peak corresponds to the exact mass of a
peptide ion. The resulting peak molecular weights from the MALDI spectrum were
then used to search for corresponding proteins using the Mascot program available on
the Matrix Sciences web page (http://www.matrixscience.com).
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5.2.5 Measurement of purity and estimation of concentration
Estimation of LVI-I-GST fusion proteins concentration by silver staining
Equal volumes of 1:40 diluted LVI-I-GST fusion proteins and different dilutions (3.9-
780 ng) of protein standard BSA were resolved on a 1.0 mm NuPAGE® Novex 4-
I2~ Bis-Tris Gel (Invitrogen Life Technologies) using l x NuPAGE® MES (2-(N-
morpholino) ethane sulfonic acid)-SDS Running Buffer (Invitrogen Life
Technologies) as detailed in the NuPAGE® Technical Guide from Invitrogen Life
Technologies. After gel electrophoresis, the proteins were silver stained using the
SilverQuest Silver Staining Kit (Invitrogen Life Technologies) according to the
manufacturer's protocol.
Estimation of LVI-I-GST fusion protein by Bio-Rad Protein Assay
Pooled preparations of LVI-I-GST fusion proteins were measured using the Bio-Rad
Protein Assay as detailed in Section 2.2.7. Typically, BSA was diluted with ddH20 to
concentrations ranging from 0.025 to 1.4 mg/ml to enable the production of a standard
curve each time the assay was performed.
5.2.6 Production of polyclonal antibodies against GST fusion protein and its
immunodetection by western blotting
Immunizations of 2 New Zealand White-Barrier Reared rabbits per fusion protein
proteins, (hLVI-l and mLvi-l) were performed by Harlan Sera-Lab (Leicester, UK)
in accordance with the Animals (Scientific Procedures) Act. The rabbits were
immunized subcutaneously with 95.46 ug of hLVI-I-GST protein and 105 ug of
mLvi-I-GST prqtein in Freunds Complete adjuvant and boosted a further 5 times, at 2
weekly intervals, with the same amount of antigen in Freunds incomplete adjuvant
and the animals were sacrificed at II weeks. Bleeds were taken 7 days after each
immunisation and the serum divided into aliquots for long term storage at -70°C.
d
The pre-immune and test bleeds were submitted to western blot analysis to confirm
the anti GST fusion protein antibody status. Fusion protein samples and GST protein
alone were separated on 10% SDS-PAGE gels and subsequently electroblotted onto a
nitrocellulose ECL membrane (Section 2.2.7). Western blotting was performed as
described previously (Section 2.2.7). The pre immune and test sera were diluted
I: 1000 and I :2000 and incubated on strip blots for 3 hours at room temperature.
Protein A linked to HPR (Amersham Biosciences). was used as a secondary antibody
according to the manufacturer's instructions.
5.2.7 Validation of polyclonal antisera
Sera affinity chromatography
The intrinsic specificity of the test sera for their cognate proteins was assessed by the
sequential removal of OST and then LVI-I-OST reactive moieties by affinity
chromatography. Essentially Glutathione Sepharose beads (Amersham Biosciences)
were prepared as 50% slurry according to the manufacturer's instructions and 4 ml
coupled with 4 mg of OST protein (Sigma) by incubation with gentle agitation at 4 QC
overnight. After coupling of OST, the beads were pelleted by centrifugation at 500 g
for 5 minutes, washed with lObed volumes of PBS (1 bed volume is 0.5 x the volume
of 50% ·glutathione sepharose slurry used) and repelleted by centrifugation at 500 g
for 5 minutes. The wash was repeated twice for a total of three washes. 2 ml ice-cold
PBS was added to the pellet to make 50% glutathione sepharose slurry coupled with
OST. Then, 250 III of neat or diluted (1: 10, 1:100, and 1:1000) anti-mLvi-l-OST sera
(7328 rabbit) or anti-hL VI-I-OST sera (7330 rabbit) were added to 1 ml of OST
coupled slurry and the mixtures were incubated with gentle agitation at 4 QC
overnight. The beads were collected by centrifugation 500 g for 5 minutes and the
OST reactive depleted supernatant tested for reactivity against OST by western
blotting of OST protein (I ug and 0.1 ug.) at I :3000 dilution for 4 hours at room
temperature (Section 2.2.7). A second round of affinity chromatography was then
performed using the respective LVI-I-OST fusion proteins as the immobilised
substrate. 50% glutathione sepharose slurry was coupled with 76.5 ug mLvi-I-OST...
or 9.1 ug hLVI-I-OST fusion proteins as described above. The LVI-I-OST depleted
supernatants were collected as before and compared with their original and OST-
absorbed sera for reactivity against their respective LVI-I-OST fusion proteins.
Detection of specificity
To analyse the specificity of each antisera for their native proteins whole cell lysates
were prepared from Hl3T3 and Jurkat cells as described in Section 2.2.7. 30 ug of
lysate was loaded into multiple wells and resolved on a 10% SDS-PAGE gel. Parallel
strip blots were probed against an appropriate dilution of neat, GST absorbed, and
LVI-I-GST absorbed fractions and the reactive bands visualised by ECL detection
(Section 2.2.7).
5.3-Construction and purification of LVI -1 fusion proteins
5.3.1 Peptide selection
Immunogenicity or the capacity of a molecule to induce an immune response is
determined by the intrinsic chemical structure of the injected molecule and its
recognition by the host animal. In choosing a region of LVI-I to generate a
polyclonal antibody a number of independent factors were taken into account. Firstly
a hydrophilicity plot of the human and murine amino acids sequences was generated
to locate hydrophilic peptides (Figure 5-1). Previous studies (273-275) suggest that
hydrophilic peptides are more likely to be exposed on the surface of native proteins
and therefore be more antigenic to the host animal. Care must be taken with these
plots because many hydrophilic amino acid sequences can be buried in water pockets
or form intra or inter-molecular bonds thus excluding other potential interactions with
anti-native antibodies. To minimise the risk of this we focussed on the extreme
carboxyl (C) and amino (N) termini as these regions are commonly exposed in native
proteins (276) and therefore make good antigenic targets. The murine and human
amino acid sequences of LVI-I differ most markedly at their amino termini so the
carboxyl region encoded by the nucleotide sequence of exon 13 was identified as the
main sequence of interest. It was predominantly hydrophilic and was sufficiently
homologous (78% homology) between human and murine sequences to potentially
generate an antibody with cross species reactivity.
5.3.2 GST gene fusion system
To produce a sufficient quantity of murine and human LVI-l proteins, within a
limited time scale, we used the GST gene fusion system for the expression,
purification, and detection of fusion proteins (Figure 2-1). The system utilises pGEX
vectors for inducible, high-level intracellular expression in E. coli of genes or gene
fragments fused to the C-terminus of Schistosoma japonicum GST (277).
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Figure 5-1. Kyle-Doolittle amino acid hydrophilicity plot of AK023035 and
mLvi-l amino acid sequences. The positive values indicate the hydrophilic regions.
The numbered boxes indicate the translated exons of L VI-I gene. The blue stippled
portions of exon 13 and blue lettered amino acid sequences letters indicate the peptide
regions included in the GST fusion proteins. An alignment of human and murine
amino acid sequences encoded by exon 13 is shown below.
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Expression of the GST fusion proteins is under control of the tac promoter, a
modified form of lac promoter, which is inducedby the lactose analog IPTG. The
pGEX vectors also carry the lacIq gene that encodes a protein that binds to the
operator region of the tac promoter, thereby preventing expression until induction by
IPTG. Purification of the GST fusion proteins from bacterial lysates is a one step
precedure that uses the intrinsic affinity of GST for glutathione residues present on
glutathione sepharose beads. In addition, the GST gene fusion system also permits
elution of the GST fusion proteins from the glutathione sepharose under mild, non-
denaturing conditions that preserve both protein antigenicity and function. In fact,
this system is widely used for recombinant protein expression because proteins appear
to be relatively stable and folded when fused to GST and also due to its ease of
production, reproducibility.
5.3.3 Generation and expression of LVI -l-GST fusion proteins
An hLVI-I-GST fusion protein encoding 77 amino acids (540 - 617) from the C
terminus of human LVI-l was generated by PCR amplification of cDNA using EcoRI
flanked primers (see Table 5-1a). The amplified human exon 13 sequence was
inserted into an EcoRI digested pGEX-5X-l bacterial expression vector (Figure 5-2a).
The translated fragment lacks the 9 terminal amino acids of human LVI-l and utilises
the stop codon present in the multiple cloning site of the vector.
Murine Lvi-I exon }3 was isolated as an EcoRI fragment from pCR®n- TOPOl
exon 13 (Section 4.2.1) and subcloned into an EcoRI digested pGEX-5X-2 bacterial
expression vector. Use of pGEX-5X2 was necessary to preserve the reading frame of
the inserted fragment. Translation terminates at the Lvi-I stop codon thus encoding
the entire carboxyl-terminal sequence of the protein (amino acids 446-524) (Figure 5-
2b).
Expression of the fusion proteins was confirmed by transformation of E. coli BL21
cells with the recombinant vectors. Cell lysates were extracted pre and post IPTG
induction and analysed for LVI-1 expression using Coomassie Brilliant Blue to
visualise the proteins (Figure 5-3). The predicted molecular weights of human and
murine LVI-I-GST fusion proteins are 37.03 kDa and 36.09 kDa respectively, of
which 26 kDa is acquired from the GST moiety (http://www.expasy.ch). As can be
seen in Figure 5-3 a predominant protein species was observed in each track that
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a.
Human L VI-l selected nucleotide sequence
F H N T F T G R W L T R F Q A M W D P K QED C V I
aattccacaacactttcactgggcgatggctgaccaggttcca~gccatgtgggatcctaaacaagaagactgtgtcata
V G S M A H P R R V ElF HET G K R V H S F G G E Y
gttggcagcatggcccatccacgacgggtagaaatcttccatgagacaggaaagagggtgcattcgtttggtggagaatac
L V S V C SIN A M H P TRY I LAG G N SSG K I
cttgtctctgtgtgttccatcaatgccatgcacccaactcggtatattttggctggaggtaattccagcgggaagatag I
~
pGEX-5X-l Ile Glu Gly Arg Gly Ile Pro Gly Phe Pro Gly Arg Leu Glu Arg Pro His Arg Asp
Cloning site ATC GAA GGT CGT GGG ATC CCC ~ TTC CCG GGT CGA CTC GAG CGG CCG CAT CGT Q!S TGA
EcoR I Stop codon
b.
Murine Lvi-I selected nucleotide sequence
R P W L T R F Q A V W D P K QED C F I V G S M D H
aattcgcccttggctaacgaggttccaggctgtgtgggaccctaaacaagaagattgcttcatagttggtagcatggaccac
P R R V E V F H E S G K N V H S L W GEe L V S v C S
ccacgacgggtggaagtcttccacgagtcgggaaagaatgtgcattctctttggggagaatgtcttgtatctgtgtgttcc
L S A V H P TRY I LAG G N SSG K L H V F M H Q E T
ctcagtgctgtgcatcctacgcgatatatcctggctggaggtaattccagtggcaagttacatgtttttatgcatcaagaaacc
~gtcattggataggttcaacaaattgttcaacttgttctgcagctagggaacctagagactcagcttagtgcatctgtttgg
tcacgtgttatatttagtaaatataacactgctttctcagtgagacctccacacagaatgtaatattagcaagggaggaacttg
I aaggccatttctagaggatgagggagagacctggagcagaaacgggtgttttcatgaagggcg I
~
pGEX-5X-2 !le Glu Gly Arg Gly Ile Pro Gly Ile Pro Gly Ser Thr Arg Ala Ala Ala Ser
Cloning site ATC GAA GGT CGT GGG ATC CCC GG,AATT CCC GGG TCG ACT CGA GCG GCC GCA TCG TGA
EcoR I
Figure 5-2. Strategy for construction of pGEX-5X-l-hLVI-l and pGEX-5X-2-
mLvi-l plasmids. a. Human LV/-J nucleotide sequence encoding the peptide
sequence starting from 540 to 617 was digested with EcoRI restriction enzyme and
inserted into EcoRI cloning site on pGEX-5X-1. h. Murine Lvi-I nucleotide of
sequence encoding the peptide sequences starting from 446 to 524 from the pCR®n-
TOPO vector was digested with EcoRI restriction enzyme and inserted into EcoRI
cloning site pGEX-5X-2. The blue, green, underlined, and red letters represent the
EcoRI site, nucleotides encoded by the pCR®n- TOPO vector, the stop codon, and the
amino acids encoded by the vector pGEX-5X-2 that are not translated in the GST
fusion protein, respectively.
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Figure 5-3. Induction of the hLVI-I-GST and mLvi-l-GST fusion proteins with
IPTG. Bacterial cells carrying the recombinant pGEX-5X-J (lane 1) and pGEX-5X-
2 (lane 2) plasmids were induced with IPTG, analysed by SDS gel electrophoresis on
a 12% polyacrylamide gel and stained with Coomassie Brilliant Blue. Red arrows
indicate the hLVI-I-GST and mLvi-l-GST fusion proteins. M denotes protein
molecular weight markers (Precision Plus Protein Standards, BioRad) shown in
kilodaltons.
correlated with the predicted molecular weight of human (lane 1) and murine (lane 2)
LVI-l supporting the conclusion that both pr.oteins are expressed from their
recombinant vectors and are non-toxic to bacterial cells.
5.3.4 Purification of LVI-I-GST fusion proteins
Purification of IPTG-induced GST fusion proteins from bacterial lysates depends on
their solubility (277). Examination of the soluble and insoluble fractions after
bacterial cell lysis and centrifugation revealed that both recombinant proteins
consistently partitioned to the insoluble fraction irrespective of the temperature or
incubation times used during IPTG induction (Figure 5-4). It has been reported that
insolubility can be associated with binding to bacterial cell membranes and
subsequent sequestration into insoluble inclusion bodies (278). The sodium salt of the
alkyl anionic detergent N-Iauryl-sarcosine (sarkosyl) can be used to disrupt
interactions between a fusion protein and the outer membrane components or to
prevent such an interaction from occurring if present during bacterial cell lysis (279).
Using the recommended concentration of sarkosyl (1.5%) both human and murine
LVI-I-GST partitioned to the soluble fraction after bacterial cell lysis (Figure 5-5).
However, the presence of sarkosyl in the cell lysate severely reduced the affinity of
the GST fusion proteins for glutathione sepharose beads (Figure 5-5). The non-ionic
detergent Triton X-WO was used in an attempt to sequester sarkosyl into micelles and
improve glutathione affinity but with little success. Consequently sarkosyl solubilised
LVI-l fusion proteins were typically resolved on PAGE SDS gels, visualised with
"Simply Blue Safe Stain" (Invitrogen Life Technologies), electroeluted, dialysed and
concentrated prior to use. The extracted proteins were verified by western blotting
using an anti-GST antibody. Proteins corresponding to the predicted molecular
weight for hum n and murine LVI-I-GST fusion proteins were detected indicating
that the combination of sarkosyl solubilisation and gel extraction was a valid method
for purification of these fusion proteins (Figure 5-6).
5.3.5 Validation by mass spectrometry
To confirm the molecular identity of both GST reactive proteins MALDI- TOF mass
spectrometry was performed at the Sir Henry Wellcorne Functional Genomics Facility
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Figure 5-4. Small scale purification of the human and murine pGEX
recombinants for fusion protein expression. Bacterial cells carrying the
recombinant pGEX vectors expressing hLVI-l (Janes 1, 2) and mLvi-l (lanes 3, 4)
fusion proteins were induced with IPT,G and whole cell Iysates analysed by 12%
SDS-PAGE. The gels were stained with Coomassie Brilliant Blue. Lanes 1 and 3 are
the cleared Iysates (soluble fractions) from the bacterial cultures with hLVI-l and
mLvi-l, respectively. Lane 2 and 4 are the corresponding pellets (insoluble
fractions). Red arrows indicate the hLVI-I-GST and mLvi-l-GST fusion proteins. M
is the protein molecular weight markers (Precision Plus Protein Standards, BioRad)
shown in kilodaltons.
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Figure 5-5. Solubilisation of mLvi-l-GST and hLVI-I-GST fusion proteins.
Bacterial cell lysates expressing murine and human LVI-l pGEX fusion proteins were
solubilised with 1.5% sarkosyl. Lanes I and 2 show soluble and insoluble fractions
from an analytical scale preparation of cells expressing the murine fusion protein.
Lanes 3 and 4 show soluble and insoluble fractions from a preparative scale
preparation of cells expressing the human fusion protein. Red arrows indicate the
hLVI-I-GST and mLvi-l-GST fusion proteins. M is the protein molecular weight
markers (Precision Plus Protein Standards, BioRad) shown in kilodaltons.
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Figure 5-6. Western blot analysis of ,LVI-I-GST fusion proteins. Gel purified
sarkosyl solubilised mLvi-l-GST and hLVI-I-GST fusion proteins were separated on
10% SDS-PAGE and transferred to nitrocellulose membrane. The membrane was
incubated with the anti-GST antibody followed by an anti-goat secondary antibody
and processed for immunodetection. Lanes 1 to 3 and 4 to 6 represent the mLvi-l-
GST fusion protein (3'6.09 kDa) and hLVI-I-GST fusion protein (37.03 kDa). The
blot exposure time was 10 seconds. M is the protein molecular weight markers
(Precision Plus. Protein Standards, BioRad) shown in kilodaltons.
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(SHWFGF) based in the University of Glasgow. Essentially, molecular masses of the
peptide fragments derived from the putative human and murine LVI-I-GST fusion
proteins were compared with known trypsin digest databases using the Mascot
program. As shown in Figure 5-7 two predicted amino acid sequences were identified
from each peptide fragment mixture (GST fusion proteins) for both human and
murine LVI-l proteins and thus, confirming their molecular identity and validating
their use in subsequent immunisations.
5.3.6 Quantification of LVI-I-GST fusion proteins for immunisation
In rabbits the recommended dose of protein antigen in adjuvant at each immunisation
is between 0.05-1 mg (276). Doses within this range provide sufficient stimules to
generate a strong antibody response and are unlikely to induce tolerance.
Preparations of LVI-l- GST fusion proteins were quantitated by silver staining. After
dialysis and concentration, aliquots of several gel extracted murine and human LVI-l-
GST proteins were resolved on a 12% PAGE/SOS gels with a serial dilution of BSA
standards. The gels were silver stained and the human and murine LVI-l-GST
concentrations estimated from the intensity of the standards. An example of this
quantification is shown in Figure 5-8 in which the concentration of one of the samples
of murine Lvi -J-GST protein was estimated at 0.78 f..lg/f..ll.Parallel samples were
pooled and the approximate concentrations confirmed using a modification of the
Bradford method (260). In this way I estimated the concentration of the human and
murine LVI-I-GST preparations to be approximately 0.74 f..lg/f..lland 3 f..lg/f..ll,
respectively.
5.3.7 Immunisation Schedule
'"
The production of polyclonal antibodies against human and murine LVI-l-GST
fusion proteins was carried out by the Harlan Sera-Laboratory in Leicester (Section
5.2.6). The sera were tested for reactivity against the appropriate LVI-I fusion and
GST protein alone by western blotting. As expected the pre-immune sera gave no
reactivity against either GST or the LVI-I fusion protein (Figure 5-9). Reactivity was
observed using the first test bleed of all 4 animals. Protein species that did not
correspond to the predicted molecular weight of LVI-I-GST or GST alone were also

37 kDa-
25 kDa_
BSA protein
mLvi-l-
GST
protein
Figure 5-8. Silver staining detection of mLvi-l-GST fusion proteins. Equal
volumes of aliquots of 1:50 diluted gel purified sarkosyl solubilised mLvi-l-GST
fusion protein and different dilutions (3.9-780 ng) of BSA protein standard were
resolved by NuPAGE® Novex 4-12% Bis-Tris gel and silver stained. Lane 1 contains
the mLvi-l-GST fusion protein. The next lanes show dilutions of BSA, 1:5 (780 ng),
1:10 (390 ng), 1:25 (156 ng), 1:50 (78 ng), 1:100 (39 ng), 1:250 (15.6 ng), 1:500 (7.8
ng), and 1:1000 (3.9 rig). M is the protein molecular weight marker (Precision Plus
Protein Standards, BioRad) shown in kilodaltons.
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detected. These persisted throughout the analysis of anti human LVI-I-GST sera
(compare bleed 2 with terminal bleed for Rabbits 7329 and 7330) but were abolished
when the terminal bleeds of rabbits injected with mLvi-l-GST (7327 and 7328) were
used in the detection. In conclusion, it appeared that the specificity of the murine
antisera increased during the immune response. This conclusion is supported by the
increased signal intensity observed between test bleed 1 and 2 (rabbit 7327). A
similar increase was not observed at later time points. This could indicate that the
secondary immune response had peaked or more likely that the increased dilution of
sera used (l :2000 compared to 1:1000) had ablated the effect. Similar conclusions
could not be drawn for the human antisera, as despite an increased signal intensity
between test bleeds 1 and 2 (rabbit 7329) the intensity of additional non-specific
bands remained high throughout the immunisation regime.
5.3.8 Validation of polyclonal antisera
When GST fusion proteins are used as immunogens an antibody response to both
components is expected. To ensure that LVI-l reactive species were present within
the generated polyclonal antisera, GST reactive antibodies were immunoabsorbed
against GST protein immobilised onto glutathione sepharose beads. The non reactive
supernatant was screened by western blotting against GST protein. As shown in
Figure 5-10 the reacti vity of both sera ag,ainst GST was severel y compromised by pre-
absorption to GST. The effect was more dramatic using the anti human LVI-l sera
and was accentuated with increasing dilution. GST reactivity was never completely
abolished with the anti-murine LVI-I antisera indicating a higher titre compared to
the human equivalent. Because we were unable to remove all GST reactive moieties
from the anti mLvi-l-GST serum (Figure 5-10) a second round of immunoabsorption
was performed using the respective LVI-I-GST fusion protein as the immobilised
substrate. The final flow through was compared with the original and GST absorbed
fractions for their reactivity against LVI-l using whole cell Iysates prepared from
Jurkat (human) and H/3T3 (murine) cells. These cell lines were chosen because they
had been shown to express the LV/-J transcript in northern analysis of total RNA
(Figure 4-5). The predicted molecular weights of murine and human LVI-l proteins
were estimated at 57.96 kDa and 69.75 kDa, respectively (http://www.expasv.ch).As
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Pre purified Purified PurifiedPrepurified
Anti-mLvi-I-GST serum Anti-hLVI-I-GST serum
Neat
I: 10
I: 100
I: 1000
Figure 5-10. Absorption of GST reactivity from antisera to LVI-! fusion protein.
1 and 0.1 ug of GST protein samples were separated by 10% SDS-PAGE, and
immobilized onto a nitrocellulose membranes. The membranes were incubated with
dilutions (neat, 1:10, 1:100 and 1:1000) of rabbit sera as shown. Prepurified and
purified denote antiserum before and after absorption with GST. The blot exposure
time was 15 seconds.
shown in Figure 5-11a a smaller protein of approximately 59.3 kDa was detected in
Jurkat cells using the neat anti-hLVI-I-GST serum:' The immunoreactive band would
correspond to the human protein if translated from the conserved ATG in exon 2
(Section 3.3) but disappointingly the reactivity was virtually completely abolished
after immuno-absorption of anti hLVI-l to GST. These results suggest that reactivity
of the hLVI-l antisera for the hLVI-I-GST fusion protein was largely if not entirely
directed to GST moieties and that the band in Jurkat cells was essentially GST
reactive. In conclusion, the anti-hLVI-l antiserum did not appear to be specific for
the native human LVI-l protein.
A protein of the predicted molecular weight (57.96 kDa) was detected in W3T3 cells
using the non-absorbed anti-mLvi-l-GST serum (Figure 5-1 ]b). The intensity of the
immunoreactive band was preserved after absorption to GST but completely ablated
after removal of anti-mLvi-l antibodies by immunoabsorption to the mLvi-l-GST
fusion protein. This result coupled with the lack of reactivity displayed by the pre-
immune serum strongly supports the specificity of the anti ml.vi-I -GST serum for
endogenous murine Lvi-l protein and validates its use in subsequent expression
analyses.
5.3.9 Endogenous expression of murine Lvi-I
The expression of Lvi-l protein was the~ examined using anti-ml.vi-I -GST serum on
a panel of murine cell lines previously shown to express the Lvi-I transcript (Figure 4-
5b). As shown in Figure 5-12 a protein of the predicted molecular weight (57.96
kDa) was detected in each lysate including that of W3T3 cells that had been used in
the validation exercise. A strict correlation was not observed between the levels of
Lvi-l protein and mRNA (compare BW5147 with 3T3 and W3T3) suggesting....
additional levels of post transcriptional control. The cross reactivity of anti-ml.vi-I
was then tested against two human cell lines (WI-38 and Jurkat cells); however, no
protein of the expected molecular weight (69.75 kDa) was detected (data not shown).
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Figure 5-12. Western blot analysis of Lvi-I expression in various murine cell
lines. protein extracts of p/m 16i, p/m 32i, p/rn 47i, BW5147, 3T3, and Hl3T3 cells
were resolved on 10% SDS-PAGE, transferred to nitrocellulose membrane, incubated
with anti-mLvi-1-GST serum from terminal bleed (rabbit 7328) at 1:2000 dilution for
4 hours at room temperature, and processed for immunodetection. The band
corresponding to murine Lvi-l protein is indicated by a red arrow. The blot was
reprobed using an antibody specific for ~-actin to confirm the loading levels. The
blot exposure time for the murine Lvi-l and actin expression was 1 minute and 5
seconds, respectively. M is the protein molecular weight markers (Precision Plus
Protein Standards, BioRad) shown in kilodaltons.
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5.4 Discussion
The generation and subsequent validation of polyclonal antibodies for the
characterisation of the LVI-l gene products revealed that only the anti-ml.vi-I serum
displayed strong specificity for the cognate protein. One explanation for this could be
the absence of the 9 carboxyl-terminal amino acids in the selected human fragment.
The murine fragment included the extreme carboxyl terminus of the protein and
looked more promising both in terms of titre and the specificity generated
(presumably due to its greater antigenicity, as predicted). An alternative explanation
could be the absolute quantities of LVI-I-GST fusion proteins used for the
immunisation. The poor solubility of both fusion proteins required further
solubilisation by sarkosyl and an alternative purification method by electroelution that
inevitably decreased the overall yield of protein. As a result, the injected amounts
used in the immunisation were at the lower end of the optimal range.
Although the validation exercise suggests that the anti-mLvi-l-GST serum is specific,
failure to remove all the GST reactive moieties in the first round of
immunoabsorption means that the possibility cannot be excluded that the detected
band in Hl3T3 cells was GST reactive and that the only difference between the human
and murine antisera was their respective titre. To resolve this issue multiple rounds of
immunoabsorption against GST protein would be necessary for a complete removal of
GST reactive species before the final immunoabsorption against the mLvi-l-GST
fusion protein. If successful the cross species reactivity of anti-mLvi-l-GST serum in
hLVI-I-GST fusion protein could be tested. In addition, validation of the specificity
of the antisera for the human and murine LVI-l proteins could then be confirmed by
testing each serum against in vitro translated versions of both LVI-J proteins using a
basic in vitro transcription kit. Although this approach could provide solid evidence
of LVI-l reactive moieties if reactivity is obtained and would help to resolve the cross
reactivity of both antisera, it would not exclude the possibility of false negative results
as protein folding and modifications of the in vitro translated proteins may not
represent the in vivo situation.
In conclusion, definitive confirmation of LVI-l antiserum specificity would then assit
in characterisation of the native proteins. Determination of the sizes of the products
by SDS-PAGE would also help in resolving uncertainties over the transcripts
structures and coding potential (Chapter III and IV). Additionally, MALDI-TOF
could be used to confirm the identity of LVI-l reactive proteins using
immunoprecipitation to isolate LVI-l reactive species from native cell extracts.
Chapter VI
Clues to LVI-l protein function
6.1 Introduction
Clues to mammalian gene function can often be found by comparison with
homologous genes in model eukaryotes such as Drosophila melanogaster,
Caenorhabditis elegans, and Saccharomyces cerevisiae. Homologous genes in
different species that have evolved from a common ancestor are called orthologues
and these are generally expected to share the same function (reviewed in (280». In
addition, clues to the LVI-1 protein function could also be provided by comparison
with homologues in the mammalian genome, the most closely related of which is
DDB2, the small subunit of the DNA damage binding complex which is required for
repair of UV -induced DNA damage and is defective in Xeroderma pigmentosum
patient. of complementation group E (XP-E) (58). However, identification of
orthologues of LVI-l is complicated by the fact that many functionally diverse
proteins contain the WD repeat domain (219). It is therefore difficult to determine by
sequence comparison alone which of the homologous genes in other species is a true
orthologue. Nevertheless, computer-aided analysis strongly suggested that the yeast
protein, YDL 156W is an orthologue of LVI-I. It was therefore decided to test
whether LVI-I shares functional properties with this yeast protein as well as with its
closest mammalian homologue, DDB2. Moreover, human DDB2 mRNA is induced
in a p53 dependent manner in response to DNA damage. The role of murine DDB2 is
less well characterised. It is poorly expressed in the skin and lacks the functional p53
binding site found in the human gene (226). It has been suggested that this reflects
species-specific differences in capacity for DNA repair in response to UV damage and
that rodents may have a reduced requirement for DDB2 because they are nocturnal
animals with skin protected by fur (222). It was therefore interesting to assess the
effects of UV irradiation on expression of the human and murine LV/- J genes.
6.2 Material and methods
6.2.1 Phylogenetic analysis of LVI-l amino acid sequences
LVI-l amino acid sequences were obtained from the public domain databases:
Ensembl database (http://www.ensembl.org) and UCSC human gene sorter at
h~p:llwww.genome.ucsc.edu for Homo sapiens, Pan troglodytes, Macaca mulatta,
Bos taurus, Canis familiaris, Monodelphis domestica, Rattus novergicus, Mus
musculus, Fugu rubripes, Danio rerio, Xenopus tropicalis, Saccharomyces cerevisae,
Ciona intestinalis, Drosophila melanogaster, Caenorhabditis elegans, Oryza sativa,
and Arabidopsis thaliana. Phylogenetic analysis of these peptide data was conducted
using MEGA 3.1 (Molecular Evolutionary Genetics Analysis version 3.1) software
(http://www.meagsoftware.net) in which ClustalW was used for alignment of the
amino acids sequences and the phylogenetic tree was generated using the NJ
(Neighbor-Joining) method with 500 bootstrapped replications and treating gaps as
missing data by complete deletion.
6.2.2 Cellular exposure to UV irradiation
UV treatment of adherent cells
2x106 adherent cells (Section 2.2.1) were plated onto a 100 mm diameter dish with 10
ml of medium and were grown for 24 hours before treatment. Cells were rinsed with
10 ml of warmed PBS and were then exposed to 10 J/m2 UVC irradiation
(Spectrolinker XL-1500 UV Crosslinker, Spectronics Corporation). Following
treatment, 10 ml of fresh medium was added to the plates and cells were harvested at
different time points post irradiation.
UV treatment of suspension cells
6x106 suspension cells (Section 2.2.1) were washed once with 1 ml of warmed PBS,
pelleted by centrifugation at 1000 rpm for 5 minutes, prior to resuspending in 1 ml of
warmed PBS and dispensing into the centre of a 100 mm diameter dish. Cells were
exposed to 10 J/m2 UVC irradiation (Spectrolinker XL-1500 UV Crosslinker,
Spectronics Corporation), returned to T25 cm2 culture flasks, and then harvested at
different time points post irradiation.
6.2.3 Determination of the LVI·] transcripts levels after UV irradiation by RT.
PCR
Each of the total cellular RNA samples were prepared from p/m16i and Jurkat cells
grown in tissue culture and UV treated as described in Section 6.2.2. Wt MEFs
(mouse embryonic fibroblasts) cells, and RNA from p53-null MEFs cells were
generous gifts from Dr Linda Hanlon (Faculty of Veterinary Medicine, University of
Glasgow). The RNA was isolated and quantified as detailed in Section 2.2.3.
Aliquots of 104 ng to I ug of total RNA were reverse transcribed as detailed in
Section 2.2.4 and analysis of cDNAs were carried out using 2.5 III of reverse
transcription reaction with 50 pmol of the specific primers (see Table 6-1 and Section
2.2.4 for primer sequence, primer combination, and PCR conditions). 5 III or 10 III
aliquots of each reaction were separated on 4% polyacrylamide gels, stained with
ethidium bromide and visualized by UV illumination.
6.2.4 Cell cycle analysis by flow cytometry
5x lOs Hl3T3 cells (Section 2.2.1) were plated onto a 100 mm diameter dish with 10
ml of medium and were grown for 18 hours before treatment. Cells were rinsed with
10 ml of warmed PBS and were exposed to (5, 10, 50, and 100) 11m2 UVC irradiation
(Spectrolinker XL-I500 UV Crosslinker, Spectronics Corporation). Following
treatment 10 ml of fresh medium was added to the plates and cells were harvested at
different time points post irradiation for flow cytometry analysis. Briefly, cells were
harvested by trypsinisation as described in Section 2.2.1 and then added to the
medium. The cells were then removed by centrifugation at 1000 rpm for 10 minutes,
resuspended in cold sample buffer (lg/L glucose in PBS), and repelleted (1000 rpm
for 10 minutesj, The wash in cold sample buffer was repeated twice more for a total
of three washes. The cell pellet was vigorously vortexed in residual fluid (-0.2 ml)
for 10 seconds before adding 1 ml of ice-cold 70% ethanol in a drop-wise manner.
Cells were fixed for a minimum of 18 hours at 4 QC. For staining, cells were
centrifuged at 3000 rpm for 5 minutes at 4 QC, and cell pellet gentle vortexed in
residual ethanol (-0.2 ml). 1 ml PI staining solution (Section 2.1.11) was added to
each sample, and the mixture transferred to FACS tubes. Samples were incubated at
Table 6-1. Primers used for analysis of LVI-l expression in response to UV
irradiation.
Table 6-1a. Primer sequences (by hand).
Number of Primer Strand Sequence (5'-+3')
~ primer
mFLJexonlaF Forward get taa agg get agg gtg ag
2 mFLJexon lcF Forward atg tct ggg tee aag get g
3 mFLJexon2R Reverse cag gee tgg tgc act gtc
4 mHPRT5 Forward ggg ggc tat aag ttc ttt gc
5 mHPRT3 Reverse tee aac act tcg aga ggt cc
6 huHPRT5 Forward ggg ggc tat aaa ttc ttt gc
7 huHPRT3 Reverse tee aac act tcg aga ggt ec
8 humanFLJexon 1eF Forward gaa gee gaa aga tgt cca g
9 HumanFLJexon2RSP2 Reverse gat tea tcg cat ctg ccg
Table 6-1b. Primer combinations, peR conditions, and applications.
Primer
combination
Product size Annealing
temperature (QC)
Application
1 + 3
2+3
4+5
6+7
8+9
513 bp
451 bp
294 bp
313 bp
411 bp
55
58.8
55
55
55
Analysis of Pl promoter
Analysis of P2 promoter
HPRT control
HPRT control
Analysis of P2 promoter
room temperature on a rocking platform for at least 30 minutes and analysed on a
Beckman-Coulter Epics XL within 6 hours. Analysis was performed using Exp032
software package.
6.2.5 Immunofluorescent labelling and confocal microscopy
Glass chamber slides (Nalge Nunc International) and microscope slides (BDH, VWR
International) were routinely pretreated with poly-L-Iysine (Sigma) at 37 QCovernight
according to the manufacture's instructions. Hl3T3 cell line was plated on two-well
glass chamber slides at 1 x 104 cells/well and also 2 x 104 cells/well two days before
fixation. In the case of suspension cells (Jurkat and p/m 16i cell lines), the
microscope slides were mounted with the filter card (Shandon) and the cuvette
(sample chamber) in the metal holder and 5 x 104 cells in 250 ~l were loaded in the
cuvette, cytocentrifuged onto microscope slides at 500 rpm for 5 minutes, air dried,
and then the area around the cytocentrifuged cells marked using a wax pen (DAKO
Pen S2002) before fixation. Hl3T3 cells were washed once in ice-cold PBS and then
fixed in 3.3% paraformaldehyde for 15 minutes at room temperature. Jurkat and p/m
16i cells were fixed in 3.3% paraformaldehyde for 15 minutes at room temperature.
All further steps were performed on adherent and suspension cells in parallel. The
cells were washed three times in ice-cold PBS, immersed in 20 mM glycine (Section
2.1.11) for 5 minutes at room temperature to remove free aldehyde groups to give a
clear background, and then permeabiIised with 0.1 % Triton X-I00IPBS (Section
2.1.11) three times for 10 minutes at room temperature. The slides were blocked in
0.1 % Triton X-I 00/1 O%FBS/PBS (Section 2.1.11) for 1 hour at room temperature and
then incubate overnight at 4 QC in a humid environment with the primary antibody
(rabbit polycloaal antibody against mLvi-l-GST protein from terminal bleed of rabbit
n.7328) diluted at 1:100 in block buffer (Section 2.1.11). The cells were then washed
twice in 0.1% Triton X-l00IPBS for 5 minutes and once in block buffer for 5 minutes
at room temperature before incubation with 1:100 fluorescein isothiocyanate (FITC)-
conjugated goat anti-rabbit (Jackson Immunoresearch Laboratories) in block buffer
for 45 minutes at room temperature in a humid environment. After three washes in
0.1 % Triton X-lOOIPBS for 5 minutes and one wash in ice-cold PBS at room
temperature; the slides were mounted using VECT ASHIELD® Hard + Set™
mounting medium with DAPI (4' ,6-diamidino-2-phenylindole) from Vector
Laboratories and fluorescent images captured using a confocal microscope (Leica
DMIRE 2).
6.2.6 Combined immunoprecipitation and western blot analysis
MSH6 and the LVI-l protein expression levels of Hl3T3 and SW480 cells (Section
2.1.1) were examined by immunoprecipitation and western blot analysis. Typically,
cells grown in tissue culture were washed twice with ice-cold PBS, drained
thoroughly, lysed in 100 III working IP lysis buffer (Section 2.1.11) per 106 cells and
rotated for 10 minutes at 4 QC. The crude extract was cleared in a bench top
centrifuge at 14000 rpm for 30 minutes at 4 QC and the supernatant transferred to a
fresh pre-cooled Eppendorf tube. Extracts were quantitated (Section 2.2.7) and 1 mg
of each extract in a total volume of 500 J..lIin IP lysis buffer was pre-cleared by
incubation (1 hour at 4 QCwith rocking) with 50 J..lIof 50% protein G sepharose 4B
slurry. The preparation of the 50% protein G sepharose 4B slurry was as follows:
Protein G sepharose 4B Fast Flow (Sigma) beads were washed with ice-cold PBS and
pelleted by centrifugation at 1000 rpm for I minute, for a total of three washes. The
pellet was resuspended in equal volume of PBS, washed with IP lysis buffer and
pelleted (14000 rpm for 1 minute) for a total of three washes. The pellet was then
resuspended in equal volume of IP lysis buffer.
The pre-cleared lysate was separated from the beads by centrifugation at 14000 rpm
for 1 minute and then rotated overnight at 4 QCwith 1 J..lgof anti-MSH6 monoclonal
antibody (BD Biosciences, 610918). The beads were kept at - 70 QC for further
examination by SDS-PAGE. The immune complexes were collected by incubation (1
hour at 4 QCwith rocking) with 50 J..llof 50% protein G sepharose 4B slurry, pelleted...
(14000 rpm for 1 minute), washed five times in ice-cold IP lysis buffer, repelleted,
resuspended in equal volume of 2x SDS Sample Loading Buffer (Section 2.1.11), and
boiled for 10 minutes. The immunoprecipitates were loaded on 7.5% and 10% SDS-
PAGE gels (Section 2.2.7). After electrophoresis, the proteins were transferred onto
nitrocellulose membranes (Section 2.2.7) for western blot analysis (Section 2.2.7).
The membranes were blotted with rabbit anti-MSH2 polyclonal antibody
(Calbiochem, PC57) at dilution of 1:100 for 4 hours at room temperature, and with
rabbit serum anti mLvi-l-GST at dilution 1:2000 for 4 hours at room temperature. As
a secondary antibody, HRP conjugated swine anti-rabbit IgG polyclonal antibody
(DakoCytomation) at 1:3000 dilution, for 1 hour at room temperature.
6.3 Homologues of LVI-1
T,ge LVI-l gene is a unique gene that is highly conserved in mammalian species, with
closely related genes detected in human, chimpanzee, murine, rat, canine and bovine
genomes. Other gene products related to LVI-1 were identified by BLAST searching
of the Swissprot protein database (http://www.expasy.ch/tools/blast/).This analysis
shows that many proteins from a wide range of eukaryotes show homology to LVI-I,
but most of the relatedness is seen in the C-terminal WD repeat region (Figure 6-1)
and multiple gene products from the same species appear in the list. This analysis
illustrates the problems in identifying true orthologues of LVI-l in more distantly
related organisms.
An attempt to overcome this problem was made with the use of the Inparanoid
programme (http://www.inparanoid.cgb.ki.se). which makes pairwise comparisons
between whole genomes to assign the most likely orthologues. Other sequences are
added to this group if they are closely related to one of the main orthologues and are
called In-Paralogs. A confidence value is provided for each in-paralog that shows
how closely related it is to the main orthologue. It is interesting that this programme
fails to assign orthologues in Drosophila or Caenorhabditis, but confidently predicts
the yeast gene YDL156W as an orthologue. Selected output from this analysis is
shown in Table 6-2.
To show the evolutionary relationship in graphic form, a tree was generated using the
orthologues detected by the Inparanoid and other gene products from the list provided
by the Ensembl database, which automatically assigns putative orthologues by
reciprocal BLAST analysis. The human DDB2 protein was added for comparison.
The phyloge~etic tree shown in Figure 6-2 was generated with MEGA 3.1 software
using the Neighbour Joining method. This tree shows the relatively close homology
between the mammalian proteins and the increasingly distant homology to lower
species. However, the fact that DDB2 is more distantly related than the yeast
YDL156W protein is consistent with the assignment of the latter as an orthologue.
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Figure 6-1. Output from BLAST search of UniProt protein database (Swiss-Prot
+ TrEMBL) using the full length predicted human LVI-1 protein (626 aa), Only
the first 40 hits are depicted. UniProt codes are shown in the left column. The
coloured bars illustrated the homologous regions, coloured according to the degree of
identity as shown in the key at the bottom left corner of the figure. Grey denotes
regions of non-homology in the target sequences.
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Table 6·2. Orthologues and in-paralogs of LVI·1 detected by the Inparanoid
programme.
Species Score Gene/protein * name
Canis familiaris 1.0000 ENSCAFGOOOOOO13431
Danio rerio 1.0000 ENSDARGOOOOOO12034
Fugu rubripes 1.0000 SINFRUGOOOOO129153
Mus musculus 1.0000 ENSMUSGOOOO0027242
Pan troglodytes 1.0000 ENSPTRGOOOOOO07007
Rattus norvegicus 1.0000 ENSRNOGOOOO0022491
Mus Musculus 1.0000 5830411 K 18Rik
Oryza sativa 1.0000 Q6YSI0
Oryza sativa 0.5550 Q6YZ25
Rattus norvegicus 1.0000 RGD1309616
Saccharomyces cerevisae 1.0000 YDL156W
Arabidopsis thaliana 1.0000 NP_178186*
Note: In Mus musculus, ENSMUSGOOOO0027242 and 5830411KI8Rik (RIKEN
cDNA 5830411K18 gene) represent the same gene from the ENSEMBL and NCBI
databases respectively. In Rattus norvegicus, ENSRNOG00000022491 and
RGD 1309616 represent the same gene from the ENSEMBL and RGD databases
respectively. In Oryza sativa, Q6YS to and Q6YZ25 represent independent genes
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Figure 6-2. Phylogenetic tree of homologues of LVI-I. A Neighbor-Joining tree
was constructed using MEGA 3.1 software. Numbers (neighbor-joining bootstrap
values) indicate the percentage that each branch was retained in 500 bootstrap
samplings of the data. The asterisc (*) indicates the LVI-l orthologues identified by
the Inparanoid programme (http://www.inparanoid.cgb.kLse).
6.4 Functional analysis
6.4.1 Responses of Lvi-I to UV irradiation
The close structural relationship of LVI-l to DDB2 indicates a possible role for L VI-J
gene in DNA repair pathways, particularly in response to UV damage. It was
therefore decided to test the effects of UV irradiation on the expression of LVI-l
mRNA and proteins. In human cells induction of DDB2 in response to UV damage is
dependent on p53 (236) and the possibility of p53-dependent effects on Lvi-l was
also of interest. Also, the dose of irradiation is critical, as low doses generally induce
cell cycle arrest and DNA repair, while high doses lead to apoptosis (281). Many
established cell lines have mutations in p53 or a defective response, so it was decided
to test primary fibroblasts, although these cells generally have lower expression of
Lvi-l than haematopoietic cells. Protein analysis was focused on the murine system,
as I could not be confident that the antiserum to the human LVI-l protein was
specific. There were also practical problems in irradiating non-adherent cells that had
to be irradiated in low volumes of buffer before replating.
In preliminary experiments, doses of UV irradiation were tested on Hl3T3 murine
fibroblasts (5, 10, 50 and 100 JI m2). The effects on cell viability were measured by
propidiurn iodide staining and flow cytometry at various time intervals (0-48h) (not
shown). On the basis of these results, a dose of 10 J/m2 was chosen for further studies
as a low dose that did not induce significant levels of apoptosis .
.
Effects on Lvi-} RNA
Human and murine cell lines that had previously been shown to express the LVI-J
gene (Figure 4-5) were used in this analysis. The human T-cell line Jurkat was
exposed to 10 J of"DV irradiation/m' and the cells analysed at different times
afterward (Oh, 2h, 4h, 8h, and 24h) by RT-PCR (Figure 6-3). Primer set lcF-2R
spanning P2 promoter region and exon 2 (Figure 6-3a) was chosen because
transcription of the human LVI- J gene is mainly initiated from the P2 promoter
(Section 3.3.1). The human housekeeping "gene HPRT was used as control for
relative quantification of each mRNA transcripts. During the time course after UV
exposure, the levels of the human LVI- J transcripts remained unchanged, indicating
that the human LVI-J is not induced in response to DNA damage by UV irradiation
(Figure 6-3b).
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Figure 6-3. Determination of human LVI-] transcript levels after UV irradiation.
a. Structure of the 5' region of the human LV/-J gene. The coding exons are
represented by black boxes. The yellow boxes represent the exons amplified by RT-
peR using the primer set lcF-2R (see sequences in Table 6-1 a). b. RT -Pf.R analysis
of the human LV/-J expression after UV irradiation. Jurkat cells were treated with 10
1of UV irradiation/ m2 and total RNA harvested after different time intervals. cDNA
was prepared frern RNA samples from Jurkat cells non-UV treated (Oh, lane 2, and
24h, lane 9), and UV treated (Oh, lane 3; 2h, lane 4; 4h, lane 5; 8h, lane 6; 12h, lane7;
and 24h, lane 8), as described in Section 2.2.4. peR was carried out using the primer
set lcF-2R (411 bp) and the control housekeeping gene (HPRT, 313 bp) (see
sequences inTable 6-1a). Lane 1 is a negative control (Pf'R primers only). RT-peR
products are shown following separation by 4% polyacrylamide gels. Mland M2 are
the markers <DX174RF DNA/Rae III fragments and Low DNA Mass Ladder,
respectively.
Similarly, analysis of a murine T-cell lymphoma line (p/mI6i) for expression of the
murine Lvi- J transcripts after UV irradiation was carried out by RT -peR on total
RNA from UV -exposed cells as described above. Primer set 1aF-2R spanning PI
promoter region and exon 2 (Figure 6-4a) was chosen to detect transcription of the
murine Lvi-I gene, which is initiated predominantly from the PI promoter (Section
3.3.1). The murine housekeeping gene HPRT was used as control for relative
quantification of each mRNA transcript. As shown in Figure 6-4b, no increase in the
expression levels of murine Lvi- J transcripts was evident in the p/m 16i cell line after
UV irradiation.
Effects on Lvi-I protein levels
As previous studies showed that the Lvi-I mRNA levels did not necessarily correlate
with protein levels (Section 4.3.2 and 5.3.9) it was conceivable that post-
transcriptional regulation would be affected by UV-induced damage. The p/m 16i cell
line was therefore examined for Lvi-I protein expression after UV irradiation by
western blot analysis with the 7328 rabbit serum anti-mLvi-l-GST. The cells were
exposed to a similar low dose of UV irradiation (8 J of UV irradiarion/m') and lysed
at the indicated times thereafter. Apart from a modest increase relative to the actin
control observed at 24 hours, Lvi-I protein levels were not significantly affected
during the time course after UV exposure (Figure 6-5), however, a 48 hour time point
might have shown changes similar to those observed in Hl3T3 cells as described
below. A 'similar result was observed in another lymphoid cell line (p/rn 47i) treated
with the same dose of UV irradiation (data not shown).
A concern with regard to these experiments was that the murine lymphoma cell lines
p/ml6i and p/m47i lack functional p53 (246). In view of the p53-dependence of the
human DDB2 gene, it was considered important to examine the expression of Lvi-I in
UV irradiated p53 wt cells. For this purpose Hl3T3 murine fibroblasts were treated
with 10 J of UV irradiation/m', lysed, and then analysed at different times afterward
(Oh, 8h, 12h, 24h, and 48h) by western blotting using the 7328 rabbit serum anti-
mLvi-I-GST. Interestingly, consistent induction of LVI-I protein was observed in
UV irradiated Hl3T3 cells (Figure 6-6), reaching maximum levels by 48 hours post-
UV. To examine whether these results were due to increased transcript levels, RNA
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Figure 6-4. Determination of murine Lvi-l transcript levels after UV irradiation.
a. Structure of the 5' region of the murine Lvi-I gene. The coding exons are
represented by black boxes. The yellow boxes represent the exons amplified in RT-
peR using the primer set 1aF-2R (see sequences in Table 6-1a). b. RT-peR analysis
of the murine Lvi-I expression after UV irradiation. P/m 16i cells were treated with
10 J of UV irradiation/ m2 and total RNA harvested after different time intervals.
cDNA was prepared from RNA samples from p/rn 16i cells non-UV treated (Oh, lane
2, and 24h, lane 9), and UV treated (Oh, lane 3; 2h, lane 4; 4h, lane 5; 8h, lane 6; 12h,
lane7; and 24h, lane 8), as described in Section 2.2.4. peR was carried out using the
primer set laF-2R (513 bp) and the control housekeeping gene (HPRT, 294 bp) (see
sequences in Table 6-1a). Lane 1 is a negative control (Pt.R primers only). RT-peR
products are shown following separation by 4% polyacrylamide gels. Ml and M2 are
the markers <DX174RF DNA/Rae III fragments and Low DNA Mass Ladder,
respecti vel y.
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Figure 6-5. Lvi-I expression in plm 16i cell line after UV irradiation. Plm 16i
cells were irradiated with UV (811m2). Lvi-l protein expression levels were
examined at various times after UV treatment as shown. Western blot was prepared
from whole cell lysates (70 ug) and probed with anti-Lvi-l-GST serum (rabbit 7328)
at 1:2000 dilution. The band corresponding to the murine Lvi-l protein is highlighted
with a red arrow. The blot was reprobed with an antiserum specific for B-actin as a
loading control. The blot exposure time for Lvi-l and actin expression was 30
seconds and 15 seconds, respectively. M is the protein molecular weight markers
(Precision Plus Protein Standards, BioRad) shown in kilodaltons.
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Figure 6-6. Lvi-I expression in Hl3T3 cell line after UV irradiation. H/3T3 cells
were irradiated with UV (l0 J/m2). Lvi-l protein expression levels were examined at
various times after UV treatment as shown. Western blot was prepared from whole
cell lysates (100 ug) and probed with anti-Lvi-l-GST serum (rabbit 7328) at 1:2000
dilution. The band corresponding to the murine Lvi-l protein is highlighted with a
red arrow. The blot was reprobed with an antiserum specific for ~-actin as a loading
control. The blot exposure time for Lvi-l and actin expression was 30 seconds and 1
minute, respectively. M is the protein molecular weight markers (Precision Plus
Protein Standards, BioRad) shown in kllodaltons.
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was extracted from H/3T3 cells exposed to 10 J of UV irradiation/m' and analysed by
northern blot using the a_32P-Iabeled murine lsvi-I exon 13 DNA probe (Section
3.3.1). As shown in Figure 6-7, the murine Lvi-I mRNA levels were initially low, but
then increased by 12 hours post-UV. Taken together, these results indicated that the
transcriptional and translation responses of Lvi-I to DNA damage by UV irradiation
might be dependent on the presence of p53, because its induction was only observed
in the cell line that express p53 (Hl3T3 cell line). In addition, p53 as expected was
stabilised at 12 hours after UV irradiation (Figure 6-8) and subsequently declined
with time while the Lvi-I protein continued to accumulate (Figure 6-6). This finding
suggests that Lvi-I accumulation is a relatively late event after UV irradiation, like its
homologue DDB2, which is upregulated as a late event 48 h after UV irradiation
(282, 283). However, basal levels of murine Lvi-I protein appeared to be
independent of p53 status in a panel of cell lines (Figure 6-9). In addition, analysis of
Lvi-I transcription using primers derived from the PI and P2 promoter regions
revealed its presence in primary murine fibroblasts (MEFs) with wt or inactive p53,
showing again that the basal levels of Lvi-I transcripts from the PI or from P2
promoter regions are independent of p53 status (Figure 6-10).
Effects on LVI·1 protein localisation
In addition to effects on protein levels, the subcellular location of DDB is regulated in
response to DNA damage. Thus, while in undamaged wild type cells DDB2 localizes
to the nucleus and DDB 1 is found in both cytoplasm and the nucleus (222) in UV
damaged cells DDB2 plays a role in transporting DDB 1 to the nucleus. To examine
whether Lvi-I might behave in a similar fashion, expression of the human and murine
LVI-l gene products was analysed in intact cells by confocal immunofluorescence
microscopy. An adherent cell line (Hl3T3) and the suspension cell lines (p/m I6i and
Jurkat) were exposed to 10 J of UV irradiation/m", fixed with paraformaldehyde 48
hours and 24 hours after UV treatment, respectively; and then probed with the
prepurified rabbit serum anti-mLvi-I protein followed by incubation with a FITC-
labelled secondary antibody. A similar cytoplasmic staining pattern was detected for
all the cell lines before and after UV treatment (Figure 6-11), indicating that Lvi-I
protein is predominantly located in the cytoplasm and that UV treatment did not
M
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Figure 6-7. Detection of Lvi-I transcript after UV irradiation of W3T3 cells.
H/3T3 cells were irradiated with UV (10 J/m2) and Lvi-I transcript levels were
examined at various times after UV treatment as shown. A northern blot was
prepared from total RNA (20 ug samples), probed with a-32P-labeled murine Lvi-I
exon 13 DNA probe (Section 4.3.1) and the products detected by autoradiography.
The band corresponding to the murine Lvi-I transcript (4.5 kb) is indicated with a
black arrow. The blot was reprobed with GAPDH (1.4 kb) probe to control for
loading of mRNA. Unirrad, unirradiated. The relative migration of RNA size
markers (0.24-9.5 kb RNA ladder, Invitrogen Life Technologies) is indicated. The
blot exposure time for murine Lvi-I transcripts and control (GAPDH) was 7 days and
9 hours, respectively.
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Figure 6-8. PS3 protein expression in Hl3T3 cell line after UV irradiation. H/3T3
cells were irradiated with UV (10 J/m2). p53 protein expression levels were
examined at various times after UV treatment as shown. Western blot was prepared
from whole celllysates (lOO ug) and probed with mouse anti-p53 (lC12) monoclonal
antibody, at 1:2000 dilution. The band corresponding to the murine p53 protein is
highlighted with a black arrow. The blot was reprobed with an antiserum specific for
~-actin ~s a loading control. The blot exposure time for p53 and actin expression was
10 seconds and 2 seconds, respectively. M is the protein molecular weight markers
(Precision Plus Protein Standards, BioRad) shown in kilodaltons.
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Figure 6-9. Analysis of p53 expression in various murine cell lines by western
blot. A western blot was prepared from whole celJ lysates (100 Ilg) from the cell
lines as shown and probed with anti-Lvi-l-GST serum (rabbit 7328) at 1:2000
dilutionand with mouse anti-p53 (lC12) monoclonal antibody at 1:2000 dilution.
The band corresponding to murine Lvi-l and p53 proteins are indicated with a black
arrow. The blot was reprobed with an antiserum specific for B-actin as a loading
control. The blot exposure time for Lvi-I, p53 and actin expression was 1 minute, 15
minutes and $> seconds, respectively. M is the protein molecular weight markers
(Precision Plus Protein Standards, BioRad) shown in kilodaltons.
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Figure 6-11. Localisation of LVI-1 protein by immunofluorescence in W3T3, p/m
16i, and Jurkat cell lines. Cells which had been untreated (normal), or treated with
UV (+ UV) a a dose of 10 11m2 were fixed on poly-L-Iysine coated glass slides with
paraformaldehyde after 48 hours post-UV irradiation (H/3T3 cell line) and 24 hours
post-UV irradiation (p/m 16i and Jurkat cell lines) and then stained with anti-rnl.vi-I-
GST serum (rabbit 7328) followed by incubation with FITC-Iabeled secondary
antibody (al , a2, b l , b2, cl, and c2). NPA (no primary antibody) was included as
control, showing no fluorescent patterns when imaged under the same conditions as
experimental samples (a3, b3, and c3). Bars, 20 11m (H/3T3 and Jurkat) and 16 11m
(p/rn 16i).
significantly alter its location. This was confirmed by quantitative analysis of serial
confocal sections using the Image J software package (http://rsb.info.nih.gov/ij/) as
shown in Figure 6-12.
6.4.2 Lvi-I protein interactions
Yeast deficient in YDL156W are viable but have not been characterised in depth with
regard to more subtle phenotypes. At our request a preliminary study was conducted
by Professor Ian Hickson's laboratory (University of Oxford) to test the possibility
that yeast deficient in YDL156W would be more sensitive to DNA damage. This
hypothesis was based on the possibility that the protein may play a role in DNA
damage detection or repair by analogy with the human DDB2 gene product.
However, a series of studies failed to reveal any unusual sensitivity to DNA damage
by various agents including UV light, hydroxyurea, methyl methane sulphonate and
mitomycin C. However, these studies do not exclude the possibility of a role in DNA
repair as not all functions are tested by these agents. Moreover, studies of
YDL 156W -interacting proteins by yeast 2-hybrid and co-precipitation analyses has
revealed an interaction with YDR097C, the yeast orthologue of the mismatch repair
protein MSH6 (MutS homologue 6) (284). It is interesting that Msh6 knockout mice
are viable but are highly predisposed to B- and T-cell lymphomas (285) and have a
specific deficit in repair of somatic hyperrnutation in B-cells (286). It was therefore
decided to test the possibility of a similar interaction between the LV/-J gene product
and MSH6 in a mammalian system.
To address this issue, a combined immunoprecipitation/western blot analysis was
carried out in H/3T3 cells and also in SW480 cells that were used as a positive control
that is known to express MSH2. In case complex formation might be dependent on
induction by DNA damage, Hl3T3 cells were exposed to 10 J of UV irradiation/rn'',
and total cell extract was harvested by 48 hours after treatment. MSH2 in complex
with MSH6 was detected by immunoprecipitation with MSH6-specific antibody
followed by western blotting with the MSH2-specific antibody. This analysis
demonstrated the interaction between MSH6 and MSH2 not only in the positive
control, SW480 cells (Figure 6-13, lane 6) as expected, but also in the Hl3T3 cells.
No significant effect was seen in H/3T3 cells following UV treatment (Figure 6-13,
lanes 4 and 5). A similar blot was then probed with rabbit anti-mLvi-l serum in the
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Figure 6-12. Percentage of cytoplasmic staining of the murine (Hl3T3 and p/m
16i) and human (Jurkat) cell lines before and after DV treatment. Serial confocal
sections of the murine and human cell lines were quantitated using the Image J
software package with multiple colour analysis macro (http://rsb.info.nih.goy/ij/).
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Figure 6-13. Interaction of MSH6 with MSH2 is detected by Co-
immunoprecipitation. 1 mg aliquots of total protein from H/3T3 cells, which had
been untreated (lanes I and 4) or treated with UV dose at 10 11m2 (harvested 48 hours
post-U'V irradiation, lanes 2 and 5), and unirradiated SW480 cells (lanes 3 and 6)
were immunprecipitated with anti-MSH6 antibody (Section 6.2.6). The
immunoprecipitated proteins (lanes 4, 5 and 6) and the protein non-specifically bound
to the protein G sepharose beads (lanes 1, 2, and 3) were resolved by a 7.5% SDS-
PAGE and trensferred to a nitrocellulose membrane. The membrane was then
immunoblotted with anti-MSH2 antibody. The band corresponding to MSH2 protein
(lOO kDa) is highlighted with a black arrow. The blot exposure time was 10 minutes.
M is the protein molecular weight markers (~recision Plus Protein Standards, BioRad)
shown in kilodaltons.
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western blot analysis, but no signal was detected (data not shown). Therefore, no
interaction was detected between LVI-l protein and MSH6 protein in mammalian
cells under the conditions tested. In addition, an attempt at immunoprecipitation with
the rabbit anti-ml.vi-I serum in Hl3T3 cells failed to detect Lvi-I protein (data not
shown).
6.5 Discussion
Evolutionary analysis shows that LVI-l is a unique and highly conserved gene.
However, due to the widespread occurrence of WD repeat in functionally diverse
proteins, it is difficult to identify orthologues in distantly related eukaryotes. The
Inparanoid programme was employed to try to circumvent this problem and this
analysis strongly suggested that yeast YDL156W is a true orthologue. Some
preliminary functional analyses were therefore attempted based on this observation.
Also, despite the large number of WD repeat proteins in the mammalian, the
organisation and sequence of LVI-l is closest to DDB2, a gene whose product is
known to playa role in responses to UV irradiation. It therefore seemed logical to
test the effect of UV irradiation on Lvi-l expression and protein localisation.
With hindsight, the design of the UV irradiation experiments could have been
improved by inclusion of more controls and testing of a wider range of UV doses.
Moreover, better quantitation and sensitivity might have been achieved by real-time
peR, but there was insufficient time available to generate and optimise such assays.
The cell lines available were in many cases tumour cells that have mutations in p53
and other pathways that control responses to irradiation and other stresses, which may
explain the rather heterogeneous results obtained. Also, the human and murine LVI-l
genes are driven by distinct promoters (PI, P2) that may well be regulated differently.
Furthermore, I was unable to analyse effects on human LVI-I protein expression with
confidence due to concerns over the specificity of the antiserum raised to this protein.
Some evidence of UV responses were seen on murine Lvi-l mRNA and protein
levels. Lvi-l mRNA and protein accumulated following low-dose UV irradiation of
H/3T3 fibroblasts. Responses were less pronounced in lymphoid tumour cell lines
that lack functional p53. Additional analysis of Lvi-l transcription in wt MEFs and
p53-null MEFS revealed that the basal levels of Lvi-J transcripts from the PI or from
P2 promoter regions are independent of p53 status. However, the basal Lvi-l protein
levels in the wt MEFs and p53-null MEFs remains to be established.
Experiments on yeast deficient in YDLJ 56W, have so far failed to show any effect on
responses to a number of DNA damaging agents, but these experiments are not
exhaustive or conclusive (Prof. I. Hickson, personal communication). However, the
interaction between this protein and the yeast orthologue of MSH6 is suggestive of a
role in DNA repair. My preliminary analysis showed no evidence of such a complex
in Hl3T3 cells, but studies on cells with more abundant protein expression and under
different conditions would be required before drawing clear conclusions.
Initial studies of Lvi-l protein localisation by confocal microscopy suggested a
predominantly cytoplasmic location. This finding is rather surprising from computer-
based predictions of a nuclear localisation (Chapter III). However, it was noted that
this approach was poor at predicting proteins that shuttle between cellular
compartments. It is also interesting that the yeast YDL156W is detected in both
nuclear and cytoplasmic fractions (287).
Chapter VII
General Discussion
The investigations carried out during this project were principally concerned with the
characterisation of LVI-J gene and its patterns of expression. The LVI-J gene was
discovered as a candidate tumour suppressor gene in a case of feline lymphoma,
where it appeared to be inactivated by a combination of retroviral insertion and
transcriptional down-regulation of the unoccupied allele (58). It was decided at the
outset of this project that attempts to define the function of the LV/- J gene would be
focused initially on murine and human genes. This decision was taken due to the
strong conservation of the gene in mammals and the superior genomic and proteomic
resources available for human and laboratory mouse systems.
Analysis of the pattern of transcription of the LVI-J in murine and human provided
clear evidence of differential expression between species. The difference in major
transcript size between human and murine (2.8 kb vs 4.5 kb) was found to be due
mainly to the differing length of the 3'UTR. Non-coding regions often contain
important signals that determine transcript stability or affect nuclear export and
subsequent translation (288), suggesting that this difference might be significant.
However, an even more remarkable difference was observed at the 5' end of the
mammalian LVI-J genes. In the murine, the gene appears to be driven mainly by a
bidirectional promoter (PI), which is shared with the adjacent MJapJ gene. However,
the human gene is expressed from a second promoter (P2) located further downstream
at a prominent CpO island, which is only partially conserved in the murine. While the
human gene appears to be expressed exclusively from the P2 promoter, the murine
gene appears to be capable of utilising P2, particularly in tissues where expression is
relatively low. These findings were not only based on the evidence of the available
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human and murine cDNAs and ESTs, but also from promoter prediction analyses,
which scored the forward PI promoter only for the murine gene, whereas the P2
promoter adjacent to exon le is more strongly predicted in the human genome. It is
possible that the use of the distal Pl promoter by the murine gene suppresses
transcription here by the phenomenon of promoter interference (270).
These results suggest that there may be significant differences in regulation of the
human and murine LV/- J genes at the transcriptional level, although northern blot
analyses revealed that both human and murine LVJ- J expression are highest in
lymphoid-derived tissues, especially thymus. Preliminary experiments on UV
irradiation of cells provided some evidence of differential regulation, but as the results
of these studies were inconsistent and in some cases difficult to interpret, it would be
useful to extend these analyses using a wider range of UV dose levels. Also, the
potential role of p53 in coordinating these responses is worthy of further
investigation. The possibility that the gene responds to other non-genotoxic stress
signals is also worth considering, particularly in view of the conserved heat shock
transcription factor binding site in the PI promoter region.
The observed differences at the 5' ends of the human and mouse genes also have
major implications for the proteins encoded by the respective genes. The major
human mRNA has the capacity to encode a larger 70 kDa protein (MSRSG), while
the most common murine mRNA species encodes a 58 kDa protein (MKALS). These
predictions are not clear-cut, however, as the use of alternative P2 promoter of the
murine gene would lead to an mRNA with the capacity to encode the larger 69 kDa
protein (MSGSK), while the human mRNA could conceivably be translated from an
internal AUG corresponding to the murine initiator, leading to expression of a 59 kDa
protein (MKNTS). It is interesting that computer-based predictions based on a
consensus of initiation sites favoured the second AUG in the human mRNA
suggesting an intermediate product of 68 kDa (MKVNE). These results highlight the
uncertainty of computer-based predictions and the importance of testing these by
direct experimental analysis.
To investigate the expression of the LVI-J genes at the protein level, I attempted to
raise antisera to the human and murine gene products using the GST fusion system
where C-terminal fragments were expressed in bacterial cells. Some difficulties with
protein solubility were overcome and these fusion proteins were used to immunise
rabbits and derive polyclonal antisera. The antiserum to the mouse protein appeared
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to be the better reagent and it was possible to demonstrate its specific reactivity in
western blot analyses. The specificity of the antiserum to the human protein could not
be demonstrated clearly, however. This difference may have been due to the fact that
the human LVI-I-GST fusion protein did not contain the authentic C-terminus and
consisted of a tripartite fusion with GST, LVI-I and additional read-through
sequences from the plasmid vector. Based on these observations, it would be helpful
to attempt immunisation with a GST fusion expressing the authentic C-terminus of
human LVI-I protein. Also, it would be useful to use these fusion proteins to raise
monoclonal antibodies where specificity could be' assessed with greater confidence.
Use of the murine antiserum in western blotting identified a protein of the expected
size based on translation of the major mRNA species (58 kDa). The use of the
antiserum in immunofluorescence and confocal microscopy suggested that this
protein is predominantly cytoplasmic. This was surprising in view of the prediction
of a nuclear location on the basis of sequence content (Chapter III). One possibility is
that the antiserum is cross-reactive with some cytoplasmic antigen(s), and that the
observed pattern does not genuinely reflect the distribution of the protein in the cell.
Again, the availability of monoclonal antibodies of more defined specificity would be
useful to resolve this question. Also, it would be possible to address the question of
subcellular localisation by an independent technique such as cell fractionation
followed by western blotting. Another possibility is that the Lvi-l protein shuttles
between the cytoplasm and the nucleus, and this possibility could be addressed by
testingthe effects of inhibitors of nuclear export such as leptomycin B (289).
WD-40 repeats proteins comprise a large family that encompass many different
functions (Chapter I). This complexity makes prediction of the function of a novel
family member such as LVI-l difficult. The leads that were followed in this thesis
were based mainly on analogy with the most closely related mammalian homologue,
DDB2, and its role in repair of UV-induced damage. Another clue that was followed
was based on the presumptive yeast orthologue, YDL156W. Preliminary analysis of
YDL156W deficient yeast cells for sensitivity to DNA damaging agents did not reveal
any unusual sensitivity (Prof Ian Hickson, personal communication). However, the
YDL156W protein has been shown to interact with YDR097C, the yeast orthologue
of the mismatch repair protein MSH6 (284). Interestingly, mice deficient in MSH2 or
MSH6 seem destined to develop hematologic malignancy, predominantly B-cell
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lymphoblastic lymphomas, even in the absence of a thymus and a greatly reduced T-
cell component (290).
My studies failed to show evidence that LVI-I protein interacts with MSH6, but it
would be interesting to test this hypothetical interaction under a wider range of
conditions, particularly genotoxic stresses, where DNA repair complex formation
might be induced. Also, as a further clue to function, it would be interesting to use
the Lvi-l protein as target in yeast two-hybrid screens for interacting proteins (291) in
which the full length Lvi-l gene product will be used as bait to detect interacting
proteins from various expression libraries.
As reviewed in Chapter I, the LVI-l homologue DDB2 is an essential component of a
complex that binds damaged DNA and suppresses UV -induced mutagenesis (237).
Moreover, rodents and humans regulate DDB2 transcription differently. Thus, pS3
binds and activates transcription of the human DDB2 gene after DNA damage, while
murine DDB2 gene does not contain a functional p53 response element (226). This
suggests that pS3 protein regulates DDB2 only in human cells. Therefore, based on
these findings it was decided to determine the relationship between pS3 induction and
LV/-J expression.
My data showed that the basal expression level of the murine Lvi-l gene and protein
in primary fibroblasts and T-cell lymphoma lines is independent of their p53 status.
However, protein levels appeared to be induced in the H3T3 fibroblast cell line, but
not in the p53-deficient lymphoma line plm 16i. Unfortunately, the lack of a
validated antiserum for the human LVI-l protein meant that it was not possible to test
for post-transcriptional changes in levels of the human LVI-l protein.
In conclusion, while the LVI-l gene shows evidence of responses to UV irradiation at
both transcriptional and post-transcriptional levels, there was insufficient time
available to test these responses systematically to determine the effects of radiation
dose and p53 status as well as possible differences in the responses of the human and
murine promoters. As radiation induces distinct gene sets at low and high doses,
corresponding to DNA repair and apoptotic pathways respectively (292), it would be
very interesting to discover whether LV/-J falls into one or other of these gene sets.
Moreover, it will be interesting to study the effects of inhibition of LVI-J by ablating
gene expression in vitro using small interfering RNA molecules (siRNA) (293).
As discussed in Chapter I, the LV/-J gene was discovered as a target for inactivation
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in a case of pre-B cell lymphoma. It will be intriguing to examine other B-cell
lymphomas from FlV infected cats for evidence of similar genetic events.
Furthermore, high expression of Lvi-l in lymphoid cells suggests that its loss of
expression may predispose to lymphoid neoplasia and or other forms of cancer in
other species and it will be equally important to investigate this possibility. Genetic
evidence for loci involved in tumour predisposition or somatic tumour suppression at
human chromosome 15q15 has been incompletely explored (294), although one study
ruled out LVI-J point mutations in a series of colorectal cancers (295).
The most direct approach to the putative tumour suppressor function of Lvi- J would
be to attempt to knock out the function of Lvi- J if}the mouse and assess the effects of
this deletion on phenotype and tumour susceptibility. Recent analysis of public
domain resources identified mouse embryonic stem (ES) cell lines carrying gene trap
vector insertions within the murine Lvi- J gene. If it is established that these insertions
result in complete functional inactivation of Lvi- J, this resource may aid the
generation of Lvi- t" mouse lines after blastocyst injection. If mice homozygous for
the inactive gene are non-viable, the causal pathology may be examined, which may
be informative with respect to gene function. The pattern of Lvi- J expression could
also be examined in homozygous and heterozygous animals making use of the ~-geo
(fusion of ~-galactosidase and neomycin transferase) gene expressed by the gene trap
vector. The intrinsic effects of Lvi- J knockout or heterozygosity could be examined
by following groups of mice and assessing general health, background tumour rates
and the integrity of the haematopoietic system. Another useful approach would be to
cross the knockout mice with strains expressing dominant oncogenes (Myc, Runx,
Pim, or Myb) and to challenge mice or cell lines derived from these with mutagenic
agents to reveal more subtle roles in responses to genotoxic damage (296).
Unfortunately, these approaches to Lvi-I function were beyond the scope of this
study. However, it is hoped that the work described here will provide the groundwork
for future characterisation of this highly conserved and potentially important
eukaryotic gene.
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